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Résumé 
Au cours des dernières décennies, les stents coronaires et les stents déviateurs de flux 
intracrâniens ont révolutionné le traitement endovasculaire de deux pathologies artérielles 
différentes : la maladie coronarienne et les anévrismes intracrâniens. Ces deux types 
d’endoprothèses métalliques ont des mécanismes de fonctionnement différents, mais ils sont tous 
deux associés à des complications qui découlent de problèmes de biocompatibilité. En particulier, 
la couverture rapide de ces endoprothèses par des cellules endothéliales présentant un 
phénotype anti-inflammatoire et anti-thrombotique est cruciale pour leur intégration à 
l’interface vaisseau/sang. Par conséquent, le développement de solutions visant à améliorer 
l’endothélialisation et l’intégration de ces deux types de stents dans la paroi vasculaire 
représenterait un progrès majeur dans leur domaine respectif. 
Dans ce contexte, cette thèse porte sur l’immobilisation d’une molécule bioactive à la surface 
de stents coronaires et de stents déviateurs de flux, afin de résoudre leurs problèmes de 
biocompatibilité. La molécule bioactive utilisée est un peptide synthétique, appelé P8RI, qui 
promeut les fonctions régulatrices de la glycoprotéine transmembranaire CD31 : l’inhibition de 
l’activation des plaquettes et des leucocytes, ainsi que l’amélioration de la survie, de la migration 
et de la fonction de barrière des cellules endothéliales. 
La première partie de ce travail de thèse a consisté à développer un procédé d’immobilisation 
du P8RI sur des stents métalliques. Nous avons successivement adopté trois approches : 
l’immobilisation directe du peptide sur des surfaces d’alliage fonctionnalisées par plasma ; le 
dépôt chimique en phase vapeur assisté par plasma d’une couche intermédiaire de polymère ; et 
le dépôt d’une couche de polydopamine par auto-polymérisation, suivi de l’immobilisation d’un 
bras d’ancrage et de la liaison du P8RI par chimie click sans cuivre. 
Nous avons ensuite réalisé une évaluation in vitro de la biocompatibilité des surfaces d’alliage 
ainsi revêtues, en termes de propriétés anti-thrombotiques, anti-inflammatoires et pro-
endothélialisation. Les surfaces sur lesquelles le P8RI avait été immobilisé ont montré une 
tendance à diminuer l’adhésion plaquettaire, à améliorer l’adhérence et la fonction de barrière de 
cellules endothéliales vasculaires humaines, et à promouvoir un phénotype anti-inflammatoire et 
anti-thrombotique chez ces dernières. 
Enfin, nous avons évalué in vivo des stents coronaires et déviateurs de flux recouverts de P8RI. 
Les stents coronaires ont été implantés dans des artères coronaires de porcs, et les résultats 
préliminaires ont montré une endothélialisation plus complète et une moindre densité de 
leucocytes adhérents sur les stents recouverts de P8RI que sur les témoins. Quant aux stents 
déviateurs de flux recouverts de P8RI, implantés dans un modèle d’anévrisme carotidien induit 
par incubation d'élastase chez le lapin, ils ont été associés à la formation d’une néointima plus 
épaisse et mieux organisée que sur les témoins, en particulier au niveau du collet anévrismal, ce 
qui implique de moindres risques de persistance du flux sanguin et de rupture d’anévrisme. 
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Abstract 
Over the last decades, coronary stents and intracranial flow diverting stents have 
revolutionized the endovascular treatment of two different arterial pathologies: coronary artery 
disease and intracranial aneurysms. The working mechanisms of these metallic endoprostheses 
are different but both are associated with complications stemming from biocompatibility issues. 
In particular, the rapid covering by endothelial cells presenting an anti-inflammatory and anti-
thrombotic phenotype is key to the integration of the endoprosthesis at the blood/vessel 
interface. Thus, the development of solutions to improve the endothelialization and the 
integration of these two types of stents in the vessel wall would represent a major progress in 
their respective field. 
In this context, this thesis work deals with the immobilization of a bioactive molecule on 
coronary stents and flow diverting stents in order to solve their biocompatibility issues. The 
bioactive molecule that we used is a synthetic peptide, named P8RI, which promotes the 
regulatory functions of the transmembrane glycoprotein CD31: the inhibition of platelets and 
leukocytes activation, as well as the enhancement of endothelial cell survival, migration and 
barrier function. 
The first part of this thesis work consisted in the development of a process for the 
immobilization of P8RI on metallic stents. We adopted three successive approaches: the direct 
immobilization of the peptide on plasma-functionalized alloy surfaces; the plasma-enhanced 
chemical vapor deposition of an intermediate polymeric layer; and the deposition of a 
polydopamine coating by self-polymerization, followed with the immobilization of a linker and 
the binding of P8RI by copper-free click chemistry. 
We then carried out an in vitro evaluation of the biocompatibility of the resulting coated alloy 
surfaces, in terms of anti-thrombotic, anti-inflammatory, and pro-endothelialization properties. 
The surfaces on which P8RI had been immobilized were shown to exhibit a tendency to decrease 
platelet adhesion, increase endothelial cell adhesion and barrier function, and promote an anti-
inflammatory and anti-thrombotic phenotype in human vascular endothelial cells. 
Finally, coronary stents and flow diverting stents were evaluated in vivo. Coronary stents 
were implanted in the coronary arteries of farm pigs, and preliminary results showed a more 
complete endothelialization and a lesser density of adherent leukocytes on ‘P8RI-coated’ stents 
than on the controls. ‘P8RI-coated’ flow diverting stents were implanted in a rabbit elastase-
induced carotid aneurysm model. Compared with the controls, they were associated with the 
formation of a thicker and better organized neointima, in particular on the stent struts in front of 
the aneurysm neck, which implies lesser risks of persistence of blood flow and aneurysm rupture. 
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I. Stents 
This work aims at improving the biocompatibility of two types of arterial endoprostheses: the 
balloon-inflatable coronary stents and the self-expanding intracranial flow diverting stents. In 
order to set the stage for the presentation of my experimental work, the pathologies that led to 
the development of these stents will be briefly presented, and the current challenges associated 
with the use of these medical devices will be detailed. 
 
I.1. Coronary stents 
I.1.a. Origins and evolution of coronary artery disease 
Coronary stents are used for the revascularization of obstructed coronary arteries. The 
obstruction of the coronary lumen area, called “stenosis” is caused by atherosclerosis, a chronic 
and multifactorial pathologic process of the arterial wall. 
 
 
The arterial wall is made of three layers, as shown on Figure 1. The innermost layer is the 
tunica intima (or simply ‘intima’). It contains a monolayer of endothelial cells (ECs) attached to a 
basal lamina that they produce, and an elastic membrane, the ‘internal elastic lamina’, which 
separates the intima from the tunica media (also called just ‘media’). The media, which is 
responsible for the contractility of the arteries, is composed of vascular smooth muscle cells 
(VSMCs), collagen and elastic fibers. The external elastic lamina separates the media from the 
Figure 1. Structure of an artery wall. Picture from Servier Medical Art image bank. 
Intima 
Internal elastic lamina 
Media 
External elastic lamina 
Adventitia 
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outermost layer, the tunica adventitia (or ‘adventitia’), made of fibroblasts, fibrous connective 
tissue, feeding adventitial vessels, draining lymphatics, and terminal nervous motor fibers. 
 
 
Figure 2 shows the different stages of atherosclerosis evolution, which are detailed below. 
According to the current paradigm, atherosclerosis is initiated by the deposition and the 
accumulation of low-density lipoproteins (LDLs) in the sub-intimal space, under the endothelium. 
This accumulation is enhanced by high concentrations of circulating LDLs (Steinberg 1983; 
Schwenke and Carew 1989; Nievelstein et al. 1991), and it occurs preferentially at the sites where 
blood flow is turbulent (Caro et al. 1969; Zarins et al. 1983; Moore et al. 1992), which might 
increase endothelial permeability. In particular, an association between low shear rate and high 
concentration of atherosclerosis has been identified in some areas of the coronary arteries 
(Sabbah et al. 1986). 
The LDLs that accumulate in the subendothelial space undergo several biochemical 
modifications, and notably, oxidation (Henriksen et al. 1981; Morel et al. 1984; Palinski et al. 
1989; Steinberg 1997). Oxidized LDLs are known to induce leukocyte recruitment (Steinberg et 
al. 1989; Frostegård et al. 1990; Lehr et al. 1991), in particular through the release of oxidation 
products such as lysophosphatidylcholine, which is a chemoattractant for monocytes (Quinn et 
Figure 2. Progression of atherosclerosis. A. Figure adapted from Koenig and Khuseyinova (2007). B. 
Photographs of human samples from our biobank at the LVTS (Inserm U1148). 
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al. 1988) and induces the expression of various leukocyte adhesion molecules and chemokines in 
ECs (Kume et al. 1992; Takahara et al. 1996; Takabe et al. 2004). 
As a result, monocytes and T lymphocytes are recruited (Gerrity et al. 1979; Jonasson et al. 
1986; Babaev et al. 1993). Once they have infiltrated the subendothelial space, monocytes 
differentiate into macrophages and take up oxidized LDLs (Poole and Florey 1958; Schaffner et 
al. 1980; Gerrity 1981). The ingestion of oxidized LDLs by the macrophages, mediated by the 
“scavenger receptors", is not regulated and leads to the transformation of the macrophages into 
lipid-laden ‘foam cells’, so named because of their histological aspect (de Villiers and Smart 1999). 
The accumulation of foam cells in the subendothelial space results in the formation of the so-
called ‘fatty streaks’. These macroscopically visible, clinically harmless lesions are already 
present in the arteries of newborns and children (Klotz and Manning 1911; Napoli et al. 1997). A 
photograph of fatty streaks is shown on Figure 2B. Some fatty streaks regress, while others 
progress to intermediate lesions (as summarized on Figure 2A). 
The progression of atherosclerosis is marked by the formation of a necrotic lipid core, 
resulting from macrophage necrosis (Tabas 2005). The lipid core contains extracellular lipids and 
pro-coagulant and inflammatory factors released by necrotic macrophages. It also contains 
calcium deposits, which accumulate with time (Stary 2001). In parallel with the formation of foam 
cells and the lipid core, VSMCs migrate towards the subendothelial space, proliferate and 
synthesize extracellular matrix (ECM) components, in response to cytokines and growth factors 
released by leukocytes and ECs (Dzau et al. 2002). Thereby, they create a ‘fibrous cap’ between 
the lipid core and the endothelium. 
The resulting ‘fibrofatty’ plaque tends to grow with the persistant accumulation of LDLs and 
inflammatory cells. This growth is often accompanied by arterial remodeling: the external elastic 
membrane can either shrink and drive vessel restriction (this is called ‘negative remodeling’) or 
expand (‘positive remodeling’) (Schoenhagen et al. 2001). A sketch of these situations is shown 
on Figure 3. Thus, the size of the plaque itself does not directly determine the degree of stenosis, 
but the progressive growth of the plaque along with a negative remodeling causes increasing 
stenosis of the atherosclerotic arteries. When the process is situated in a coronary artery (shown 
on Figure 4), this progressive luminal narrowing causes a reduction of blood flow (‘ischemia’) in 
the myocardium, and the first symptoms of coronary artery disease (CAD) appear: chest pain 
(‘angina’) and short breath are experienced first during exertion, and then, as the occlusion 
progresses, also at rest. 
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Besides this progressive stenosis process, full stenosis can be achieved acutely on lesions that 
were clinically silent. This acute obstruction results from the formation of a luminal thrombus 
forming on eroded or ruptured atherosclerotic lesions. The exact causes of plaque erosion and 
plaque rupture are not yet known. Concerning plaque rupture, a large body of evidence suggests 
a role for the matrix proteinases produced by leukocytes infiltrated within the plaque. The 
rupture of the plaque causes the exposure of the procoagulant factors contained in the necrotic 
core (such as tissue factor) to the circulating blood, resulting in the formation of a thrombus 
(Libby 2002). Still, this event can be asymptomatic, as thrombolysis also takes place, and the 
plaque ‘heals’ through the formation a thicker fibrous cap. 
However, when the lumen of the artery is already largely reduced by the plaque, the thrombus 
created after the rupture of the lesion can cause a total occlusion of the artery. When the lesion is 
situated in a coronary artery, this results in acute myocardial infarction (commonly known as 
‘heart attack’). Myocardial infarction (MI) is the final and most severe manifestation of CAD, and 
it requires emergency treatment in order to prevent the death of the patient. 
 
 
Figure 3. Schematic representations of positive and negative arterial remodeling.
Pictures from Servier Medical Art image bank. 
Figure 4. Coronary arteries.The coronary arteries surround the myocardium, which they supply in 
oxygen. 
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I.1.b. Endovascular treatment of coronary artery disease: balloons and 
scaffolds 
An estimated 15.9 million people suffered from myocardial infarction worldwide in 2015 
(Hay et al. 2017), and cardiovascular diseases are the first cause of death in Western countries 
such as the United States (Thom et al. 2006). CAD is therefore a major health concern. 
Tremendous progress has been made in the treatment of this disease over the past decades. The 
decrease in mortality rates after hospitalization for myocardial infarction reflects this progress. 
For instance, a Danish nationwide cohort study showed that the 30-day mortality after 
myocardial infarction dropped from about 30% in the period 1984-1988 to 15% in 2004-2008 
(Schmidt et al. 2012). This progress was correlated to the generalization of the use of medications 
such as beta-blockers and thrombolytics (as reported by Gheorghiade and colleagues (1996)), 
and is also due to two successive ‘revolutions’ in the treatment of CAD: the revascularization of 
the stenotic coronary arteries by balloon angioplasty, next followed by intravascular stenting 
techniques. 
A more detailed description of the historical evolution and current challenges of 
percutaneous transluminal coronary angioplasty can be found in a review that I co-authored 
(Caligiuri et al. 2017). This review is presented in annex. 
Balloon angioplasty without stents (also called ‘plain old balloon angioplasty’ or POBA) was 
first performed by Andreas Gruntzig in 1977 (Gruntzig 1978). It consists in inserting a deflated 
balloon in the occluded artery (by percutaneous intervention) and inflating it in order to 
mechanically restore the luminal diameter. It is a minimally invasive technique, requiring only 
the insertion of a catheter at a peripheral entry point. As it demonstrated high success rates (de 
Feyter et al. 1991), its use became general over the years, and it became a gold standard treatment 
for myocardial infarction (Iannone et al. 1993; Zijlstra 1995). However, the clinical efficiency of 
POBA was limited by elastic recoil and post-angioplasty restenosis, with rates as high as 30 to 
60% (Bauters et al. 1996). Coronary stents were developed in order to solve this issue. 
Coronary stents are metallic endoprostheses that are mounted on a deflated angioplasty 
balloon. When the balloon is inflated, they expand, and they remain in place after the balloon is 
removed, thus acting as a scaffold for the artery and maintaining open the lumen. The deployment 
of a coronary stent is represented on Figure 5. 
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A coronary stent was implanted in a human for the first time in 1986 (Sigwart et al. 1987). 
Several models were developed by different companies in the early 1990s, and the results of two 
major clinical trials, BENESTENT and STRESS (Fischman et al. 1994; Serruys et al. 1994), 
established the efficiency of stents in preventing restenosis after balloon angioplasty. Stents 
became more and more common, and in 1999, they were used in nearly 85% of the percutaneous 
coronary interventions (PCIs) (Serruys et al. 2006). PCIs are either primary (performed in 
emergency to treat acute myocardial infarction) or elective (performed to treat CAD that has not 
yet led to acute myocardial infarction). 
The incidence rate of in-stent restenosis in the 6 months following the implantation of these 
‘bare metal stents’ (BMSs) was considerable, at 20 to 30% (Fischman et al. 1994; Serruys et al. 
1994; Ijsselmuiden et al. 2003). In-stent restenosis (ISR) is a result of a ‘neointimal’ formation. 
The injury caused by the stent to the vascular wall triggers an inflammatory reaction involving 
platelets and leukocytes. This inflammatory reaction causes smooth muscle cells to migrate in the 
plaque towards the lumen, proliferate and produce ECM matrix components (Virmani and Farb 
1999; Mitra and Agrawal 2006). The resulting neointimal hyperplasia covers the stent struts and 
obstructs the arterial lumen. In addition, our laboratory has recently shown that local peristrut 
microhemorrhages, cholesterol accumulation, and oxidation, trigger together in-stent 
neoatherosclerosis (Terzian et al. 2017). 
The high rate of in-stent restenosis associated with BMSs prompted the development of a new 
type of stents: drug-eluting stents (DESs), which are coated with a polymer matrix containing an 
antimitotic or cytostatic drugs. The drugs aim at inhibiting the local inflammation process and the 
Figure 5. Stent deployment. A. The stent, mounted on a deflated balloon, on a catheter, is 
placed in the occluded artery segment. B. The balloon is inflated, which causes the stent to 
expand and the atheromatous plaque to be compressed against the artery wall. C. After 
retraction of the catheter, the stent stays in place in order to maintain the lumen diameter. 
Figure from the Encyclopædia Britannica.  
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VSMCs proliferation that lead to restenosis. The first generation of DESs, launched in 1999, were 
the Taxus stent (produced by Boston Scientific) and the Cypher stent (manufactured by Cordis), 
eluting paclitaxel and sirolimus respectively. Their use led to a major decrease in restenosis rate 
compared with BMSs (Morice et al. 2002; Colombo et al. 2003). However, it appeared that, 
compared with BMSs, they both induced a higher rate of ‘late’ thrombosis, that is to say 
thrombosis that happened several months after stent implantation, generally after the 
discontinuation of the recommended anti-platelet therapy (Pfisterer et al. 2006; Lagerqvist et al. 
2009; Stone et al. 2011). This increased risk of late stent thrombosis, which resulted in higher 
mortality and target lesion revascularization rates, was correlated with a local hypersensitivity 
reaction provoked by the polymer (or possibly the drugs) (Virmani et al. 2004) and delayed stent 
strut endothelialization (Joner et al. 2006). The delay in stent endothelialization can be explained 
by the cytostatic effect of the drugs, which do not only impact leukocytes and VSMCs, but also 
endothelial cells (Pasquier et al. 2004; Prasad et al. 2005; Reineke et al. 2015). 
During the last fifteen years, BMSs and DESs have evolved. Cobalt-chromium alloys (CoCr) 
and, more recently, platinum-chromium alloys (PtCr) have largely replaced 316L stainless steel 
as stents core material (Foin et al. 2014). The superior mechanical properties of these new alloys 
made it possible to increase the flexibility of the stents and decrease stent strut thickness, which 
resulted in lower restenosis rates (Briguori et al. 2002; Pache et al. 2003). 
As regards DESs, their second generation is characterized by the use of sirolimus-derived 
drugs (everolimus, zotarolimus, novolimus, Biolimus A9) and new polymer coatings, in order to 
avoid the hypersensitivity reactions associated with the coatings of first-generation stents. A 
third generation of DESs, coated with bioresorbable poly(lactic acid)-based polymers, was later 
developed. 
The superiority of second-generation DESs over first-generation DESs in terms of late 
thrombosis risk and myocardial infarction incidence was shown by a meta-analysis (Navarese et 
al. 2013) and the study of a registry of more than 18000 patients (Tada et al. 2013). However, 
two meta-analyses showed no superiority of third-generation DESs over second-generation DESs, 
in terms of stent thrombosis, myocardial infarction and mortality (Navarese et al. 2013; Pandya 
et al. 2016). 
 
I.1.c. Current challenges for coronary stents 
The biological complications currently associated with coronary stents (thrombosis and 
restenosis) stem from biocompatibility issues. The stent surface induces pro-thrombotic and pro-
inflammatory reactions in the cells that contact it: platelets and leukocytes at first, then migrating 
endothelial cells. Indeed, the phenotype of the endothelial cells that cover the stent struts is not 
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physiological, since they display defective intercellular junctions and decreased expression of 
antithrombotic molecules (Otsuka et al. 2012). 
New stent coatings are needed to address this issue. A great part of the current research and 
development in coronary stents actually focuses on strategies to improve stents 
endothelialization, either by promoting endothelial cells migration through the immobilization of 
ECM-derived components (Li et al. 2011; Joner et al. 2012; Castellanos et al. 2017; Montaño-
Machado et al. 2017), or by recruiting endothelial progenitor cells (Kutryk et al. 2008; Lin et al. 
2010; van Beusekom et al. 2012; Li et al. 2016). Only one of these approaches has already been 
transferred to a commercially available stent: a coating with anti-CD34 antibodies, which aims at 
capturing circulating endothelial progenitor cells, on OrbusNeich’s Genous and Combo stents. 
The strategy that we propose aims at improving stents endothelialization, in terms of both 
shortening of the delay before complete covering and induction of a physiologic EC phenotype, in 
order to prevent biological complications. 
A similar strategy can also be applied to another type of arterial stent, the ‘flow diverting 
stents’, used for the treatment of intracranial aneurysms. The pathology and clinical challenges 
associated with this type of stent differ from those seen with the use of balloon-expandable stents. 
Thus, prior to discussing the stent improving strategy used in this work, I will introduce the 
challenges associated with the use of flow diverting stents. 
 
I.2. Flow diverting stents 
Flow diverting stents were developed for the endovascular treatment of intracranial 
aneurysms. The following section presents the medical context for the use of these stents. 
 
I.2.a. Intracranial aneurysms 
Aneurysms are abnormal bulges of a blood vessel. There are two main types of aneurysms: 
saccular (or ‘berry’) aneurysms, which protrude on one side of a vessel, and fusiform aneurysms, 
which consist in a symmetrical enlargement of the vessel diameter. A drawing of the two types of 
aneurysms is provided on Figure 6. 
Figure 6. Schematic drawings of aneurysms. A. Saccular aneurysm. B. Fusiform aneurysm. 
Pictures from Servier Medical Art image bank. 
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Aneurysms can form in both arteries and veins, but are far more common in arteries (Gillespie 
et al. 1997). In particular, most aneurysms are found in the aorta or in intracranial arteries 
(Ruigrok et al. 2008). We will henceforth focus on intracranial aneurysms, since flow diverting 
stents were developed for their treatment. Most intracranial aneurysms are saccular, and are 
situated in the subarachnoid space at the base of the brain, as shown on Figure 7. 
 
 
 The pathogenesis of intracranial aneurysms is not well understood. They may result from a 
deformation of the vessel wall under the effect of arterial blood flow. However, the initial 
mechanisms which can lead to excessive local blood pressure and vessel wall weakening are very 
diverse, and as a consequence, intracranial aneurysms are a common manifestation of many 
different diseases (Krings et al. 2011). Genetic connective-tissue disorders, smoking and 
hypertension are the most important risk factors associated with intracranial aneurysms 
(Schievink 1997). 
Aneurysms are generally asymptomatic until a catastrophic event happen: the rupture of the 
arterial wall at the apex of the aneurysm. Most of the aneurysms never rupture: according to a 
systematic review (Rinkel et al. 1998), the prevalence of intracranial aneurysms in adults without 
specific risk factors is 2%, and they have an annual risk of rupture of approximatively 2%. 
However, when intracranial aneurysms do rupture, it results in subarachnoid haemorrhage, a 
form of stroke which has a fatality rate of 30-40%, and causes the individual to become 
functionally dependent in 10-20% of the cases (Nieuwkamp et al. 2009). Today, the treatment of 
ruptured and unruptured intracranial aneurysms is a public health priority. 
Figure 7. Major localization of intracranial aneurysms. A. Sketch of the base of the brain, with the 
most common sites of aneurysms evidenced by blue circles. Picture from van Gijn et al. (2007). B. Tissue 
layers surrounding the brain. The arteries in which most intracranial aneurysms occur are localized in 
the subarachnoid space. Picture from Servier Medical Art image bank. 
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I.2.b. Historical treatments of intracranial aneurysms 
The first developed method to treat intracranial aneurysms was microsurgical clipping. As 
shown on Figure 8A, it consists in pinching the aneurysm neck with a metallic clip. Thus, the 
aneurysm is isolated from blood flow, and cannot cause hemorrhages. This procedure involves 
general anesthesia and craniotomy, which is why it is generally not recommended in patients 
with a weak health status. 
 
 
An endovascular treatment of intracranial aneurysms was developed in the 1990s: ‘aneurysm 
coiling’ (cf Figure 8B). This method consists in inserting a catheter in the aneurysm neck, and 
filling the aneurysm with thin radio-opaque platinum coils, so as to allow the formation of a stable 
thrombus, isolated from the circulation. In the ISUIA study (Wiebers 2003), which included more 
than 2000 patients who had undergone either open surgical or endovascular treatment of 
unruptured aneurysms, coiling demonstrated similar or better outcomes for patients in terms of 
morbidity and mortality at 30 days and 1 year, compared with clipping. The ATENA study (Pierot 
et al. 2008) later confirmed the feasibility and low morbidity and mortality rates associated with 
coiling of unruptured aneurysms. As for the treatment of ruptured intracranial aneurysms, the 
multi-center, randomized ISAT study (Molyneux et al. 2015) showed better outcomes for coiling 
than clipping, in terms of mortality and dependency at 10 years. 
Aneurysm coiling was not recommended for wide-neck aneurysms, due to the risk of the coils 
obstructing the parent artery rather than the aneurysm. In the 2000s, ‘stent-assisted coiling’ was 
developed in order to overcome this limitation. As shown in Figure 8C, it consists in deploying a 
stent in the parent artery before filling the aneurysm with coils, in order to insure the proper 
positioning of the coils. Although there are some concerns about the complications associated 
with stent-assisted coiling, the demonstration of its efficacy in terms of recurrence rate has led to 
the generalization of its use (Piotin et al. 2010; Chalouhi et al. 2013; Hong et al. 2014). 
Figure 8. Most common treatments of intracranial aneurysms. A. Clipping. B. Coiling. C. Stent-
assisted coiling. Note: the aneurysms represented here are unruptured, but these treatments are 
also applied to ruptured aneurysms. Pictures from Mayfield Clinic. 
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Today, surgical clipping and endovascular coiling (stent-assisted or not) are the two main 
treatment options for intracranial aneurysm. However, a third option has emerged in the last 
decade and brought a revolution to the treatment of complex aneurysms: flow diverting stents. 
 
I.2.c. Design and performances of flow diverting stents 
Flow diverting stents (FDSs) are self-expanding, low porosity stents, which are positioned in 
the parent artery, in front of the aneurysm neck (as shown on Figure 9). As their name implies, 
they keep the blood in the parent artery, thus isolating the aneurysm from the circulation. After a 
local inflammatory response, thrombosis and remodeling take place in the aneurysm, while the 
aneurysm neck is progressively occluded by the endothelialization of the FDS and the subsequent 
neointimal proliferation (Kadirvel et al. 2013). 
 
 
FDSs perform very well in terms of aneurysmal occlusion: a systematic review of the 
literature, which included 1451 patients implanted with FDSs, reported an aneurysmal occlusion 
rate of 76% at 6 months (Brinjikji et al. 2013), while a clinical study on 633 patients reported 
occlusion rates of 90% at 1 year and 100% at 8 years (Lundquist et al. 2016). However, the morbi-
mortality rate is not negligible: 5.9% at 30 days and 9% at 6 months, according to the same studies 
by Lundquist et al. and Brinjikji et al. respectively. It is partially due to the two most common non-
technical complications associated with FDS implantation: delayed aneurysm rupture and 
delayed intraparenchymal hemorrhage. 
The occurrence rate of delayed aneurysm rupture was reported to be 1.9% in a retrospective 
study (Kulcsár and Szikora 2012). The causes of delayed aneurysm rupture have yet to be 
identified. The most plausible hypotheses are the persistence of flow inside the aneurysm and the 
Figure 9. Schematic representation of a flow diverting 
stent in an artery. Picture from Mayfield Clinic. 
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degradation of the aneurysm wall by proteases from the inflamed aneurysmal thrombus 
(Fontaine et al. 2002; Carrell et al. 2006; Cebral et al. 2011; Kulcsár et al. 2011; Rajah et al. 2017). 
Concerning delayed intraparenchymal hemorrhages (DIPHs), their occurrence rate is 
reported to be 3% in a meta-analysis grouping 1451 patients (Brinjikji et al. 2013), and 2.4% in a 
retrospective study on 793 patients (Kallmes et al. 2015). Like for delayed aneurysm rupture, the 
mechanisms behind DIPH are not understood yet. However, the vast majority (80%) of DIPHs 
were reported to occur in the arterial segment containing the FDS, which suggests that they are 
caused by the stent or the procedure itself. The remaining 20% of DIPHs occur far from the FDS, 
which points to the involvement of antiplatelet therapy in this complication (Rouchaud et al. 
2016a). Antiplatelet therapy is systematically administered to the patients after FDS implantation 
in order to prevent in-stent thrombosis. 
It is worth noting that, unlike in coronary stents, in-stent restenosis is not a major issue in 
FDSs despite the fact that small studies reported in-stent stenosis occurrences to be between 10 
and 40% in the first months after implantation (Pierot 2011; Cohen et al. 2014; John et al. 2016), 
Indeed, almost all in-stent stenoses were asymptomatic, and later angiographic follow-up showed 
their partial regression (John et al. 2016). 
The primary indication of FDSs is the treatment of unruptured anatomically complex 
aneurysms (e.g. wide-neck or giant saccular aneurysms, fusiform aneurysms). However, the 
promising results of the first clinical studies in terms of clinical outcomes and aneurysm occlusion 
rates (Fiorella et al. 2009; Szikora et al. 2010; de Barros Faria et al. 2011; Nelson et al. 2011; 
Fischer et al. 2012; Martin et al. 2012; McAuliffe et al. 2012; Narata et al. 2012; Cruz et al. 2013) 
have led to a progressive extension of their use to other types of aneurysms, including ruptured 
aneurysms (Brouillard et al. 2016). 
Thus, although the flow diverters market is relatively small today (414 FDSs were implanted 
in France between October 2012 and February 2014, according to the Société Française de 
Neuroradiologie (2016), it is quickly expanding.  
The various models of FDSs currently in use in Europe are listed in Table 1. Contrary to the 
coronary stents, which are mostly produced by laser cutting (Martinez and Chaikof 2011), FDSs 
consist of braided wires. Most wires are made of either CoCr or ‘nitinol’, a shape-memory, super-
elastic alloy composed of nickel and titanium in approximately equal atomic percentages. A few 
platinum, platinum-tungsten or tantalum wires are added in order to increase the radio-opacity 
of the devices. 
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CE marking Manufacturer Model Alloy 
2008 Balt Silk Nitinol + Pt 
2008 Medtronic Pipeline CoCr + PtW 
2011 Stryker Neurovascular Surpass CoCr + PtW 
2012 Phenox p64 Nitinol + Pt 
2013 MicroVention FRED Nitinol + Ta 
Table 1. Flow diverting stents currently in use in Europe. Pt: Platinum. W: Tungsten. Ta: Tantalum. 
Similar models of the same line (e.g.: Pipeline and Pipeline Flex) have been omitted. 
 
I.2.d. Towards better flow diverting stents  
Flow diverting stents have not yet celebrated the tenth anniversary of their first CE marking, 
and the evaluation of their performances and potential complications still lacks some precision. 
The results of several ongoing randomized clinical trials (FIAT, LARGE and EVIDENCE trials) are 
therefore eagerly awaited. However, as detailed in the previous section, FDSs have largely proven 
their value as a treatment option for various types of aneurysms, and the issues that the next 
generation of FDSs should address can already be identified. Indeed, although the precise 
mechanisms behind the main complications of FDSs (delayed aneurysm rupture and DIPH) have 
not been elucidated, three types of biological causes have been isolated: the persistence of blood 
flow in the supposedly occluded aneurysm, the effect of antiplatelet therapy, and the degradation 
of the aneurysmal wall by proteases released from the thrombus. 
The aneurysm occlusion and healing have been shown to depend on the endothelialization 
and the subsequent formation of an ‘impermeable’ neointima on the stent struts in front of the 
aneurysm neck (Kadirvel et al. 2013). Therefore, both the persistence of blood flow in the 
aneurysm and the proteolytic activity of the thrombus should decrease if the stent could promote 
the fast formation of a functional neointima. As for the antiplatelet therapy, its use is required to 
prevent in-stent thrombosis, which is caused by the pro-thrombotic action of the FDS on the cells 
that contact it (blood circulating cells first, then ECs and SMCs). 
Thus, the issues identified with intracranial FDSs are similar to the ones associated with 
coronary stents: they concern the biocompatibility of the devices towards the cells present in 
their in vivo environment. The solution developed for one device can therefore be applicable to 
the other, provided that it is adapted to the materials and the mechanical properties of both 
stents. 
Medtronic, the world leader of the FDS market, is currently studying a phosphorylcholine 
coating (called ‘Shield Technology’) to reduce the thrombogenicity of its FDS (Pipeline). 
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Medtronic’s French competitor, Balt, was involved in the current study, which aimed at 
developing a coating that would decrease platelet adhesion, but also promote stent 
endothelialization and favor a physiological, anti-thrombotic phenotype in the endothelial cells. 
The bioactive molecule that we chose to immobilize on both balloon-inflatable and auto-
expandable stents, in order to improve their biocompatibility, is derived from the CD31 protein. 
The reasons for this choice are explained in the next section. 
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II. CD31 and agonist peptides 
II.1. General presentation of CD31 
CD31 is a transmembrane glycoprotein which is constitutively and exclusively expressed on 
platelets, leukocytes and endothelial cells (Ohto et al. 1985; Goyert et al. 1986; Stockinger et al. 
1990). The sequence of human CD31 contains 738 amino acid residues, including a 27-residue 
signal peptide which is cleaved during the maturation of the protein in the endoplasmic reticulum 
(Newman et al. 1990; Stockinger et al. 1990). This sequence corresponds to a molecular weight 
of 83 kDa. However, CD31 is heavily glycosylated, so the molecular weight of the mature 
glycoprotein is actually 130 kDa (Newton et al. 1999). 
As shown on Figure 10, CD31 consists of six extracellular immunoglobulin-like (Ig-like) 
domains (characterized by a specific arrangement of 100-residue long β strands stabilized by a 
disulfide bridge), a transmembrane region, and a cytoplasmic tail containing two 
immunoreceptor tyrosine-based inhibitory motifs (ITIMs). 
  
Because of its Ig-like extracellular domains, CD31 was first classified within the 
Immunoglobulin Cell Adhesion Molecule (IgCAM) family. Since it was expressed on both platelets 
and endothelial cells, it was named Platelet-Endothelial Cell Adhesion Molecule-1 (PECAM-1). Its 
function was thought to primarily mediate the adhesion between platelets and endothelial cells 
(Newman et al. 1990). 
However, a few years later, the discovery that PECAM-1 possessed two ITIMs on its 
cytoplasmic tail led to its switching to the Ig-ITIM family (Newman 1999). The Ig-ITIMs drive 
inhibitory signaling cascades and henceforth, CD31 was not considered as a cell adhesion 
molecule anymore, but as an inhibitory receptor which performs regulatory functions in the cells 
that express it (Newman and Newman 2003). 
 
Figure 10. Schematic structure of CD31. The six loops of the extracellular region represent the Ig-like 
domains. By convention, they are numbered from the most distal to the most proximal, relatively to the 
membrane. The dash lines represent the disulfide bridges that stabilize the Ig-like domains. 
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II.2. CD31 activation and signaling pathways 
The regulatory functions of CD31 act primarily through the recruitment and activation of 
phosphatases by the phosphorylated ITIMs of its cytoplasmic tail. ITIMs are short residue 
sequences of the form: S/I/V/L – x – Y – x – x - I/V/L. Upon phosphorylation of their central 
tyrosine (Y), they become a binding motif for the Src homology 2 (SH2) domains of protein 
tyrosine phosphatases (Unkeless and Jin 1997).  
The activation of these ITIMs requires the clustering of CD31 and the presence of neighboring 
activated tyrosine kinases. The following explanation of the activation and signaling mechanisms 
of CD31 is summarized on Figure 11. 
Two mechanisms are involved in the clustering of CD31: a trans-homophilic interaction 
involving the distal domains 1 and 2 (Sun et al. 1996; Paddock et al. 2016) and a cis-homophilic 
engagement at the domain 6 (Newton et al. 1997). The two ITIMs on the cytoplasmic tails of the 
clustered CD31 molecules are then phosphorylated by tyrosine kinases. Several research groups 
have identified members of the Src kinase family (the Src family kinases, or SFKs) as the kinases 
which phosphorylate the ITIMs of CD31 (Lu et al. 1997; Cao et al. 1998; Cicmil et al. 2000; 
Newman et al. 2001). 
 It is important to note that CD31 is not endowed with autocatalytic properties and its ITIM 
motifs are not phosphorylated in resting cells. The stimulation of cell signaling through other 
receptors is needed and, as reported by P. Newman (1999), various cellular stimuli can lead to 
CD31 ITIM phosphorylation in the different types of cells which express it. These stimuli include 
platelet aggregation (Jackson et al. 1996), shear stress (Osawa et al. 1997), oxidative stress (Wang 
et al. 1998), exposure to lysophosphatidylcholine (Ochi et al. 1998), cross-linking of the Fcε 
receptor (Sagawa et al. 1997) and cross-linking of CD31 itself (Varon et al. 1998). 
Once phosphorylated, the ITIMs recruit and activate SH2-containing phosphatases (SHPs), 
SHP-2 in particular (Cao et al. 1998; Pumphrey et al. 1999; Henshall et al. 2001). The subsequent 
effects downstream of SHPs activation greatly vary depending on the type of cell considered and 
the activation stimuli it has received. Like all ITIM receptors, CD31 negatively regulates the 
activation pathway of ITAM (Immunoreceptor Tyrosine-Based Activation Motif) receptors, 
thereby lowering the activation threshold of immune cells (Ravetch and Lanier 2000). However, 
as detailed in the next paragraph, CD31 is far from just being an ITIM-bearing receptor (Newman 
and Newman 2003). The main known functions of CD31 in different cell types are detailed in the 
next section. 
For instance, CD31 appears to be involved in serine/threonine signalization pathways. Serine 
residues of CD31’s cytoplasmic tail are known to undergo phosphorylation, at levels increasing 
with activation (Newman et al. 1992; Ilan et al. 2000). The effects of this phosphorylation have 
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not yet been elucidated. CD31 was also shown to bind to elements of the cytoskeleton such as 
actin filaments, and to be functionally involved in their assembly (Matsumura et al. 1997). Finally, 
CD31 was also shown to engage in heterophilic interactions, in particular with CD177 and CD38 
(Dianzani et al. 1994; Deaglio et al. 1998; Fedele et al. 2004; Sachs et al. 2007; Bayat et al. 2010). 
However, the in vivo effects of these interactions have not been clearly evidenced, contrary to the 
effects of homophilic CD31 interactions and ITIM-driven cellular functions. 
 
 
II.3. Cellular functions of CD31 
CD31 is constitutively expressed on endothelial cells, as well as on platelets, monocytes, 
neutrophils, eosinophils, basophils, mast cells, lymphocytes, that is to say on all hematopoietic 
cells except for red blood cells. CD31 levels of expression differ depending on the cells: there are 
approximately 5000 CD31 molecules per platelet, 50 000 per T cell, 100 000 per neutrophil and 
Figure 11. CD31 activation and signaling pathway. 1) Clustering of CD31 by trans-homophilic 
engagement of the distal domains 1 and 2. 2) Consolidation of the cluster by cis-homophilic 
engagement of the proximal domain 6. 3) Phosphorylation of the ITIMs of the cytoplasmic tail by 
SFKs (Src family kinases). 4) Recruitment and activation of SHPs (SH2-containing phosphatases) by 
the phosphorylated ITIMs. 5) Signaling cascade of the SHPs: inhibition of ITAM-depending cascades, 
and other actions depending on the cell type. 
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1 000 000 per endothelial cell (Newman 1994). CD31 regulatory functions are also very different 
in endothelial cells, platelets and leukocytes. 
 
II.3.a. CD31 in platelets 
It is globally agreed upon that CD31 functions in platelets are mainly inhibitory. CD31 
engagement has been shown to induce ITIMs phosphorylation and to inhibit aggregation, 
degranulation and intracellular calcium mobilization in platelets activated in vitro with specific 
agonists, namely collagen, collagen-related peptide and convulxin (Jones et al. 2001; Cicmil 2002; 
Jones et al. 2009). Besides, platelets from CD31 KO mice are more prone to aggregation and α-
granule secretion than platelets from wild-type mice, when stimulated with collagen (Patil et al. 
2001). In vitro and in vivo studies also showed that CD31 engagement inhibits thrombus growth 
(Jones et al. 2001; Rathore et al. 2003; Falati 2006). 
 
II.3.b. CD31 in leukocytes 
In T lymphocytes, the crosslinking of CD31 with the T cell receptor (TCR) was shown to 
inhibit TCR-dependent activation (Newton-Nash and Newman 1999). CD31 engagement with a 
recombinant CD31 was also shown to decrease the production of pro-inflammatory cytokines 
and to inhibit the proliferation of TCR-stimulated T cells (Prager et al. 2001). 
In B cells, the co-ligation of the B cell receptor with CD31 chimeras attenuates downstream 
mechanisms such as calcium mobilization (Henshall et al. 2001). On the contrary, B cells from 
CD31 KO mice were shown to exhibit increase calcium mobilization and proliferation in response 
to BCR ligation (Wilkinson et al. 2002). 
For mast cells, an in vivo study showed that, in response to anaphylaxis, CD31 KO mice 
exhibited higher serum histamine concentrations than wild-type mice. This points to an 
inhibitory function of CD31 in the regulation of mast cells activation in allergic diseases (Wong et 
al. 2002). 
The function of CD31 in polymorphonuclear cells is not well known yet. However, several 
studies point at the involvement of CD31 in neutrophil migration and transmigration (Berman 
and Muller 1995; Miller et al. 2001; Wu et al. 2005; Bayat et al. 2010). Recent work carried out in 
our laboratory, by Francesco Andreata and colleagues, expands upon the role of CD31 in 
neutrophil transmigration, suggesting that CD31 signaling is essential for controlling neutrophil 
oxidative burst and degranulation at sites of inflammation (abstract presented at the 
International Immunology Congress, Melbourne 21-26 August 2016, manuscript in preparation). 
CD31 was shown to perform inhibitory functions in macrophages: its engagement regulates 
negatively Toll-like receptor 4 signaling and decreases pro-inflammatory cytokines production 
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by LPS-activated macrophages (Rui et al. 2007). CD31 also inhibits phagocytosis by transmitting 
‘detachment’ signals between a healthy cell and a contacting macrophage, through homophilic 
engagement (Brown et al. 2002). 
 
II.3.c. CD31 in endothelial cells 
CD31 has been shown to play many different roles in endothelial cells. We will present here 
the best known functions and the ones that are most relevant to the issues of stent 
endothelialization. The following description partly relies on a review written by Privratsky and 
Newman (2014). 
CD31 is known to localize at the intercellular junctions of endothelial cells as they become 
confluent (Muller et al. 1989; Newman et al. 1990). It plays a role in the initial formation of 
endothelial intercellular junctions, since the blocking of CD31 by antibodies prevents the 
formation of these contacts (Albelda et al. 1990). Moreover, CD31 was shown to localize at the 
cell-cell junctions between fibroblast-like or enteroendocrine cells which had been transfected 
with CD31 cDNA. On the contrary, the CD31 surface distribution remained homogeneous when a 
CD31-transfected cell contacted a cell that did not express CD31 (Albelda et al. 1991). These 
results point at an involvement of CD31 in intercellular junctions through trans-homophilic 
engagement. The homophilic nature of CD31 engagement at intercellular junctions was later 
confirmed by further studies (Sun et al. 1996; Newton et al. 1997). 
 In vitro and in vivo experiments also showed that the endothelium permeability to 
macromolecules was much increased in the presence of anti-CD31 antibodies (Ferrero et al. 
1995), thus evidencing the involvement of CD31 in the maintenance of the vascular barrier 
function. Biswas et al. (2006) proved that CD31 plays a key role in the reconstitution of 
endothelial intercellular junctions after a breach. Besides, the CD31-dependent promotion of 
endothelial cell survival has been extensively reported (Evans et al. 2001; Ferrero et al. 2003; Gao 
et al. 2003; Limaye et al. 2005).  
CD31 is also involved in angiogenesis, and in particular in promoting endothelial cells 
migration (DeLisser et al. 1997; Zhou et al. 1999; RayChaudhury et al. 2001; Cao et al. 2002; Wu 
and Sheibani 2003; Kondo et al. 2007). 
Finally, numerous in vitro and in vivo studies also showed the involvement of CD31 in the 
regulation of leukocyte extravasation through the endothelial barrier (Muller et al. 1993; 
Vaporciyan et al. 1993; Newman 1994). 
 
In summary, CD31 performs different roles in platelets, leukocytes and endothelial cells. In 
platelets and leukocytes, its functions are essentially inhibitory, whereas in endothelial cells, it 
INTRODUCTION 
46 
promotes migration and survival of the cells, as well as the formation and maintenance of the 
intercellular junctions responsible for the integrity of the vessel barrier function. 
These characteristics correspond to the properties wanted on the surface of coronary stents 
and FDSs. Thus, it seems desirable for a stent coating to promote CD31 regulatory functions. 
 
II.4. CD31 shedding and identification of rescue agonist peptides 
II.4.a. CD31 shedding 
Upon cell activation or stressful condition, CD31 has been shown to undergo cleavage in its 
extracellular domain, and thus shedding, in several types of cells. 
In endothelial cells, Ilan et al. (2001) discovered that CD31 is shed during starving-induced 
apoptosis. A 100 kDa soluble protein is released during this process; this fragment consists of the 
extracellular domain of CD31. A truncated protein, which comprises the cytoplasmic and 
transmembrane domains of CD31, remains anchored to the plasma membrane. 
CD31 was also shown to be shed in platelets treated with an inhibitor of the cytosolic 
calmodulin (Wong et al. 2004), in HIV-infected leukocytes (Eugenin et al. 2006), and in T 
lymphocytes following TCR activation (Fornasa et al. 2010). 
In the cases where it was investigated, the effect of CD31 shedding on the cells was the loss of 
the regulatory functions of CD31 (Ilan et al. 2001; Fornasa et al. 2010). This result is no surprise, 
since the primary signaling pathway of CD31 requires its clustering, which is maintained by 
homophilic interactions in the extracellular domain (as detailed in section II.2). 
The mechanisms of CD31 shedding – in particular, the identity of the proteases responsible 
for the cleavage – have not been elucidated. Besides, most studies which report a decrease of 
CD31 surface expression in a given context have not looked for soluble CD31 fragments that could 
have been released. Thus, CD31 shedding is probably a much more common phenomenon than 
what might be inferred from the few cases that have been reported with certainty so far. 
A previous work from our laboratory, by Giulia Fornasa and colleagues (Fornasa et al. 2010), 
showed that, contrary to what previous studies had implied, CD31 does not completely disappear 
from the cell surface. Instead, it is shed and after its shedding, a CD31 fragment remains anchored 
to the membrane. The truncated CD31 that remains anchored to the cell includes the cytoplasmic 
domain, the transmembrane segment, and a portion of the extracellular domain consisting of a 
part of the membrane-proximal Ig-like domain 6. 
This observation paved the way for the use of synthetic CD31 peptides, targeting the 
membrane-proximal sequence of the extracellular domain, as bioactive molecules for the 
restoration of CD31 regulatory functions, as detailed in the following section. 
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II.4.b. CD31 agonist peptides 
Fifteen years before the work published by Fornasa and colleagues, Zehnder et al. (Zehnder 
et al. 1995) had discovered that a synthetic peptide, corresponding to the 23 most membrane-
proximal extracellular residues of CD31, was able to inhibit T cell proliferation in a mixed 
lymphocyte reaction, in a specific and dose-dependent manner. Surprisingly, this inhibition, 
which was known to be associated with CD31 engagement, was observed even on ‘CD31 low’ T 
cells. At the time, the authors hypothesized that the CD31 peptide had interacted with a 
heterotypic ligand. 
However, in light of the findings of Fornasa et al., the ‘CD31 low’ cells that were responding to 
the 23 aa synthetic peptide were indeed cells in which CD31 had been shed. This re-interpretation 
led to the proposal that the CD31 peptide had engaged in homophilic interactions with the 
remaining portion of the extracellular domain of CD31, as shown on Figure 12. This hypothesis 
was confirmed by the direct observation of the contacts between the CD31 peptide and the 
remaining portion of CD31 extracellular domain by TIRF microscopy (Fornasa et al. 2010). 
 
 
Thus, the cleavage site of CD31 shedding leaves an extracellular therapeutic target which can 
be used to restore CD31 regulatory functions thanks to a CD31-derived peptide. Such a peptide 
could be used for the promotion of CD31 functions in the various contexts where cell activation 
leads to CD31 shedding. 
In the years following this finding, our laboratory developed different CD31-derived peptides. 
An 8-residue long sequence, included in the original 23-residue long peptide, was finally chosen 
Figure 12. The CD31-derived peptide maintains a cluster of shed CD31. The homophilic engagement 
of the peptide with the remaining extracellular portion of the shed CD31 molecules stabilizes the CD31 
cluster. The signaling cascade of CD31, including the recruitment of SHPs, is maintained. 
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because it is highly conserved among species and because it showed high specificity towards 
CD31 in in vitro assays (unpublished work). Since it is known that dextrorotatory amino acids 
exhibit better stability against enzymatic degradation than the natural levorotatory enantiomers 
(Tugyi et al. 2005), the CD31 peptide was designed with D-amino acids. Thus, the peptidic 
sequence was assembled in reverse order so as to retain the original spatial orientation and the 
chirality of the side chains. The resulting peptide was named ‘P8RI’, where P stands for peptide, 
8 is the number of amino acids, and RI means retro-inverso. The sequence of P8RI is: 
(D-Lys)-(D-Trp)-(D-Pro)-(D-Ala)-(D-Leu)-(D-Phe)-(D-Val)-(D-Arg). 
The structure of P8RI is shown on Figure 13, along with that of the original, non-inverted 
sequence (called P8F).  
Figure 13. Representation of the structures of P8RI and P8F. ’P8F’ designates the original sequence 
from the CD31 molecule, in forward sense, whereas P8RI is the retro-inverso sequence, where both the 
order and the chirality of the residues are inversed. Drawings realized with the software Pepdraw. 
INTRODUCTION 
49 
III. Rationale of the thesis work 
Coronary stents and intracranial flow diverting stents were developed in the past decades for 
the endovascular treatment of two different arterial pathologies: coronary artery disease 
(stenosis of the artery) and intracranial aneurysms (enlargement of the artery). The working 
mechanisms of these devices is different but both are associated with complications stemming 
from biocompatibility issues. In particular, the rapid covering by endothelial cells presenting an 
anti-inflammatory and anti-thrombotic phenotype is key to the integration of the endoprosthesis 
at the blood/vessel interface. Thus, the implementation of solutions to improve their 
endothelialization and integration in the vessel wall would represent a major progress in their 
respective field. 
My thesis work deals with the immobilization of a bioactive molecule on these stents in order 
to solve their biocompatibility issues. We propose to use a peptide which promotes CD31 
regulatory functions: the inhibition of platelets and leukocytes activation, as well as the 
enhancement of endothelial cell survival, migration and barrier function.  
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IV. Stent coating with bioactive molecules 
The idea to coat medical devices such as stents with bioactive molecules is not new: the most 
common examples are drug eluting stents. However, the mechanism of action of a peptide such 
as P8RI differs from that of small-molecule drugs, and this must be taken into account in the 
design of the coating method. The first challenge thus consists in developing a process to 
immobilize this peptide, named P8RI, on the surface of metallic endoprostheses. 
 
IV.1. Elution vs immobilization 
All the drugs in current DESs are eluted. Most derive from sirolimus and target the mTOR 
pathway which regulates cell growth (Tsang et al. 2007). They aim at preventing restenosis by 
inhibiting SMC proliferation. For this application, it is highly desirable that the drug should diffuse 
in the tissue surrounding the stent struts, in order to increase its efficacy. Therefore, the current 
design of the DESs coatings, which allows the release of the drug over the course of a few months, 
is perfectly adapted to their needs. 
Our approach to the issue of stent biocompatibility is quite different, since we chose to 
promote the regulatory functions of CD31 in the cells that directly enter in contact with the stent. 
Thus, the CD31 coating would confer anti-thrombotic and anti-inflammatory properties to the 
surface, and, above all, it would promote the rapid formation of a functional endothelium on the 
stent struts. The CD31 agonist P8RI peptide is designed to achieve this goal by targeting the CD31 
sequence involved in the cis-homophilic engagement which naturally occurs when endothelial 
cells, leukocytes, or platelets enter in contact with each others, and which is essential for the 
intracellular CD31 signaling. 
Since our aim was to target the cells that directly contact the stent, the elution of the peptide 
did not fit our purpose. Instead, the biological mechanism of action of our bioactive molecule 
required its immobilization on the surface. Its anchoring needed to be strong enough to withstand 
in vivo flow conditions, which is why we chose to immobilize the peptide by covalent binding, 
rather than simple surface adsorption. Therefore, we designed a stent coating which would 
support the covalent immobilization of P8RI, rather than its elution. 
For optimal biological efficacy, P8RI should stay on the stents at least during the period 
needed for complete endothelialization. This period was estimated to be one week for BMSs in 
healthy farm pigs (Pérez de Prado et al. 2011), and a few months for BMSs in humans (Joner et al. 
2006).  
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IV.2. Polymer coatings 
IV.2.a. Usefulness and drawbacks of polymer coatings 
Coronary stents and FDSs are metallic devices, whose surfaces do not display the chemical 
functions required for the conjugation of biomolecules. Thus, their surface must be 
‘functionalized’ for the subsequent covalent immobilization of a bioactive molecule such as the 
P8RI peptide. A possible approach that allows the direct immobilization of the peptide on an alloy 
is the plasma-assisted surface functionalization, which was the subject of the first part of this 
study. However, the use of this technique on metallic surfaces is challenging, and alternative 
polymer-based solutions had to be considered. 
The use of polymer coatings as intermediate layers for the immobilization of bioactive 
molecules has several advantages. The first one is that, unlike almost all other types of materials, 
most polymers either contain functional groups that can react with bioactive molecules, or are 
easy to functionalize with such groups. The second one is that polymers are generally inexpensive 
and easy to process into coatings. Finally, there exists a very broad range of polymers, which 
allows for the fine-tuning of the chemical properties of the coatings. For these reasons, the use of 
polymer films is generally considered as an optimal solution for the immobilization of bioactive 
molecules and has been the preferred system in the design of coated stents. 
However, polymer films do have some limitations, especially in their application as 
biomaterials coating. Their adhesion to the metal, their resistance to stent deployment, and their 
stability properties must be adapted to the intended use, in order to prevent the deleterious 
biological effects of delamination (the detachment of the film from its substrate) and uncontrolled 
degradation. Above all, the biocompatibility of the polymer coatings and of their degradation 
products is key to the biological performances of coated stents. We kept these considerations in 
mind when we chose the intermediate layers that we used for the immobilization of the P8RI 
peptide. 
 
IV.2.b. Plasma-polymerized HMDSN 
The first coating that we developed in this study was plasma-polymerized 
hexamethyldisilazane (PP-HMDSN). Indeed, when it came to the choice of a precursor monomer 
for the atmospheric pressure plasma deposition system we used, we had to consider, besides the 
requirements outlined above, the compatibility of the precursor with our technique. In that 
regard, HMDSN had the advantage that its successful deposition by atmospheric pressure plasma 
had already been largely reported (Kim and Lee 1997; Gengenbach and Griesser 1999; Yang et al. 
2009; Hody et al. 2010). Moreover, it had been shown to exhibit appropriate adhesion properties 
in scratch tests (Kuo and Yang 2000; Nowling et al. 2005), and it was known to be compatible 
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with the culture of various types of cells (Li and Ho 2008; Krasteva et al. 2009; Radeva et al. 2009). 
PP-HMDSN thus appeared to fulfil the required conditions for its use as a biomaterials coating. 
 
IV.2.c. Polydopamine 
Polydopamine (PDA) is a bio-inspired, self-assembling polymer which was discovered in 
2007 by Messersmith and colleagues. This discovery originated from their investigations on the 
adhesive proteins of marine mussels. They found that the proteins that allow mussels to adhere 
strongly on any type of substrate are very rich in quinone and amine groups (Lee et al. 2006). 
This led them to study dopamine, a small molecule previously known for its biological role as a 
neurotransmitter, which combines an amine and a catechol group (which is converted into 
quinone by oxidation). They discovered that, when dissolved in an aqueous buffer at a slightly 
basic pH, dopamine self-polymerizes into a very adherent film, on various types of substrates. 
Besides, PDA exhibits latent reactivity towards amine and thiol groups, which makes it a very 
attractive substrate for bioactive molecule immobilization (Lee et al. 2007).  
PDA capitulates the outstanding adhesive properties of mussel adhesion proteins, as 
demonstrated by tape peel tests (Zhu and Edmondson 2011). This has led several groups to use 
it as an intermediate layer to improve the adhesion of other films (Ou et al. 2011; Beckford and 
Zou 2014; Sobocinski et al. 2014). Moreover, PDA coatings have been shown to be stable in 
aqueous medium for at least one month (Yang et al. 2012; Saidin et al. 2013). As for the 
biocompatibility properties of PDA, they appeared to be very adapted to its application as a stent 
coating application: it was shown to promote endothelial cell adhesion and proliferation, to 
decrease platelet adhesion and to reduce SMC proliferation (Ku et al. 2010; Yang et al. 2012; Luo 
et al. 2013b). 
For all these reasons, the final coating that we developed in this study for the immobilization 
of the P8RI peptide contained polydopamine as an intermediate layer. Indeed, since PDA seems 
an attractive choice for biomaterials coating, many research groups have proposed its use as an 
intermediate layer for stent coatings (Kim et al. 2009; Bae et al. 2012; Ding et al. 2014; Liu et al. 
2014; Sobocinski et al. 2014; Wang et al. 2014; Liu et al. 2015a; Song et al. 2015; Chen et al. 2016; 
Kim et al. 2016). 
 
IV.3. Coating techniques 
Polymer films can be deposited through a multitude of coating methods. The objective of this 
section is not to provide a comprehensive review of all the available techniques, but rather to 
present the coating techniques that were used in this study, and to outline the essential 
considerations that should be taken into account when developing a process for the deposition of 
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a polymer-based coating for an application in biomaterials. Reproducibility, scalability and 
limited cost are essential requirements for any process developed for an industrial application, 
and coating methods for medical devices are no exception. In addition, processes used in the 
manufacturing of medical devices need to be meet some extra criteria regarding the safety and 
sterility of the end product, stated by the authorities in the “Good Manufacturing Practices”. 
 
IV.3.a. Plasma-assisted treatments 
The first part of the experimental work conducted in this study concerned low-pressure and 
atmospheric-pressure cold plasma treatments. 
Plasma, often referred to as ‘the fourth state of matter’, is a gas medium in which part of the 
species are ionised. Most technological applications rely on ‘cold’, or ‘non-thermal’ plasmas, in 
which the temperature of the electrons is higher than that of the heavy species (neutral and ionic 
atoms and molecules). 
Cold plasma are obtained by applying an electric or electromagnetic field to a gas. This causes 
the ionisation of the gas and the acceleration of the resulting electrons. The plasma is 
characterized by a high number of collisions between the electrons and the heavy species, which 
essentially results in ionization, dissociation and excitation of the species. Excited species emit 
photons of different energies, from infrared to ultraviolet wavelengths. Since only a small part of 
the gas is ionized, the macroscopic temperature of the gas remains close to the ambient 
temperature, while many reactive species (free radicals, ions and excited atoms) are produced. 
These characteristics (low macroscopic temperature and generation of reactive species) 
make plasma processes well adapted to the deposition and the surface functionalization of 
polymers. 
The plasma-assisted deposition of polymer coatings is called ‘PECVD’ (plasma-enhanced 
chemical vapor deposition). It consists in generating a plasma, containing gaseous or nebulized 
monomers, above a substrate, in a reactor. The resulting polymer coatings generally exhibit high 
levels of cross-linking, low permeability and good adhesion on the substrate, compared with 
conventional wet polymerization techniques. 
The surface functionalization of substrates can be performed in a similar way, in the same 
reactors as those designed for PECVD, without the addition of monomers in the gas. 
Most cold plasma reactors operate at low pressure, and thus require closed chambers in order 
to establish a partial vacuum, but atmospheric-pressure cold plasma reactors also exist. These 
last ones involve much higher gas flows, but also shorter treatment times. As they do not operate 
under vacuum, cold plasma sources can even be integrated into continuous production processes. 
They are therefore of great interest for industrial surface treatment processes, including the 
coating of medical devices. 
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Both low-pressure and atmospheric-pressure cold plasma reactors have been used in the 
present study, for the surface functionalization or the coating of alloy substrates. 
 
IV.3.b. Polydopamine deposition 
The second type of coating process that we used was the self-polymerization of 
polydopamine, by dip-coating of the substrates in an aqueous medium. The extreme simplicity 
and versatility of this method are great advantages for its potential future applications in the 
coating of medical devices. 
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Objectives of the thesis work 
 
This thesis work is based on the hypothesis that a CD31-mimicking coating could improve the 
biocompatibility of two types of metallic stents (coronary and flow-diverting stents), regarding 
in particular the endothelialization of the stent struts, in terms of delay, extent, and of anti-
inflammatory and anti-thrombotic phenotype of the endothelial cells. 
To address this issue, we chose to use a synthetic peptide termed P8RI, which acts as a CD31 
agonist peptide, for the coating of the surface of stents. 
Thus, the first objective of this thesis work was to develop a process for the immobilization of 
P8RI on alloy surfaces. 
The second objective was to perform an in vitro assessment of the P8RI-coated surfaces, in 
terms of anti-thrombotic, anti-inflammatory, and, above all, pro-endothelialization properties. 
The third and last objective was the in vivo evaluation of P8RI-coated flow diverting stents 
and coronary stents, in two relevant animal models. 
 
 
  
  
 
 
 
 
 
Experimental work 
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I. Immobilization of the CD31 agonist peptide on alloy 
surfaces 
Different methods were evaluated in order to immobilize the P8RI peptide on the surface of 
metallic samples. The first ones were plasma-based techniques, as detailed in the following 
sections. 
 
I.1. Direct amination by low pressure plasma 
The first strategy that we tested in order to immobilize the P8RI peptide on CoCr alloy was 
the direct amination of the oxide surface, by means of an N2-H2 plasma. The amination would be 
followed by the binding of the COOH terminus of the P8RI peptide to the surface by carbodiimide 
chemistry, as sketched on Figure 14. EDC (1-ethyl-3-(-3-dimethylaminopropyl) carbodiimide 
hydrochloride) and s-NHS (N-hydroxysulfosuccinimide) would be used to perform the 
esterification of the peptide. This last reaction was chosen because it takes place in aqueous 
solution, at room temperature, it does not require any peptide modification and it is highly 
efficient (Hermanson 2013). Therefore, it is adapted to laboratory practice as well as future 
possible industrial scaling-up. 
 
Figure 14. Immobilization reaction of P8RI on an aminated alloy surface. The binding reaction takes 
place between the COOH terminus of P8RI and grafted amines on the alloy surface, by EDC/s-NHS 
carbodiimide chemistry. All chemical reaction diagrams were drawn using ChemSketch software. 
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This approach would result in the direct immobilization of the P8RI peptide on the alloy 
surface, without any intermediate polymeric layer. As there have been concerns about the 
biocompatibility of several polymers used in stents coatings (this will be further detailed in the 
discussion), the direct immobilization of P8RI appears as a very attractive solution. In addition, 
this should minimize the loss of the coated molecules during stent deployment. 
The other side of the coin is that the optimization of the direct amination process is 
necessarily substrate-dependent. In particular, this technique, if developed for the 
functionalization of L-605 CoCr alloy, might not be applied to FDSs made of nitinol. However, 
since the use of coronary stents made of CoCr L-605 alloy is by far more frequent that that of FDSs, 
we considered that it was worth evaluating extensively this approach, in spite of this limitation. 
 
The direct plasma amination of different polymers and carbon-based materials (for instance 
graphene or carbon nanotubes) has been performed by many research groups, and its 
mechanisms are partially known (Chevallier et al. 2001; Klages and Grishin 2008; Borris et al. 
2009; Lachmann et al. 2009; Sharma and Mutharasan 2012; Artemenko et al. 2015; Yang et al. 
2015; Motrescu and Nagatsu 2016; Alam et al. 2017). On the contrary, the literature on direct 
amination of metallic oxides is scarce (Wang et al. 2012; Ciolan et al. 2014), which made the 
empirical optimization of the plasma parameters all the more necessary. 
 
The first experiments of plasma amination of CoCr samples were performed with an 
inductively coupled low-pressure radio frequency plasma reactor (ICP-RF low-pressure plasma 
reactor). As can be seen on the schematic diagram of an ICP-RF reactor provided on Figure 15, 
the electric field necessary for the creation of the plasma derives from the magnetic field created 
by the RF current circulating in the coil that surrounds the reaction chamber. Contrary to the 
setup of capacitively coupled plasma reactors (CCP reactors), where the electric field is created 
between two electrodes inside the reactor, the ICP-RF setup has the advantage of preventing 
possible contaminations from electrodes inside the reactor chamber. 
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The ICP-RF plasma reactor that was used in this study was the FLR-300 model manufactured 
by Plasmionique. A picture of the reactor is shown on Figure 16. 
 
 
I.1.a. N2-H2 low-pressure plasma treatment increases the nitrogen 
content of CoCr samples but also introduces surface contaminations 
All the experiments were performed on polished CoCr L-605 disks, with a thickness of 250 
µm and a diameter of either 5 or 20 mm, purchased from Goodfellow Cambridge Ltd (UK). In 
Figure 15. Schematic drawing of an ICP-RF plasma reactor. 
Reproduced from Gao et al., 2009. 
Figure 16. Photograph of the ICP-RF low-pressure plasma reactor used in this study. A: general view. 
B: close-up of the reactor chamber with the plasma discharge on. 
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order to remove surface organic contaminants, the CoCr disks were systematically ultrasound 
cleaned in three successive 10-minute baths of acetone, ethanol and deionized water before 
further treatment. This cleaning process was applied before all the treatments presented in 
sections II and III. 
After the introduction of the CoCr samples in the reactor, the reactor chamber was purged 
under high vacuum (2 ± 1 x10-3 Pa) for 30 minutes. The first gas mixture was then introduced in 
the chamber and the operating frequency of the vacuum pump was adjusted in order to reach the 
desired pressure inside the chamber. Once the pressure and the composition of the outlet gas 
(monitored by mass spectrometry) were stabilized, the plasma discharge was started. 
When the plasma treatment involved two successive discharges with different gas mixtures, 
the previous step was repeated. 
After the last plasma discharge had ended, the reactor chamber was purged one last time 
under high vacuum. Nitrogen gas was then introduced in the chamber until atmospheric pressure 
was reached and the samples could be retrieved. 
Two types of plasma treatment were consecutively used: 
- a 50% argon, 50% dioxygen mixture was used to further clean the surface of the samples by 
physical and chemical etching, by removing organic contaminants in the form of gaseous H2O and 
CO2 (Choi et al. 2003). This type of discharge will be referred to below as “Ar-O2 pretreatment”.  
- a mixture of dinitrogen and dihydrogen gases in variable proportions was used for the 
amination process. This treatment will be designated hereafter as “N2-H2 treatment”. 
The parameters used for these treatments are listed in Table 2. 
 
 
Total gas flow 
rate 
Gases ratios Duration RF power Pressure 
Ar-O2 pretreatment 50 sccm 1:1 5 min 100 W 4.5 ± 0.5 Pa 
N2-H2 treatment 100 sccm 3:1 to 97:3 20 min 100 W 45 ± 5 Pa 
Table 2. Parameters used for the plasma treatments. sccm: standard cubic centimeters. 
 
Quantitative information on the chemical composition of the plasma-treated CoCr samples 
was obtained by X-ray Photoelectron Spectroscopy (XPS). In this technique, the sample is 
illuminated with monochromatic X-rays, which cause the atoms of the surface (top 1-10 nm) to 
emit core electrons (named “photoelectrons”). The kinetic energy of these photoelectrons is 
measured by a detector. The original binding energy of each photoelectron is easily deduced by 
the following formula: 𝐸௕௜௡ௗ௜௡௚ = 𝐸௑ି௥௔௬௦ − 𝐸௞௜௡௘௧௜௖ . A spectrum of the number of electrons 
detected versus the binding energy is thus obtained. The atomic composition of the sample is 
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determined by associating each peak of the spectrum with the corresponding atomic orbital. The 
relative quantity of the atoms is calculated by measuring the relative area of the peaks and 
correcting with atomic sensitivity factors. 
It is worth noting that XPS cannot detect hydrogen atoms, as they do not have core electrons 
when they form compounds.  
Information on the chemical bonds of the surface of the sample can also be obtained by 
analyzing the shape of specific atomic peaks on high-resolution spectra. Since the binding energy 
of the electrons slightly varies according to the chemical bonds the atom is involved in, atomic 
peaks can be separated in several components by deconvolution. The relative areas of the 
component peaks are correlated to the relative frequency of each type of chemical bond. An 
example of peak deconvolution is shown on Figure 17. 
XPS spectra were recorded on treated and untreated CoCr disks, using a PHI 5600-CI 
spectrometer (Physical Electronics). Survey spectra were acquired with a monochromatic 
aluminum X-ray source (300 W) whereas high-resolution spectra were recorded with a 
monochromatic magnesium X-ray source (300 W). The detection angle was set to 45°. The 
analysis was done on three spots per disk to assess the homogeneity of the coating. 
We analyzed the spectra with the software MultiPak (Physical Electronics). 
  
 
The surface atomic percentages calculated from the XPS spectra of the samples are presented 
on Table 3. As this XPS analysis was the first we performed on the CoCr disks, an “as received” 
sample (which had not been submitted to any cleaning procedure in our laboratory) was included 
as well as an ultrasound cleaned sample in order to assess the efficiency of the cleaning procedure 
and the original level of surface organic contamination of the disks. 
Figure 17. Example of deconvolution of an XPS high-resolution 
spectrum.  The C1s region is deconvoluted in three component 
peaks. The chemical bonds attributed to each peak are indicated. 
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CoCr sample O 1s C 1s N 1s Co 2p3 Cr 2p3 W 4f Zn 2p Si 2p F 1s 
As received 20.3 73.7 1.3 0.3 1.5 - 3.0 - - 
Ultrasound cleaned 38.6 50.1 2.3 2.3 4.1 - 2.7 - - 
N2-H2 plasma 
without Ar-O2 
pretreatment 
3% H2 40.2 28.2 1.8 6.3 7.7 - 1.6 6.2 7.9 
10% H2 41.8 28.4 2.8 3.6 7.6 - 4.5 6.4 5.0 
75% H2 39.8 28.7 5.5 4.6 6.7 - 3.7 5.5 5.5 
Ar-O2 pretreatment 48.5 21.7 0.9 9.8 2.7 - 4.5 7.2 4.7 
N2-H2 plasma 
after Ar-O2 
pretreatment 
3% H2 45.5 29.2 1.7 2.1 2.8 1.9 2.9 - 13.8 
10% H2 37.4 21.5 1.6 15.0 2.8 - 1.0 8.8 11.9 
75% H2 38.6 25.0 3.0 9.4 1.7 0.1 4.7 5.5 12.0 
Table 3. Surface atomic percentages of CoCr disks after different treatments. 
 
As Table 3 contains a great amount of qualitative and quantitative information, we will first 
discuss the nature of the detected elements, before focusing on some key quantitative values. 
Oxygen and carbon were detected on all samples. This is explained by the presence of metal 
oxides and (to a lesser extent) carbides, as well as residual surface organic contaminants. 
Nitrogen was also detected on all samples, including the ones that had not undergone N2-H2 
plasma treatment. On the untreated samples, nitrogen most probably originated from organic 
contaminants. Cobalt, chromium, and sometimes tungsten were identified, which was expected 
as these are the main elements that compose the L-605 CoCr alloy (see Table 4).  
 
Cobalt (Co) Chromium (Cr) Tungsten (W) Nickel (Ni) Iron (Fe) Manganese (Mn) 
50 20 15 10 3 2 
Table 4. Elemental composition of the L-605 CoCr alloy(in %). 
 
Unexpectedly, zinc, silicon and fluorine were detected in significant proportions (1-5% zinc, 
5-12% silicon and fluorine). The L-605 alloy does not contain zinc or fluorine, and contains only 
0.4% silicon, which cannot explain the detected amounts. Zinc was present on all samples, 
whereas silicon and fluorine were detected only on the samples that had been treated in the 
plasma reactor (either by Ar-O2 pretreatment or by N2-H2 treatment). Therefore, the most 
probable explanation was that zinc contaminated the surface of the samples during their 
manufacturing process (the disks had been cut out of L-605 sheets in a not particularly clean 
industrial workshop, probably using galvanized workbenches and tools), whereas silicon and 
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fluorine were adsorbed on the inner walls of the plasma reactor (silicon- and fluorine-containing 
precursor gases had been previously used in the reactor by other researchers) and had possibly 
contaminated the surface of the samples during the plasma treatments. 
The measures that were taken to eliminate these contaminations were the electropolishing 
of the samples (as detailed in I.2) and the cleaning of the low-pressure plasma reactor by 
prolonged Ar-O2 plasma discharge. 
With the quantitative information obtained from the XPS analysis, we focused on the two 
most significant values: 
- the nitrogen percentage, as it is of course correlated to the success of the amination process 
- the carbon/oxygen ratio, which is an indicator of the level of organic contamination, and 
thus of the efficiency of the cleaning procedure. 
These values are plotted on Figure 18. The “as received” disk exhibited a high C/O ratio 
(around 3.5), which was greatly decreased by the ultrasound cleaning, indicating the successful 
removal of most of the organic contaminants. Plasma treatments further eliminated organic 
contaminants, reducing the C/O ratio to about 0.6 with Ar-O2 pretreatment, and 0.7 without 
pretreatment. 
For both pretreated and not pretreated samples, the amount of nitrogen on the surface 
increased with increasing H2 content in the N2-H2 plasma discharge. Higher nitrogen percentages 
were obtained on not pretreated disks compared to the pretreated ones. This observation might 
be explained by the fact that the C/O ratio of pretreated disks is lower than that of the others, and 
that nitrogen bonding is most efficient on carbon atoms in organic compounds than on metal 
oxide. 
  
Figure 18. C/O ratio and nitrogen percentage of CoCr disks after different plasma treatments.  
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The highest measured nitrogen percentage was obtained after a 25% N2 - 75% H2 plasma 
discharge. It was more than twice as high as the nitrogen surface amount of the cleaned sample 
(5.5% against 2.3%), which proves that the plasma treatment successfully incorporated nitrogen 
compounds at the surface of the CoCr samples. However, the immobilization of the peptide on 
these surfaces by carbodiimide chemistry would be possible only if a significant part of the 
nitrogen atoms were under the form of amine functions. Deconvoluting high-resolution XPS 
spectra of the N1s region would give information on the chemical state of the nitrogen atoms. 
However, as shown on Figure 19, the signal/noise ratio of the high-resolution spectra of N1s 
peaks was too low to allow for a reliable deconvolution. Thus, the surface density of amine 
functions on plasma-treated CoCr samples could not be determined from this XPS analysis. 
After this experience, we used another method for the identification of amine functions on 
plasma-treated surfaces: derivatization, as detailed below in I.2. 
  
Despite repeated attempts to eliminate the residual contaminants from the walls of the 
reactor chamber by argon and oxygen-based plasma treatments, later XPS analyses of samples 
treated in the reactor still showed significant silicon and fluorine contaminations. These 
contaminations were a major obstacle for a reliable amination of CoCr samples in the FLR-300 
reactor. Thus, the decision was taken to stop the low-pressure plasma treatments with this 
reactor. This part of the work was pursued with a low-pressure microwave plasma reactor at the 
Laboratory for Biomaterials and Bioengineering (LBB, Université Laval, Québec City, Canada), 
where I later spent a two-month period as a visiting scientist during my PhD program, in the 
framework of a research collaboration. 
The direct plasma amination of CoCr samples in a low-pressure microwave plasma reactor 
was developed at the LBB by Sergio Díaz-Rodriguez, a PhD student under the supervision of Dr 
Figure 19. Representative high-resolution XPS spectra of nitrogen peaks on N2-H2 plasma-
treated CoCr samples. Left: Sample after 3% H2 – 97% N2 plasma treatment, without Ar-O2 
pretreatment. Right: Sample after 75% H2 – 25% N2 plasma treatment, without Ar-O2 
pretreatment. As the nitrogen percentage is low (a few percent), the spectra appear very noisy. 
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Pascale Chevallier and Pr Diego Mantovani, whose PhD work focuses on the surface treatments 
and uses P8RI as a model peptide. He subsequently immobilized a PEG (Polyethylene glycol) 
linker with two carboxylic acid extremities on the aminated surfaces and covalently bonded the 
P8RI peptide to the linker, by carbodiimide chemistry. I later undertook the in vitro and in vivo 
assessment of the biological properties of these surfaces covered with P8RI at the Laboratory for 
Vascular Translational Science. 
 In the meanwhile, I pursued the plasma amination approach in Paris using another type of 
reactor: an atmospheric-pressure plasma jet, as detailed in the following section. 
 
I.2. Direct amination by atmospheric pressure plasma  
In parallel with the experiments performed with the low-pressure ICP-RF reactor, N2-H2 
plasma treatments of CoCr samples were performed with an atmospheric-pressure plasma jet 
(APPJ). As can be seen on the schematic drawing presented on Figure 20, the samples treated by 
APPJ are not directly in contact with the plasma but only with the afterglow, a few centimeters 
away from the core of the plasma. As the afterglow carries the reactive species created in the 
plasma, this setup allows for the surface modification of all types of samples, including 
temperature-sensitive polymers. 
 
 
The main differences between APPJ and ICP-RF low pressure plasma reactors are the 
pressure at which the reactions occur (105 Pa against 1-100 Pa) and the gas flows involved (about 
40 L/min against 0.1 L/min). The power density of the discharge is also much lower, as the APPJ 
operates at about 700 W for 40 L/min, whereas the ICP-RF operates at 100 W for 0.1 L/min. In 
addition, the surface modifications of samples in an ICP-RF low-pressure reactor take place in a 
controlled atmosphere, in a closed reaction chamber, whereas, with an APPJ, the afterglow and 
the substrate surface are in contact with atmospheric air. Another important difference between 
Figure 20. Schematic drawing of the atmospheric-pressure plasma jet. 
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the two reactors is the area of the surface of contact between the plasma (or the afterglow) and 
the sample. In the ICP-RF reactor, the plasma covers the entire surface of the substrate holder 
(about 100 cm2), whereas the projected area of the afterglow of an APPJ is only a few square 
millimetres. Thus, the APPJ nozzle is mounted on a motorized xyz table, so that it can sweep the 
surface of the sample at constant speed in order to deliver a homogeneous treatment. Finally, 
since it operates at high flow rates and at atmospheric pressure, the APPJ treatment is much faster 
and more scalable than the low-pressure plasma treatment. A photograph of the atmospheric 
pressure plasma reactor used in this study, which was manufactured by AcXys Technologies, is 
shown on Figure 21. 
 
 
As the plasma is generated at atmospheric pressure and in contact with air, safety precautions 
have to be taken regarding the use of gases such as dioxygen (which is highly oxidizing) or 
dihydrogen (highly flammable). Thus, dioxygen and dihydrogen cannot be used in their pure form 
but only as diluted mixtures with inert gases. As the process generator was not yet suitable for 
argon discharges at the time of the experiments, Ar-O2 pretreatment was not performed with the 
APPJ. A dinitrogen-dihydrogen mixture containing 3% dihydrogen was used for the N2-H2 
treatments. This concentration ensured the safety of the experiments, since the lower 
flammability limit for hydrogen in air, with nitrogen as a diluent, is 5.7% at room temperature 
and atmospheric pressure (CHEMSAFE database). 
 
I.2.a. N2-H2 APPJ treatment increases the nitrogen content of CoCr 
samples with high variability 
As the first APPJ treatments were performed in parallel with the low-pressure plasma 
treatments exposed in the previous section, the CoCr disks used for both types of treatments were 
Figure 21. Photograph of the atmospheric-pressure plasma reactor.  
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submitted to the same cleaning procedure: ultrasound baths in different solvents, without 
electropolishing, as detailed in section II.1. After ultrasound cleaning, the CoCr disks were stuck 
on the motorized table with double-sided carbon tape. A small piece of tape was stuck in the 
centre of each sample, so that the surface of the tape would not be exposed and etched by the 
APPJ and thus contaminate the surface of the samples. 
In order to ensure that the plasma nozzle would sweep the whole surface of the sample at 
constant speed, its trajectory was defined in a zigzag pattern, as shown on Figure 22. The 
parameters used for the APPJ treatments are presented on Table 5. XPS spectra were recorded as 
detailed in the previous section. 
 
 
 
Gas flow rate N2:H2 ratio RF power 
Sample-surface 
distance 
Nozzle speed Number of passes 
45 L/min 97:3 600 W 10 mm 25-50 mm/s 1-6 
Table 5. Parameters of the plasma treatments performed by APPJ for the direct amination of CoCr 
samples. 
 
The surface atomic percentages calculated from the XPS spectra of the samples are presented 
on Table 6. As in the analysis of low-pressure plasma treated samples (I.1), oxygen, carbon and 
nitrogen were detected on all samples, as well as the main elements constitutive of the L-605 alloy 
(cobalt, chromium, and tungsten in lower proportions), and zinc, that had contaminated the 
samples during manufacturing processes. 
Silicon was also identified on three plasma-treated samples. This contamination most 
probably originated from silicon-based coatings previously deposited on the motorized table 
during experiments performed by other users of the APPJ reactor. A more careful cleaning of the 
motorized table was thus carried out before later experiments. 
Figure 22. Schematic diagram of the trajectory of the APPJ nozzle above a 20 mm diameter CoCr 
disk. The width of the zigzag pattern was adjusted so that the nozzle would sweep the sample’s surface at 
constant speed. 
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 O 1s C 1s N 1s Co 2p3 Cr 2p3 W 4f Zn 2p3 Si 2s 
Ultrasound cleaned 46.1 ± 1.4 36.4 ± 0.5 0.6 ± 0.6 7.2 ± 1.1 5.5 ± 0.9 - 4.3 ± 0.6 - 
N2-H2 
plasma 
treated 
50 mm/s - x1 49.4 ± 0.6 33.5 ± 0.5 1.3 ± 0.1 7.2 ± 1.0 5.6 ± 1.1 - 2.8 ± 0.2 - 
50 mm/s - x2 49.5 ± 2.0 34.1 ± 2.3 0.4 ± 0.7 6.8 ± 1.0 5.1 ±0.5 0.3 ± 0.5 2.2 ± 0.1 2.1 ± 2.0 
50 mm/s - x4 52.9 ± 0.8 25.4 ±2.2 2.7 ± 0.3 6.4 ± 0.6 2.2 ± 0.1 0.8 ± 0.1 1.0 ± 0.1 8.4 ± 0.5 
50 mm/s - x6 50.9 ± 3.1 28.7 ± 4.1 2.2 ± 0.6 8.9 ± 0.9 2.3 ± 0.5 0.5 ± 0.2 0.7 ± 0.0 5.9 ± 0.5 
25 mm/s - x1 55.4 ± 4.0 26.3 ± 6.8 1.6 ± 0.4 8.6 ± 3.5 5.6 ± 1.1 0.8 ± 0.1 1.7 ± 0.5 - 
25 mm/s - x2 53.9 ± 0.6 24.4 ± 2.1 2.1 ± 0.8 12.8 ± 0.8 4.1 ± 0.6 0.8 ± 0.2 1.8 ± 0.5 - 
Table 6. Surface atomic percentages of ultrasound cleaned CoCr disks, after different atmospheric-
pressure N2-H2 plasma treatments. For each plasma treated sample, the value in mm/s is the plasma 
nozzle displacement speed, while the value preceded by an “x” is the number of passes of the nozzle over 
the sample. Standard deviations were calculated between three measurement points for each sample. 
The nitrogen atomic percentages measured on the samples are plotted on Figure 23. There 
was a general increase of the nitrogen content on the plasma-treated samples, especially on the 
ones that had been submitted to the most intensive treatments (with the highest number of 
passes and lowest nozzle speed). However, no consistent trend was observed. This might be 
attributed to the variability of the initial organic and zinc contamination of the samples, as well 
as the silicon-based contaminations that occurred during the plasma treatments. 
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Figure 23. Nitrogen surface percentage of CoCr disks after different N2-H2 treatments by APPJ. The 
N2-H2 plasma treatment resulted in an increase of the nitrogen content of the surface on all samples but 
one. The variability between measurement points was high, and the influence of the number of passages of 
the plasma nozzle and of its displacement speed did not result in a consistent trend. Error bars: Standard 
deviations between three measurement points. 
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Overall, these first analyses revealed that the surface condition of the CoCr disks was not 
satisfactory, as significant amounts of contaminants were still present on the surface after the 
ultrasound cleaning procedure. Therefore, an electropolishing procedure was developed to 
provide a controlled surface status of the samples before the plasma treatments. 
 
I.2.b. An optimized electropolishing treatment removes the zinc 
contamination and smoothens the surface of the CoCr samples 
The development of the electropolishing procedure presented in this section was carried out 
during a research period at the Laboratory for Biomaterials and Bioengineering of the University 
of Laval, at Québec City (Canada). 
A schematic view of the electropolishing setup is presented on Figure 24. A. The metallic 
sample is integrated in an electric circuit as the anode, thus leading to the release of metal ions 
from the surface into an electrolyte solution, usually composed of a mixture of acids such as 
sulfuric and phosphoric acids. As protruding regions of the sample are submitted to a higher 
current density, the treated surface is smoothened, as illustrated on Figure 24. B. Controlled 
electropolishing thus results in the dissolution of the original oxide layer, and the formation of a 
smoother and cleaner oxide layer. However, an excessive applied voltage provokes an oxygen 
evolution reaction at the anode (2 H2O → O2 + 4 H+ + 4 e-), which causes pits of the anode surface 
(Watanabe 2004). 
 
The electropolishing protocol used is in this study was adapted from a protocol previously 
developed by other researchers at the Laboratory for Biomaterials and Bioengineering. The CoCr 
sample to be electropolished was ultrasound cleaned as previously described. After drying by 
Figure 24. Principle of electropolishing. A. Schematic view of the electropolishing system. B. Principle of 
surface smoothening by electropolishing. Image reproduced from the website of Cleaning Technologies 
Group. 
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medical grade compressed air, it was connected to the electric circuit by a crocodile clip. A similar 
CoCr disk was used as the cathode. Both disks were immersed in a beaker containing the 
electrolyte solution, surrounded by ice. The composition of the electrolyte solution is presented 
in Table 7. The electropolishing current intensity and duration was experimentally adjusted, as 
detailed below. At the end of each electropolishing cycle, the sample was extensively rinsed with 
deionized water. After the electropolishing treatment, three successive ultrasound baths in 
deionized water / NaOH 2N / deionized water were carried out in order to neutralize any 
remaining acid and rinse the surface of the sample. 
 
Component H3PO4 H2SO4 HF Glycerol Water 
Concentration (% v/v) 57  20 1.5 1 20.5 
Table 7. Composition of the electropolishing solution used in this study. 
The samples were analyzed by scanning electron microscopy, atomic force microscopy and 
XPS. Scanning electron microscopy (SEM) was carried out in Secondary Electrons mode, at 15 kV, 
on a JMS-35CF (JEOL). Atomic force microscopy (AFM) was performed in tapping mode on a 
DimensionTM 3100 (Digital Instrument). XPS spectra were recorded as detailed is section II.1. 
In order to obtain a smooth, mirror-bright surface, without pits, the electropolishing current 
intensity and duration were experimentally optimized. To that end, the treated samples were 
analyzed by visual inspection and scanning electron microscopy. An example of macroscopically 
damaged sample is provided on Figure 25, whereas the microscopic effects of moderate and 
excessively intense electropolishing are shown on Figure 26. 
 
 
 
Figure 25. Photograph of a CoCr disk after excessively intensive electropolishing (two 2-minute 
cycles at 9.4A). The surface appears mirror-bright, but the edges of the sample are visibly etched. The 
marks at the top of the image were produced by the crocodile clip that held the sample during the 
electropolishing process. 
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The optimal electropolishing treatment was found to be two cycles of 3 minutes, with a 
current intensity of 4 A. The samples treated with these parameters will be referred to simply as 
“electropolished” from now on. As shown on Figure 27, the surface of the samples after this 
treatment appeared flat, free from organic contaminants and scratching grooves, when observed 
by SEM. The inclusions that were revealed by the electropolishing are most probably chromium 
and tungsten carbides, which are known to form in L-605 alloy (Tiwari and Nordin 2014). 
 
Electropolished 
4 A, 2 x 3 min 
Electropolished 
9.4 A, 2 x 2 min Ultrasound cleaned 
A B C 
D E F 
Figure 26. SEM pictures of the edges of CoCr disks. A, B, C: Scale bar = 1 mm. D, E, F: Scale 
bar = 100 µm. Moderate electropolishing smoothens the surface and the edges (B, E), whereas 
excessively intense electropolishing roughens the edges (C, F). 
As received Ultrasound cleaned Electropolished 
Figure 27. SEM pictures of CoCr samples after different surface treatments. Scale bar = 100 µm. 
Scratching grooves are visible on the “as received” and ultrasound cleaned samples, as a result of the 
mechanical polishing performed by the manufacturer. Black streaks, identified as organic 
contaminants, are present in the grooves, in particular on the “as received” sample. The grain 
structure is weakly visible on the ultrasound cleaned sample, and indiscernible on the “as received” 
sample. On the electropolished sample, the surface appears perfectly flat and free from grooves and 
organic contaminants. The grain structure is revealed, as well as some inclusions. 
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The visual characterization of CoCr samples before and after electropolishing was completed 
by AFM analysis, as presented on Figure 28. The images taken by AFM at intermediate 
magnification (10 µm-wide pictures) are consistent with the observations made by SEM: the 
ultrasound cleaning removes most of the surface organic contaminants, and electropolishing 
flattens the surface by eliminating scratching grooves. Higher magnification (1 µm-wide images) 
reveals a change in the nanometric roughness of the samples after electropolishing. 
Finally, the surface chemical composition of an electropolished sample was analyzed by XPS. 
The resulting surface atomic percentages are presented on Table 8. Zinc was eliminated from the 
electropolished sample, and the cobalt/chromium ratio was modified. The presence of fluorine 
and sodium contamination (from hydrofluoric acid and sodium hydroxide respectively) on the 
electropolished samples points to the necessity of a more extensive rinsing. 
 
 O 1s C 1s N 1s Co 2p3 Cr 2p3 Zn 2p3 Na 1s F 1s 
Ultrasound 
cleaned 46.0 ± 0.5 35.5 ± 0.4 0.7 ± 0.9 7.1 ± 0.9 6.7 ± 0.9 3.9 ± 0.7 - - 
Electropolished 44.5 ± 3.3 32.7 ± 5.9 - 3.5 ± 0.6 10.1 ± 0.9 - 5.3 ± 1.5 3.7 ± 0.1 
Table 8. Surface atomic percentages of ultrasound cleaned and electropolished CoCr samples, 
measured from XPS spectra. Standard deviations were calculated between three measurement points for 
each sample. Electropolishing results in an elimination of the zinc surface contamination and an inversion 
of the Co/Cr ratio. The sodium and fluorine detected on the electropolished sample were adsorbed from 
the etching and neutralizing solutions. 
In conclusion, after optimization of the duration and current intensity of the process, 
electropolishing resulted in smooth, mirror-bright and zinc contamination-free CoCr samples. 
Thus, the subsequent plasma treatments were carried out on electropolished CoCr samples. 
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Figure 28. AFM pictures of CoCr disks. The “as received” sample appears covered with irregular particles, 
identified as organic contaminants. On the ultrasound cleaned samples, some irregular particles are also 
visible, but the grain boundaries are clearly revealed. The electropolished sample appears much flatter than 
the other ones at low magnification (on the 10 µm-wide images, the amplitude of altitude variation is 14 
nm for the electropolished sample against 59 and 86 nm for the other two samples). At higher magnification 
(on the 1 µm-wide picture), nanometric asperities are visible on the surface of the electropolished sample.
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I.2.c.  Derivatization provides no evidence of amines on the surface of 
CoCr disks after N2-H2 atmospheric pressure plasma treatment 
As detailed above, the first XPS analyses of CoCr samples treated by N2-H2 plasma with the 
APPJ reactor had shown an increase of the surface nitrogen concentration, depending on the 
nozzle speed and number of passes. In order to determine whether a significant proportion of 
this nitrogen was under the form of amines, we decided to carry out a more specific analysis of 
such samples: the derivatization of primary amines. Succinimidyl iodoacetate (SIA) was chosen 
because it fulfils the two requirements of a derivatization reactive: 
- as a succinimidyl ester, it reacts specifically with primary amines (Wong 1991) (reaction 
shown on Figure 29); 
- it contains iodine, an element which is absent from the surface of treated CoCr samples, and 
highly detectable by XPS (relative sensitivity factor: 20). 
Therefore, if iodine was detected on CoCr surfaces after SIA derivatization, it would 
demonstrate the presence of amines. 
 
 
An ultrasound cleaned, electropolished CoCr disk was treated by N2-H2 plasma with the APPJ 
reactor, as detailed on page 68. The plasma nozzle speed and number of passes that had resulted 
in the highest nitrogen concentration in the first experiments were selected (50 mm/s, 4 passes). 
Immediately after the plasma treatment, the sample was incubated for 2h in a 3 mg/mL 
solution of SIA, diluted in PBS with 1% DMSO, protected from light. It was then extensively rinsed 
with PBS. XPS spectra were recorded on the sample as detailed previously. Figure 30 presents the 
surface atomic percentages calculated from the XPS analysis of an electropolished sample and the 
sample which had been submitted to electropolishing, N2-H2 atmospheric-pressure plasma and 
SIA derivatization. On the derivatized sample, the nitrogen surface concentration was only 1.0%. 
Phosphorus and chlorine contaminations from the derivatization buffer were detected, but no 
iodine could be identified. Therefore, the derivatization procedure failed to evidence the presence 
of amines on the plasma-treated surface. 
Figure 29. Representation of the derivatization reaction between the SIA and the aminated CoCr 
surface. 
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Therefore, despite the great attractiveness of direct amination by APPJ in terms of process 
scalability, and, above all, as a means to avoid potential biocompatibility issues associated with 
the use of polymers, we did not pursue this approach. We switched to a more common approach: 
the use of an intermediary plasma-deposited polymeric coating, on which amines would be 
grafted by a second plasma treatment. This approach was considered to bear higher chances of 
success, since the amination of polymers is highly documented (Chevallier et al. 2001; Klages and 
Grishin 2008; Borris et al. 2009; Lachmann et al. 2009; Sharma and Mutharasan 2012; Artemenko 
et al. 2015; Yang et al. 2015; Motrescu and Nagatsu 2016). 
 
 
I.3. HMDSN film deposition by atmospheric pressure plasma 
As detailed in the introduction, hexamethyldisilazane (HMDSN, structure shown on Figure 
31) was chosen as the precursor for the plasma-deposited polymer for its compatibility with our 
deposition system and its reported biocompatibility and adhesion properties. 
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Figure 30. Surface atomic percentages of CoCr disks. “EP”: electropolished 
sample. “EP+N2-H2 plasma + SIA”: sample that had been submitted to 
electropolishing, N2-H2 atmospheric-pressure plasma and succinimidyl iodoacetate 
derivatization. Error bars: SD between three measurement points. No iodine was 
detected on the “EP+N2-H2 plasma +SIA” sample, meaning that the derivatization 
procedure failed to evidence the presence of amines on the plasma-treated surface. 
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Figure 31. Structure of the HMDSN molecule. 
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I.3.a. Characterization of the PP-HMDSN coatings 
The first depositions of atmospheric pressure plasma-polymerized HMDSN coatings (PP-
HMDSN) took place before the development of the electropolishing procedure. Therefore, the 
CoCr disks used for the deposition of PP-HMDSN were submitted to ultrasound cleaning, without 
electropolishing (procedure detailed in section II.1). The APPJ deposition was then performed as 
described in section II.2, with the addition of the HMDSN precursor being brought to the plasma 
nozzle by a carrier gas. Pure N2 was used both for the generation of the plasma and as the carrier 
gas. The parameters used for the HMDSN deposition by APPJ are presented on Table 9. 
 
Carrier gas 
(N2) flow 
rate 
Precursor 
(HMDSN) flow 
rate 
Total N2 
flow 
rate 
RF power 
Sample-
surface 
distance 
Nozzle 
speed 
Number of 
passes 
15 L/min 25-100 µL/min 50 L/min 550-800 W 10 mm 50 mm/s 3 
Table 9. Parameters used for the plasma-enhanced chemical vapor deposition of HMDSN by APPJ. 
 
XPS, SEM and AFM analyses of bare and coated CoCr disks were performed as described in 
the previous sections. The chemical composition of the PP-HMDSN coatings was analyzed by 
Fourier Transform Infrared (FTIR) spectroscopy. This technique relies on the principle that 
chemical bonds absorb infrared radiations at particular wavelengths, corresponding to 
vibrational transitions. In FTIR spectroscopy, a polychromatic infrared light goes through an 
interferometer and is then shone on the sample. After contacting the sample, the partially 
absorbed beam is directed to a detector, which records an interferogram. The interferogram is 
then converted to an absorbance spectrum as a function of wavelength by Fourier transform. The 
peaks in that spectrum give qualitative information on the chemical composition of the sample. 
There are different possible techniques to bring the infrared beam in contact with the sample 
and detect it afterwards. We used the most common one: Attenuated Total Reflectance (ATR). In 
this method, represented on Figure 32, infrared radiations go through a crystal with high 
refractive index and undergo a total internal reflection when they reach the crystal/sample 
interface. That creates an evanescent wave with a penetration depth on the order of the 
wavelength. In this way, absorbance from the top 1-10 micrometers of the sample is measured. 
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FTIR spectra were recorded on bare and coated CoCr disks, using a Cary 660 FTIR 
spectrometer (Agilent Technologies) equipped with a GladiATR module (Pike Technologies) with 
a diamond crystal. 
 
Representative pictures of a PP-HMDSN-coated CoCr disk, taken by SEM, are shown on Figure 
33. The coating appeared uniform at low magnification, and covered with round-shaped 
asperities at higher magnification. 
 
Figure 33. SEM pictures of PP-HMDSN-coated CoCr disk. (Deposition parameters: 550 W, 50 µl/min.) 
The coating appears homogeneous at low magnification (A, B). The underlying scratching grooves and grain 
boundaries are discernable (B, C). At higher magnification (C), asperities are visible on the surface of the 
coating. 
 
The AFM pictures (see Figure 34) were consistent with the observation of these spherical 
asperities. Other groups have reported the presence of such clusters (Grimoldi et al. 2009; 
Gonzalez-Macia et al. 2010) and have attributed their formation to the roughness of the 
underlying substrate, which would limit the lateral diffusion of the precursor (Grimoldi et al. 
2009). 
ATR crystal 
Sample 
Incident IR beam Reflected IR beam 
Evanescent wave 
Figure 32. ATR principle. IR: infrared. The incident IR beam undergoes multiple 
reflections at the sample-crystal interface between exiting the crystal. 
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Representative spectra of a bare CoCr disk and a PP-HMDSN-coated CoCr sample are shown 
on Figure 35. The attribution of the peaks was done in accordance with the literature on such 
coatings (Huang et al. 2010; Guruvenket et al. 2012; Ivashchenko et al. 2014). The main peaks 
corresponded to Si-O and Si-C peaks. There was no evidence of Si-N peak (which, if present, would 
be around 950 cm-1), suggesting that there had been no significant integration of nitrogen in the 
coating. No clear difference was observed between the FTIR spectra of CoCr samples on which 
HMDSN had been plasma polymerized with different deposition parameters (generator power, 
number of passes, nozzle speed, precursor flow rate). 
The absence of nitrogen was confirmed by the XPS analysis of several PP-HMDSN-coated CoCr 
disks (see Figure 36), which showed almost no nitrogen on the surface. No metal from the 
underlying substrate was detected, as expected from the uniformity of the coatings when 
observed by SEM or AFM. A high level of oxygen incorporation from the surrounding atmospheric 
air was observed. The silicon concentration remained constant with the variations of generator 
power and HMDSN flow rate. However, the oxygen/carbon ratio increased with increasing 
generator power/precursor flow rate ratio. Given that the HMDSN molecule does not contain 
oxygen atoms, this observation can be explained by the fact that, a higher power/precursor flow 
rate ratios, the dissociation of the HMDSN molecules is more complete, and therefore less carbon 
is integrated in the coating. 
 
Figure 34. AFM pictures of PP-HMDSN-coated CoCr disk. (Deposition parameters: 550 W, 50 µl/min.) 
Spherical asperities measuring a few tens of nanometers in diameter are visible on the coating. 
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Figure 35. Representative FTIR spectrum of a PP-HMDSN coating. Si-O is the preponderant peak. 
Si-C peaks are also clearly visible. The Si-N peak was not identifiable. 
Figure 36. Elemental composition of PP-HMDSN-coated CoCr disks. Left: surface atomic percentages. 
The legend indicates the generator power and the precursor flow rate used during the treatment. Right: 
oxygen/carbon ratio of the same samples, as a function of the generator power / precursor flow rate ratio. 
EXPERIMENTAL WORK 
82 
I.3.b. Thickness estimation of the PP-HMDSN coatings 
The thickness of the PP-HMDSN coatings deposited with an APPJ reactor, at the laboratory 
2PM, was not measured during this study. However, other researchers of this laboratory 
performed ellipsometry measurements on coatings deposited with the same reactor, but with a 
different precursor: tetraethyl orthosilicate (TEOS). The deposition rates of PP-HMDSN and PP-
TEOS coatings by atmospheric pressure RF plasma have been shown to be almost identical 
(Moravej and Hicks 2005). Thus, the thicknesses of PP-HMDSN and PP-TEOS coatings deposited 
in similar conditions can be expected to be very close. 
A comparison between the deposition parameters used for the PP-HMDSN coatings and the 
PP-TEOS coatings is presented on Table 10. The precursor flow rate and the nozzle sweep speed 
of the PP-TEOS were higher than that of the PP-HMDSN. An increase of the precursor flow rate 
resulted in increased deposition rates (Moravej and Hicks 2005), while an increase of the nozzle 
sweep speed resulted in a decreased residence time of the plasma, and thus a decreased 
deposition rate. Therefore, there are sound reasons to believe that the thickness measured on the 
PP-TEOS coatings is close to that of the PP-HMDSN coatings. 
The experimental ellipsometry measurements performed on PP-TEOS films yielded a 
thickness of 27±2 nm. This value can therefore be considered as a rough estimate of the thickness 
of PP-HMDSN films. 
 
Precursor 
HMDSN 
 
 
 
TEOS 
 
Precursor flow rate 25-100 µL/min 200 µL/min 
Nozzle sweep speed 50 mm/s 300 mm/s 
RF power 550-800 W 800 W 
Main gas N2, 35 L/min Air, 35 L/min 
Carrier gas N2, 15 L/min N2, 5 L/min 
Sample-surface distance 10 mm 10 mm 
Number of passes 3 3 
Table 10. Comparison between the parameters used for the deposition of the PP-HMDSN coatings 
presented in this thesis work, and the PP-TEOS coatings on which thickness measurements were 
performed by ellipsometry. Besides the nature of the precursor, the main differences are the precursor 
flow rate and the nozzle sweep speed. 
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However, it must be noted that ellipsometry can only provide an average value of the 
thickness. The observation of PP-HMDSN coatings by AFM (Figure 34) revealed the presence of 
irregular clusters of about 10 nm diameter on the surface, and the RMS roughness calculated from 
these images was approximatively 50 nm. 
In conclusion, the PP-HMDSN films can be considered to have a very rough profile, with an 
average thickness of the order of several tens of nanometers. This is much less than the typical 
thickness of polymeric coatings on stents, which range between 5 and 15 µm (Stefanini et al. 
2014). In the context of biomaterials coating, the thinness of the PP-HMDSN films can be 
considered as an advantage since it means that the total amount of PP-HMDSN present on the 
device is very small; thus, should the films release potentially toxic degradation products in vivo, 
the effects of these products would be limited by their minute quantity. 
 
I.3.c. The coating does not withstand 7 days of ageing test in flow 
conditions 
As the stability of the coating in aqueous medium is critical for its target in vivo application, it 
was assessed by an ageing test in flow conditions. The dynamic test bench is shown on Figure 37. 
It had been developed in the Laboratory for Biomaterials and Bioengineering specifically for the 
testing of degradable or coated samples in laminar, pseudo-arterial flow. 
 
 
Different types of ageing media were considered, as summarized in Table 11. The objective 
was to choose a medium comparable to blood (in which stents are placed in vivo) and free of 
compounds that would adsorb on the surface of the samples and distort the XPS analysis at the 
Figure 37. Schematic view of the dynamic test bench, from Lévesque et al. (2008) 
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end of the test. PBS was chosen, as it exhibits a physiological pH and contains no organic 
compounds, which means that it would not bring carbon or nitrogen to the coating. 
 
Liquid 
medium 
Isotonicity Physiological pH 
Absence of 
organic 
compounds 
Ionic composition 
close to that of 
human plasma 
Deionized 
water 
    
Normal 
saline 
    
PBS     
Pseudo-
phys. 
solutions 
    
      HBSS   Glucose  
      m-SBF   HEPES  
      DMEM 
  
HEPES, glucose, 
amino acids 
 
Table 11. Properties of the different liquid media considered for ageing tests.Normal saline: 0.9% 
NaCl in water. Pseudo-phys.: Pseudo-physiological. HBSS: Hank’s Balanced Salt Solution. m-SBF: modified 
Simulated Body Fluid. DMEM: Dulbecco’s Modified Eagle's Medium 
The dynamic ageing test was performed on two PP-HMDSN-coated CoCr disks (deposition 
parameters: 550 W, 50 µL/min), in two separate test benches. Each disk was fitted in a custom 
sample holder designed to expose its coated surface to the laminar flow. The test benches were 
filled with sterile PBS and placed in a thermostat bath at 37°C (human core body temperature) 
for one week. After the test, the disks were removed from their holders, thoroughly rinsed with 
deionized water, and dried with medical-grade compressed air. 
They were then examined by SEM, in Secondary Electrons mode, at 6 kV, on a JMS-35CF 
(JEOL). At the end of the seven-day ageing test, visual inspection of the coated samples showed 
that large areas of the surface were bared. This observation was confirmed by SEM, as shown on 
Figure 38: large delamination zones appeared. 
As the conclusion of the test was clear, XPS was finally not carried out on the samples. 
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The poor adhesion of the PP-HMDSN coatings in flow conditions can seem surprising, since 
the adhesion properties of these coatings on various substrates are generally considered as 
satisfactory, as demonstrated by scratch tests of low-pressure PP-HMDSN (Kuo and Yang 2000) 
and atmospheric-pressure PP-HMDSN (Nowling et al. 2005). A first remark to be made is that 
these tests are carried out on dry coatings. Thus, contrary to the dynamic test bench, they do not 
take into account the possible softening and swelling of the coatings upon exposure to aqueous 
media, which can favor delamination. Another important point is the surface condition of the 
substrates. The ageing test in flow conditions was performed on PP-HMDSN coatings that had 
been deposited on non electropolished coated samples. The substrates thus presented a rough 
surface, which is beneficial for the coatings adhesion (Amada and Hirose 1998), but also a poorly 
controlled chemical composition, due to surface contaminations (as shown above on Table 6). As 
the surface chemical properties of the substrate play a key role in film adhesion (Lewis 2009), 
electropolishing and plasma pretreatments could drastically improve the adhesion of the PP-
HMDSN coatings. Indeed, argon, dinitrogen and ammonia plasma pretreatments have been 
shown to increase adhesion of SiO2 films on stainless steel (Bertrand et al. 1998). Thus, further 
work on PP-HMDSN coatings for stent applications would first require an optimization of the 
substrates pretreatment.  
As the successful immobilization of the peptide was critical for the second part of the project 
(the assessment of the biological properties of the coated surfaces), it was decided to stop the 
optimization of the atmospheric pressure plasma processes, and to switch to a well-documented 
dip-coating process: the deposition of a polydopamine coating. 
In parallel, the work on the deposition of organosilicon precursors by APPJ was continued by 
other researchers at the laboratory 2PM. Thin films were deposited from (3-
Aminopropyl)trimethoxysilane (APTMS). XPS analyses of the chemical composition of these films 
1 mm 100 µm 20 µm 
Figure 38. SEM pictures of a PP-HMDSN-coated CoCr disk after a 7-day ageing test in flow 
conditions. Extensive delamination of the coating took place. 
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revealed that they were composed of approximately 6% of nitrogen. Derivatization recently 
showed that they contained a significant proportion of amine functions. Future work will tell 
whether these films can serve as an intermediate layer for the immobilization of bioactive 
molecules. 
 
I.4. Polydopamine-based coatings 
Based on the results of series of pilot studies exploring the opportunities and difficulties 
carried by the different tested approaches, we chose to pursue our work using the polydopamine-
based technique for the immobilization of the peptide on the stent surface. 
 
I.4.a. Polydopamine self-assembly 
The first step was the deposition of a self-assembled polydopamine layer on the L-605 CoCr 
samples. 
The CoCr disks used in the work presented in this section were different from the ones used 
for the plasma treatments. The dimensions of the disks were unchanged, but the new batch was 
made from mirror-polished L-605 sheets processed by the manufacturer (Goodfellow Cambridge 
Ltd), whereas the first batch had been cut into disks in an uncontrolled industrial workshop, from 
roughly polished sheets. Thus, the new CoCr disks were free of zinc contaminations, and 
presented a very flat surface. Therefore, the electropolishing procedure (which had been shown 
to introduce sodium and fluorine contaminations, see Table 8) was replaced with a simple acidic 
bath. 
 The CoCr disks were ultrasound cleaned in three successive 10-minute baths of acetone, 
ethanol and deionized water. This cleaning procedure ensured the removal of organic 
contaminants. They were then put in an acid bath (40% HNO3) for 40 minutes, in order to remove 
any ionic deposits from the alloy surface and to passivate it. After extensive washing with 
deionized water, the disks were sterilized by a 10-minute incubation in 70% ethanol. All 
subsequent steps were performed in sterile conditions, in a laminar flow hood. Solutions were 
filtered before use. The samples were rinsed several times with water, and, for the last wash, with 
the Tris buffer used for the dopamine solution. 
The following coating protocol was adapted from the work by Lee and colleagues (Lee et al. 
2007). A 2mg/mL dopamine solution was prepared just before use from lyophilized dopamine 
hydrochloride (Alfa Aesar A11136) dissolved in a 10 mM Tris-HCl aqueous buffer with a pH 
adjusted to 8.5. The solution was added to the wells of a sterile multi-well plate containing the 
individual experimental samples. The plate containing the samples and the dopamine solution 
was thereafter covered with a sterile lid and incubated at room temperature for 22 ± 2h, under 
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orbital shaking and protected from light. According to the literature (Lee et al. 2007), this 
incubation time results in a uniform coating, approximately 45 nm thick. The samples were then 
thoroughly rinsed with deionized water, placed in an ultrasound bath for 5 minutes in order to 
remove polydopamine aggregates from the surface, and further rinsed with deionized water. 
 
The chemical composition of the PDA (polydopamine) coating was analyzed by Fourier 
Transform Infrared (FTIR) spectroscopy. This technique has been described in section 0. 
Quantitative information on the elemental composition of the PDA coating was obtained by 
XPS (please refer to section 0 which for the description of this technique). XPS spectra were 
recorded on bare and PDA-coated CoCr disks, using a PHI 5600-CI spectrometer (Physical 
Electronics). Survey spectra were acquired with a monochromatic aluminum X-ray source 
(300 W) whereas high-resolution spectra were recorded with a monochromatic magnesium X-
ray source (300 W). The detection angle was set to 45°. The analysis was done on three spots per 
disk to assess the homogeneity of the coating. We analyzed the spectra with the software MultiPak 
(Physical Electronics). 
 
As reported in the literature (Lee et al. 2007; Zhu and Edmondson 2011), the dopamine 
solution is originally clear and turns light pink and finally black, as the polymerization process 
takes place and polydopamine aggregates form. The aspect of the solution after 22h of 
polymerization is displayed on Figure 39 A. PDA-coated CoCr disks also exhibit a dark brown 
color, as shown on Figure 39 B-C. 
 
FTIR spectra of bare and PDA-coated CoCr disks are presented on Figure 40. Several peaks 
and one band were found on the PDA spectrum and not on the bare CoCr spectrum. As shown by 
the annotations on the figure, they were all attributed to vibrations of chemical bonds that are 
A 
C 
B 
Figure 39. Photographs of dopamine solution and PDA. A. Dopamine solution after 22h of 
incubation. Polydopamine aggregates have formed in the solution, causing it to turn black. B. Bare 
CoCr disk. C. Polydopamine-coated CoCr disk, exhibiting a dark-brown surface. 
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present in polydopamine. Those attributions are in agreement with the literature (Xi et al. 2009; 
Yu et al. 2010; Zhou et al. 2011; Luo et al. 2013a) and evidence the successful deposition of a 
polydopamine coating on the disks. 
 
 
XPS survey spectra of bare and PDA-coated CoCr disks are shown on Figure 41, and the 
surface atomic percentages calculated from these spectra are presented on Table 12. On the bare 
samples, the main elements that compose the L-605 alloy were detected (chromium, cobalt, 
tungsten and nickel). The presence of oxygen and carbon can be explained by the presence of 
metal oxides and (to a lesser extent) carbides, as well as residual surface organic contaminants. 
On the PDA-coated disks, no metallic element was detected. That indicates that the PDA 
coating covered the surface in a uniform and complete manner. The only elements that were 
detected were oxygen, carbon and nitrogen, which compose the dopamine molecule. They were 
found in proportions close to those of the dopamine molecule (18% oxygen, 73% carbon, 9% 
nitrogen). These results therefore confirm the results obtained with the FTIR characterization. 
 
 
 
 
Figure 40. Representative FTIR spectra of bare and PDA-coated CoCr disks. The greyed areas of 
the PDA spectrum highlight the peaks and bands associated with the PDA coating. 
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 O 1s C 1s N 1s Cr 2p3 Co 2p3 W 4f Ni 2p3 
CoCr 44.3 ± 1.1 41.9 ± 0.8  10.4 ± 0.5 1.8 ± 0.2 1.4 ± 0.1 0.3 ± 0.3 
PDA 21.1 ± 0.3 71.1 ± 0.7 7.8 ± 0.5     
Table 12. Average surface atomic percentages of bare and PDA-coated CoCr disks. Standard deviation 
between three replicates. 
 
 
I.4.b. Direct immobilization of the peptide 
As detailed in the introduction, polydopamine coatings exhibit a latent reactivity towards 
amine and thiol functions. Therefore, covalent immobilization of amine-containing molecules, 
such as peptides, can be performed by simple incubation. The latter is the first method we used 
to bind P8RI on polydopamine-coated CoCr samples. The reaction is shown on Figure 42. 
Figure 41. XPS survey spectra of bare and PDA-coated CoCr disks. 
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P8RI binding was carried out on CoCr disks immediately after the polydopamine coating 
procedure, in a laminar flow hood. A solution containing 0.2 mg/mL P8RI (custom synthesis from 
Proteogenix) diluted in Tris buffer (10 mM Tris, pH adjusted to 8.5) was added to the wells 
containing the PDA-coated samples. They were left to incubate for 22 ± 2h under orbital shaking. 
They were then thoroughly rinsed with deionized water. This protocol was adapted from the 
work by Lee and colleagues previously cited (Lee et al. 2007). 
To assess the presence of P8RI on the samples after the binding procedure, we considered 
two analysis techniques: fluorescence microscopy and XPS. Fluorescence microscopy requires 
the use of a fluorescently labelled peptide. The insertion of a fluorescent tag is a common 
modification for custom-synthesized peptides. However, it must be noted that, given the small 
size of P8RI (molar mass: 1016 g/mol), the addition of a fluorophore such as FITC (Fluorescein 
isothiocyanate) or TAMRA (carboxytetramethylrhodamine), that have molar masses around 400 
g/mol, constitutes a significant modification of the molecule. XPS can be used either with 
unmodified or tagged peptide. As P8RI only contains elements that are also present in 
polydopamine (carbon, oxygen, nitrogen and hydrogen), the detection of unmodified P8RI 
immobilized on a PDA coating by XPS would not be straightforward. It would require the analysis 
of the ratios between elements and the deconvolution of atomic peaks in high resolution spectra, 
in order to identify amide bonds specific of the peptide. A more direct and accurate technique is 
provided by the use of P8RI with an “XPS tag”. This tag must be an element that is absent from 
polydopamine and the underlying CoCr substrate, and that has a high relative sensitivity factor 
so that it can be easily detected by XPS. Iodine fulfils both those requirements. In addition, it can 
easily be integrated in a peptide sequence, since some peptide manufacturers can use iodinated 
tyrosine amino acids, as shown on Figure 43. This peptide modification implies only a minor 
increase of the molecular mass, and, as the iodinated tyrosine can be inserted several residues 
Figure 42. Schematic representation of the binding of the peptide to the PDA coating. The reaction 
takes place between an o-quinone of the polydopamine and an amine of the peptide, by Schiff base 
reaction (left) or Michael addition (right). Figure adapted from Lynge et al. (2011) 
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away from the terminal amine, it should not interfere with the binding of the peptide to the PDA 
coating. Therefore, we opted for that method to detect the immobilized peptide with certainty 
and with minimal interference in the binding mechanism. 
We used a modified P8RI, in which the phenylalanine was replaced by a di-iodinated tyrosine 
(custom synthesized by Thermo Fisher Scientific), in the immobilization protocol described 
above, and later analyzed the surface by XPS, as detailed in I.4.a. The PDA-coated CoCr disks on 
which iodinated P8RI had been immobilized will be designated as “PDA + iodinated P8RI”. 
The surface atomic percentages measured by XPS on PDA-coated and “PDA + iodinated P8RI” 
CoCr disks are presented in Table 13. On the PDA-coated sample, the results were similar to those 
analyzed in I.4.a. On the “PDA + iodinated P8RI”, an increase in the relative quantity of nitrogen 
was noted, as expected after the immobilization of P8RI, which is richer in nitrogen than 
polydopamine is. A small percentage of iodine was detected, as evidenced on the survey spectra 
on Figure 44. Therefore, the immobilization of iodinated P8RI on the PDA coating was proven. 
 
Disk C 1s O 1s N 1s I 3d5 
PDA 72.9 20.3 6.8 0.0 
PDA + iodinated P8RI 72.3 19.1 8.2 0.5 
Table 13. Surface atomic percentages of coated CoCr disks. 
Figure 43. Unmodified and iodinated L-tyrosines. 
Figure 44. XPS survey spectra of PDA-coated and ‘PDA + iodinated P8RI’
CoCr disks. 
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Although the direct immobilization of P8RI on PDA coatings was successful, that method has 
two possible flaws. The first one is that, as the immobilization reaction takes place between the 
o-quinone functions of the surface and an amine function of the peptide, it could involve not only 
the terminal amine but also the amines present in the side chain of two amino acids in the P8RI 
sequence: lysine and arginine. As the pKa of these two side chain amines is significantly higher 
than that of the terminal amine (respectively 10.79 and 12.48 against 8.95), they are essentially 
in the protonated form at pH 8.5 (at which the immobilization reaction takes place), and thus 
much less susceptible to react, compared with the terminal amine. However, a small fraction of 
the soluble P8RI will bind by a side chain amine. This will modify its orientation in the space, 
making it potentially less prone to bind to the CD31 molecules exposed by the cells that come into 
contact with the coated surface. 
Another concern with this method is that the immobilization is performed directly between 
the PDA coating and the P8RI, which implies that some of the amino acids of the peptide are so 
close to the surface that they might be inaccessible for their putative ligand on contacting cells. 
Both these concerns were addressed with a second immobilization technique relying on the use 
of a linker, as detailed in the following section. 
 
I.4.c. Immobilization of the peptide with the help of a linker 
In order to better control the orientation of the immobilized P8RI and to render it readily 
accessible to its ligands at the surface of the cells contacting the coated surface, we used a flexible 
linker as an intermediary between the peptide and the PDA coating. The linker needed to have: 
1) either an amine or a thiol function at one extremity, to be able to react with the o-quinone 
functions of the polydopamine coating, 2) a flexible chain to improve the accessibility of the 
bound P8RI and 3) a function at the second extremity that would specifically bind to the peptide 
N-terminus. As regards that last point, we opted for a bioorthogonal reaction so as to avoid any 
interference from the side chains of the peptide and the amine functions of the polydopamine. We 
chose to use copper-free click chemistry, as it allows for a fast reaction in aqueous solution, 
without the addition of cytotoxic catalysts such as copper. 
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The two main types of copper-free click chemistry are strain-promoted azide-alkyne 
cycloaddition (SPAAC) and strain-promoted alkyne-nitrone cycloaddition (SPANC). They are 
represented on Figure 45. Numerous SPAAC and SPANC reactions have been described. However, 
they often involve the use of reactants that are difficult to synthesize, and thus not commercially 
available (Debets et al. 2011). In addition, as they are bioorthogonal, these reactions involve the 
use of a modified peptide, with one of the two chemical functions involved in the reaction added 
at the N-terminus. We searched the literature for an efficient reaction involving a commercially 
available linker and a peptide modification provided by our peptide manufacturer. We chose a 
SPAAC reaction with an azide on the peptide and a bicyclo[6.1.0]nonyne (BCN) on the linker, as 
described by Dommerholt and colleagues (2010). A “P8RI azide” was custom-synthesized, using 
a modified lysine with an azide instead of the side chain amine was introduced at the N-terminus 
of the peptide, and separated from the P8RI sequence by three glycines. The sequence of the “P8RI 
azide” was therefore: 
Lys(N3)-Gly-Gly-Gly-(D-Lys)-(D-Trp)-(D-Pro)-(D-Ala)-(D-Leu)-(D-Phe)-(D-Val)-(D-Arg). 
Concerning the linker, we opted for a short PEG chain between the BCN at one end and an 
amine at the other end. PEG was chosen for its high flexibility and biocompatibility. The resulting 
linker (Sigma 745073) will be called “BCN-amine” throughout this thesis. The two-step 
immobilization of the P8RI azide on the PDA coating through the BCN-amine linker is represented 
on Figure 46. 
 
Figure 45. Cycloaddition with azide (SPAAC) or nitrone (SPANC). Diagram 
from Dommerholt et al. (2010)  
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I.4.d. Immobilization of P8RI azide on PDA coatings with the help of the 
BCN-amine linker 
BCN-amine binding was carried out on CoCr disks immediately after the polydopamine 
coating procedure, in a laminar flow hood. A solution containing 0.1 mg/mL BCN-amine (Sigma 
745073) diluted in Tris buffer (10 mM Tris, pH adjusted to 8.5) was added to the wells containing 
the PDA-coated samples. They were incubated for 22 ± 2h under orbital shaking. After thorough 
rinsing with deionized water, a solution containing 0.2 mg/mL “P8RI azide” (custom synthesis, 
subcontracted to Proteogenix) in deionized water was added to the samples. The samples were 
thenthoroughly rinsed with deionized water. That protocol was adapted from the work by 
Messersmith’s group and van Delft’s group (Lee et al. 2007; Dommerholt et al. 2010) by Pierluigi 
Tosi at the Laboratory for Vascular Translational Science. 
As detailed in the previous section, three types of surface analysis were relevant for assessing 
the success of the immobilization of the peptide: fluorescence microscopy (with the use of a 
fluorescently tagged peptide), XPS with an untagged peptide and XPS with the use of an “XPS-
tagged” peptide. For practical reasons (lengthy delivery time of “XPS-tagged” peptides by the 
Figure 46. Linker-mediated immobilization of P8RI on PDA. A. Binding of the BCN-amine linker to 
the PDA coating by Schiff base reaction (left) or Michael addition (right). B. Binding of the peptide to the 
immobilized BCN-amine linker by click chemistry. 
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manufacturer), the latter could not be used. Fluorescence microscopy and XPS analysis of 
untagged peptide immobilized on the surface were thus performed. 
For the XPS analysis, unmodified “P8RI azide” was immobilized on CoCr disks as described 
above. The coated samples were then analyzed by XPS as detailed in I.4.a. Three points were 
analyzed on each sample. 
For the fluorescence microscopy analysis, a “P8RI azide” with an additional C-terminal lysine 
conjugated to a FITC fluorophore was custom synthesized by the manufacturer Proteogenix. The 
pseudo-peptidic sequence of that “P8RI-FITC azide” thus was:  
Lys(N3)-Gly-Gly-Gly-(D-Lys)-(D-Trp)-(D-Pro)-(D-Ala)-(D-Leu)-(D-Phe)-(D-Val)-(D-Arg)-Lys(FITC). 
The “P8RI-FITC azide” was immobilized on a BCN-amine linker on PDA-coated CoCr disks as 
described for the “P8RI azide”. The coated samples were then placed face down in imaging dishes 
to prepare their observation through an inverted microscope and covered with mounting 
medium (ProLong Gold Antifade Mountant, Thermo Fisher P36930). This medium has a 
refractive index close to that of the material through which the samples are observed (glass or 
plastic), so that light transmission is optimized. The ProLong Gold mounting medium also has 
antifading properties that minimize photobleaching, thus allowing the preservation of 
fluorescent samples for longer times. Digital photographs of the samples were acquired on an 
Axio Observer inverted fluorescence microscope (Zeiss), equipped with the software Zen (Zeiss). 
As shown on Figure 47, CoCr disks on which the “P8RI-FITC azide” had been immobilized 
(following the protocol described above) emitted a green fluorescence of much higher intensity 
than the PDA-coated disks. These results prove the presence of the fluorescent peptide at the 
surface of the disks after the immobilization protocol. 
Figure 47. Detection of the immobilized fluorescent P8RI by fluorescence 
microscopy. Fluorescence intensity histograms of photographs taken on coated CoCr disks. 
3 disks per condition.  
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The XPS analysis of the surface of coated CoCr disks revealed only the presence of the three 
elements nitrogen, oxygen and carbon on the three types of coating: PDA only, PDA + BCN-amine 
linker, PDA + linker + P8RI azide. This was consistent with the previous analyses of PDA coatings, 
which had appeared to be homogeneous. Atomic ratios of nitrogen and oxygen over carbon were 
calculated from the XPS spectra. They are presented in Table 14, along with the theoretical values 
of these ratios for the molecules involved in the coatings. A graphical representation is also 
provided on Figure 48 for greater clarity. The O/C ratio of the polydopamine samples is slightly 
higher, and the N/C ratio slightly lower, than the values of the pure dopamine molecule. The 
evolution of the ratios with the addition of the linker and the P8RI to the coatings follows the 
tendency of the theoretical values: a constant decrease of the O/C ratio, and a slight decrease 
followed by a larger increase of the N/C ratio. Therefore, these results point to the successful 
immobilization of the BCN-amine linker and of the P8RI azide. 
 
  
 O/C N/C 
Values measured by XPS 
on coated CoCr disks 
PDA 0.297 ± 0.007 0.111 ± 0.008 
PDA-linker 0.282 ± 0.003 0.106 ± 0.011 
PDA-linker-P8RI 0.254 ± 0.006 0.120 ± 0.007 
Values calculated from  
the molecular formulas 
Dopamine 0.250 0.125 
Linker 0.235 0.118 
P8RI azide 0.211 0.316 
Table 14. Theoretical and experimental elemental ratios of coatings. The ratios of surface atomic 
percentages of coated CoCr disks are derived from XPS analysis and are compared with the theoretical 
ratios of pure dopamine, BCN-amine linker and P8RI azide. Standard deviation between three replicates. 
Figure 48. O/C and N/C surface ratios of coated CoCr disks. Error bars: Standard deviation 
between three replicates. These ratios of surface atomic percentages were derived from XPS 
analysis. The decrease of the O/C ratio and the increase of the N/C ratio are a strong indicator of 
the presence of P8RI on the PDA-linker-P8RI coating. 
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I.4.e. Stability of the PDA-linker-P8RI coating in one-month ageing test 
in liquid medium 
In order to have its full effect in vivo, the “PDA-linker-P8RI” coating needs to maintain its 
integrity for the time necessary for stent endothelialization (about one week). The ageing 
behavior of the coating was assessed by an in vitro static ageing test in liquid medium. PBS was 
chosen as the liquid medium, for the same reasons as those explained in section I.4.e. Each CoCr 
disk was fitted in a custom sample holder designed to expose only its coated surface to PBS. The 
floating sample holder was placed in a beaker filled with PBS and stored in an incubator at 37°C 
(human core body temperature) for 1 or 4 weeks. Before the test, the beakers and sample holders 
were sterilized by autoclave to prevent bacterial proliferation during the study. The samples were 
manipulated in sterile conditions, under a laminar flow hood. After ageing, the disks were 
removed from their holders, thoroughly rinsed with deionized water, and dried with medical-
grade compressed air. They were then analyzed by XPS as detailed in section I.4.a. Three coated 
disks and one bare CoCr disk were tested for each time point (1 or 4 weeks).  
The ageing test was carried out by our collaborators Pascale Chevallier and Sergio Rodriguez-
Diaz, directed by professor Diego Mantovani at the Laboratory for Biomaterials and 
Bioengineering (Université Laval, Québec City). 
The surface atomic percentages of the coatings measured by XPS are presented on Figure 
49. A. The N/C ratio was considered as the most reliable indicator of the potential degradation of 
the coating since it is not influenced by oxidation or water adsorption on the coating. As shown 
on Figure 49. B, the N/C ratio of the “PDA-linker-P8RI” coating was unmodified after 4 weeks of 
ageing in PBS at 37°C, thus demonstrating that the coating did not undergo any significant 
degradation. 
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Figure 49. Elemental composition of PDA-linker-P8RI” coated samples after ageing in PBS. A. Surface 
atomic percentages. B. N/C ratio of the samples. Error bars: standard deviation over 3 replicates. 
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II. In vitro evaluation of the biocompatibility of P8RI-coated 
surfaces 
Note: For the sake of simplicity, in the subsequent section, ‘CoCr’ designates bare L-605 CoCr 
disks, ‘PDA’ means polydopamine-coated CoCr disks, and ‘P8RI’ are CoCr disks with a 
polydopamine-linker-P8RI coating. 
The concentration of P8RI used during the last step of the polydopamine-linker-P8RI coating 
process was chosen on the basis of a dose-effect curve obtained using 4-fold dilutions between 
6 and 200 µg/mL. In preliminary experiments, the concentration of 50 µg/mL yielded the least 
pro-inflammatory (as detected by the production of soluble IL-6 and VCAM-1) and the most anti-
thrombotic (based on the levels of soluble TFPI) phenotype of primary human endothelial cells 
cultured on the coated surfaces (see Figure 50). The method used for such analysis is detailed 
below, in section II.2. The concentration of 50 µg/mL was therefore used for coating the CoCr 
samples in the in vitro experiments presented in this section, and the stents in the preclinical 
studies presented in section III. The definitive choice for the development of the stents intended 
for clinical use shall be based on repeated in vitro experiments, using different endothelial cell 
donors. 
 
II.1. Hemocompatibility 
II.1.a. The bare and coated CoCr surfaces do not cause hemolysis 
The hemolysis assay is a required biocompatibility test for all blood-contacting devices. It 
shows whether a given material causes erythrocyte lysis (either by contact or by the release of 
toxic molecules). The hemolysis assay protocol we used was adapted from the one used by Bae 
and coworkers (Bae et al. 2012). It is sketched on Figure 51 and detailed below. 
Figure 50. Quantification of soluble molecules in the supernatants of endothelial cells cultured 
on coated CoCr samples. Different binding concentrations had been used for the immobilization of 
P8RI on the PDA-coated samples. A binding concentration of 50 µg/mL yielded a decrease in IL-6 and 
VCAM-1 production, and an increase in TFPI production, compared to the control (PDA coating without 
P8RI). 
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Coated and bare CoCr disks were placed in the wells of a 96-well plate and sterilized by a ten 
minute incubation in 70° ethanol. This common laboratory sterilization technique was chosen 
because the bactericidal properties of concentrated ethanol are well known, and its use does not 
induce chemical changes in peptides (Huebsch et al. 2005). The disks were rinsed several times 
in water prior to a final wash in physiological saline solution (0.9% NaCl). Human peripheral 
whole blood collected in lithium heparin (18 UI/mL) was then gently layered on each disk and 
the plate was incubated at 37°C during either 1h or 24h. Heparin was chosen for anticoagulation 
because it does not interfere with the hemolysis assays (Unger et al. 2007). 
Disk-free wells were used as negative controls and 1% Triton X-100 (which causes the lysis 
of most erythrocytes through the dissolution of their plasma cell membrane) was added in blood-
containing positive control wells. At the end of the incubation period, the blood was transferred 
from each well to an individual polypropylene tube (Eppendorf, 1.5ml) and centrifuged at 1200 
g for 15 minutes. 50 µL of platelet-poor plasma were collected at the top of all centrifuged tubes 
and transferred to a new 96-well plate. Absorbance was measured at 540 nm in a plate reader 
spectrophotometer (Infinite 200 PRO, TECAN). 540 nm corresponds to the absorbance peak of 
free hemoglobin, which is released by hemolysis from the erythrocytes. The value of the 
absorbance at 540 nm is therefore directly proportional to the extent of hemolysis caused by the 
sample disks in the experimental wells. 
The experiment was performed in technical quadruplicates and repeated three times using 
the blood of different healthy blood donors. 
 
A photograph of the microplate taken just before the measurement of the absorbance at the 
end of a hemolysis assay is shown on Figure 52. The platelet-poor plasma from whole blood 
incubated with Triton X-100 appears dark red, reflecting the effective hemolysis in these wells 
Figure 51. Visual summary of the protocol used for the hemolysis assay. 
Incubation at 37°C 
for 1h/24h 
Absorbance 
measurement 
at 540 nm 
1200g 
15 min 
96-well plate 
Coated/uncoated CoCr disks 
Negative control: no disk 
Positive control: 1% Triton X-100 
+ 
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(positive controls). No macroscopic difference in color is apparent between wells containing the 
negative control (No disk) and the three experimental groups of plasma. 
 
 
For each experiment, these observations were quantified by absorbance reading at 540 nm, 
and the measurements were normalized using the values obtained with the positive and negative 
controls, according to the following formula: 
R(x) = ୅ఱరబ౤ౣ(୶) ି ୅ఱరబ౤ౣ(୒୭ ୢ୧ୱ୩)
୅ఱరబ౤ౣ(୘୰୧୲୭୬)ି୅ఱరబ౤ౣ(୒୭ ୢ୧ୱ୩)
  
wherein R(x) is the normalized ratio of group x, and A540nm(x) is the average absorbance of 
the wells from group x. The measured ratios are presented on Figure 53. 
 
 
In the three experimental groups (blood incubated with the CoCr disks), after 1h or 24h or 
incubation, the hemolysis ratios were not significantly different from the negative controls. 
Therefore, we conclude that neither the bare CoCr surface nor the coated CoCr surfaces that 
we used were evidenced to cause hemolysis when contacted with human whole blood. 
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Figure 53. Hemolysis ratios after 1h or 24h incubation. No significant difference appear between the 
negative control and the bare and coated disks, after 1h or 24h of incubation.  
No disk 
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Figure 52. Photograph of a microplate filled with platelet-poor plasma at the end of a hemolysis 
assay. The positive control wells (‘Triton’) are the only ones which appear colored in red, as a result of 
hemoglobin release during hemolysis. 
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II.1.b. The “PDA+P8RI” coating tends to reduce platelet adhesion 
As thrombosis is one of the two main complications associated with stenting, evaluating the 
thrombogenicity of each novel stenting material is essential. To this aim, we performed a platelet 
adhesion assay, visually summarized on Figure 54. 
 
 
Coated and bare CoCr disks were incubated in 70° ethanol and rinsed, as detailed above. 
Human whole blood collected in PPack (75 mM PPACK + 0.1% D-mannitol, Haemtech SCAT-
875B) was then deposited on the disks and they were incubated at 37°C for 1h. PPack (Phe-Pro-
Arg-chloromethylketone) is a peptidomimetic thrombin inhibitor that inhibits the coagulation 
cascade without affecting the physiological concentration of ionized calcium. This is important in 
a functional test such as platelet adhesion, which is a Ca++ dependent process. At the end of the 
incubation period, the disks were taken out of the wells using delicate tweezers and rinsed by 
gently stirring in a beaker full of physiological saline solution at room temperature. They were 
then placed in a new 96-well microplate and rinsed twice in physiological saline solution, prior 
to fixation with paraformaldehyde. The disks were then processed for immunocytofluorescence. 
The general principle of this staining technique is illustrated on Figure 55. 
 
 
Figure 54. Visual summary of the platelet adhesion assay protocol. 
Epitope: small part of the antigen 
Primary antibody. Specifically binds to an epitope of the antigen 
Secondary antibody. Specifically binds to the constant fraction of the 
primary antibody 
Fluorophore covalently bound to the secondary antibody. 
Allows detection by fluorescence microscopy 
Figure 55. Principle of immunofluorescence 
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In order to visualize all adherent platelets, we chose to immunostain two antigens that are 
constitutively expressed by platelets: CD41 and von Willebrand Factor (vWF). CD41, also known 
as Integrin alpha-IIb, is the most abundant platelet adhesion receptor (Leclerc 2002), and is thus 
present on the surface of the platelets. vWF is a glycoprotein which plays a major role in blood 
coagulation (Peyvandi et al. 2011). As it is stored in intracellular compartments of platelets (the 
α-granules), its immunostaining requires the permeabilization of the platelet membrane. Since 
this “platelet adhesion assay” was performed with whole blood, leukocyte adhesion was also 
possible. Hoechst staining of cell nuclei was used to identify leukocytes (which, contrary to 
platelets, possess a cell nucleus). 
 
Designation Reference Concentration 
Bovine serum albumin  Jackson ImmunoResearch  001-000-173 5% m/v 
Fish gelatin  Sigma-Aldrich  F7041 0.1% m/v 
Mouse anti-human CD41  
primary antibody 
Beckman-Coulter  
IM045 2 µg/mL 
Rabbit anti-human vWF  
primary antibody 
Dako  
A0082 30 µg/mL 
Goat anti-mouse IgG, Cyanine3 
 secondary antibody 
Jackson ImmunoResearch 
 115-166-071 3.75 µg/mL 
Goat anti-rabbit IgG, Alexa Fluor 488 
secondary antibody 
Jackson ImmunoResearch  
111-546-046 3.75 µg/mL 
Hoechst 33342  Invitrogen H3570 10 µg/mL 
Prolong Gold Antifade Mountant Thermo Fisher P36930  
Table 15. Reagents used in the immunofluorescence protocol. 
 
The reagents used in the following protocol are presented on Table 15. The experimental 
samples were fixed in 4% paraformaldehyde at 4°C for 10 minutes, then rinsed 3 times in 
Dulbecco’s phosphate buffered saline (PBS). Fixation protects biological samples from decay by 
cross-linking the proteins. The samples were then permeabilized by a 10-minute incubation in a 
solution containing 100 mM glycine and 0.5% Triton X-100 in PBS. Triton X-100, being a non-
ionic detergent, creates pores in the cell membranes without denaturing proteins, while glycine 
EXPERIMENTAL WORK 
103 
was used to quench the formaldehyde. After PBS rinsing, blocking was then performed by a 30-
minute incubation in a solution of 5% bovine serum albumin and 0.1% fish gelatin in PBS, in order 
to reduce unspecific antibody binding, and thus decrease background noise. 
The two primary antibodies were diluted in a solution containing 1% bovin serum albumin 
(BSA) and 0.02% fish gelatin in PBS, and incubated overnight at 4°C with the samples. The 
samples were then rinsed with PBS and the secondary antibodies, diluted in a similar fashion, 
were added and incubated for 1 hour at room temperature. After PBS rinsing, the nuclei of the 
cells were stained by incubation in Hoechst solution. Finally, the samples were placed face down 
in imaging dishes (to prepare their observation by inverted microscope) and covered with 
Prolong Gold mounting medium. Digital photographs of the immunostained samples were then 
acquired on an Axio Observer inverted fluorescence microscope (Zeiss), equipped with the 
software Zen (Zeiss). The surface of the disks covered by platelets was identified by positive CD41 
and vWF staining and quantified on the digital images using the “Analyze particles” function of 
the open source software Fiji. 
The observation of the resulting photographs showed that very few leukocytes had adhered 
to the surface of the samples (where they were easily identified by their Hoechst positive nuclei). 
Representative photographs of immunostained samples are shown on Figure 56. Globally, the 
surface density of platelets (identified by positive CD41 and vWF staining) appeared lower on 
PDA than on bare CoCr, and even lower on “P8RI” disks as compared to the “PDA” ones. However, 
high variability can be noted between different disks of the same group, and this was reflected by 
the values obtained by computer-assisted quantification. Therefore, the significance of the 
differences observed between the experimental groups is questionable. The experiment was 
repeated several times, but, as intra-group variability was always high, no significant difference 
in the adhered platelets density was found between the three groups. 
It can be concluded from these experiments that the “PDA” and “P8RI” coatings do not 
increase but rather tend to reduce platelet adhesion on the surface of CoCr samples. 
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Figure 56. Fluorescence microscopy photographs of adherent platelets on CoCr disks.
A-C: CD41 in grey. Bar=100µm. D: Higher magnification photograph of a bare CoCr disk. CD41 in grey, 
von Willebrand factor in red. Bar=20 µm. E: Quantification of the disks surface coverage by platelets (in 
percents) based on photographs like A-C.  
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II.2. Endothelialization 
We sought to perform a functional evaluation of coronary artery endothelial cells upon their 
contact with the experimental (bare and coated) CoCr disks described before. Attachment and 
survival were evaluated by computer-assisted analysis of digital images after immunofluorescent 
staining whereas the pro-inflammatory and pro-thrombotic phenotypes were assessed through 
quantitative analysis of soluble biomarkers in cell culture supernatants. A sketch of the 
experimental protocol used in these studies is provided on Figure 57. 
 
 
For practical reasons, the first experiments were performed with human umbilical vein 
endothelial cells (HUVECs, from PromoCell). Human coronary artery endothelial cells from three 
different individual donors (HCAECs, purchased from Lonza) were then used, in order to better 
reproduce the environment of coronary stents. The cells were cultured in Endothelial cells 
Growth Medium MV2 (Promocell), which contained the nutrients and growth factors needed by 
ECs. Antibiotic, antifungal and antimycoplasma reagents (penicillin, streptomycin, 
amphotericin B, plasmocin and primocine) were added to the medium in order to prevent 
contaminations. The cells were used at passages 3 to 5. 
Coated and uncoated CoCr disks were placed in the wells of a 96-well plate and sterilized as 
described above. 100 000 endothelial cells suspended in their growth medium were seeded on 
each disk. After a 48h incubation at 37°C and 5% CO2, the cell culture supernatants were collected 
for multiplex assay analysis, while the adherent cells were processed for 
immunocytofluorescence. 
We chose to immunostain CD31 and VE-Cadherin, because these proteins clusters together at 
the adherens junction in functional endothelial monolayers (Lampugnani and Dejana 1997). 
CD31 is known to be truncated and miss the first, most membrane-distal, extracellular domains 
on stressed endothelial cells (Ilan and Madri 2003). Thus, to detect intact (functional) CD31 
molecules we used the mouse monoclonal antibody JC70A (Dako, #M0823) as this antibody 
Figure 57. Visual summary of the endothelial cell growth assay. ECs: endothelial cells. 
48h in a 
CO2 incubator 
Bioplex analysis 
Immunocytofluorescence 
Coated or uncoated 
CoCr disk 
ECs 
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typically fails to stain cells that express a truncated CD31 (Clement et al. 2015). The fact that a 
monoclonal antibody was available has possibly contributed to the success of this task. 
Unfortunately, the identification of VE-cadherin came out to be more difficult to standardize, 
likely due to the lack of a good monoclonal antibody. The use of the polyclonal antibody provided 
by Abcam (ref 33168) yielded good results in pilot experiments but the replacement vials we 
bought afterwards never gave satisfactory staining. 
 The staining protocol was the same as described in the previous section for adherent 
platelets, except that the permeabilization step was not performed, and that the following 
antibodies were used: 
- primary antibody: mouse anti-human CD31 (10 µg/mL, Dako M0823) 
- secondary antibody: goat anti-mouse IgG, A488 (5 µg/mL, Invitrogen A11029). 
The measure of pro-inflammatory and pro-coagulant endothelial biomarkers in the cell 
culture supernatants was achieved using a custom multiplexed cytometric bead assay (Luminex 
technology). The principle of the multiplex bead array assay is presented on Figure 58. Each bead 
contains two different types of fluorophores. This makes it possible to detect several types of 
beads in the same well: each type of bead is identified by different fluorescence intensities at two 
emission wavelengths. Each type of capture antibody is associated with one type of bead. The 
quantity of captured antigen on each bead is measured by the fluorescence intensity of the 
phycoerythrin (PE) bound to detection antibodies. Thus, the concentration of several antigens 
can be determined in the same well. 
 
Figure 58. Principle of the multiplex bead array assay. 
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In order to analyze the influence of “PDA” and “P8RI” coatings on the phenotype of cultivated 
endothelial cells, we quantified different types of soluble proteins produced by activated 
endothelial cells. A range of soluble molecules considered as markers of EC pro-inflammatory and 
pro-thrombotic phenotype were quantified in preliminary experiments. After discarding the ones 
that were present in undetectable amounts, we chose to focus on five proteins. IL-6, a pro-
inflammatory cytokine involved in lymphocyte growth and differentiation, acute phase reaction 
and fever, and IL-8, a chemokine that induces granulocytes migration and phagocytosis, but also 
promotes angiogenesis, are both known to be released by endothelial cells in response to 
inflammatory stimuli, such as LPS and TNFα (Chi et al. 2001; Oude Nijhuis et al. 2003). They were 
therefore selected as markers of EC pro-inflammatory phenotype. CD62E and VCAM-1 (Vascular 
Cell Adhesion Molecule-1) are transmembrane glycoproteins of the CAM (cell adhesion 
molecules) family and are responsible for leukocyte adhesion on ECs. Thus, they are not primarily 
expressed as soluble molecules. However, cytokine activated endothelial cells are known not only 
to exhibit increased surface expression of CD62E and VCAM-1, but also to produce soluble forms 
of these proteins, as a result of unidentified cleavage of shedding processes (Pigott et al. 1992; 
Constans and Conri 2006; Navasiolava et al. 2010). For this reason, CD62E and VCAM-1 were also 
chosen as markers of EC pro-inflammatory phenotype. The pro-thrombotic phenotype of the ECs 
was assessed by the quantification of PAI-1 (Plasminogen Activator Inhibitor-1), a serine 
protease inhibitor directed against tissue plasminogen activator (tPA) and urokinase (uPA). Since 
tPA and uPA activate plasminogen and are therefore the main initiators of fibrinolysis, the action 
of PAI-1 is pro-thrombotic. These five proteins were quantified in cell culture supernatants in 
several experiments, performed with cells from different donors. Each experiment included eight 
technical replicates. 
The endothelial cell culture supernatants were centrifuged at high speed in order to remove 
any dead cell and debris, then they were transferred to polypropylene 96-well plates, sealed and 
stored at - 80°C until the day of the assay. They were then thawed and diluted in staining buffer. 
The optimal concentration was determined according to previous experiments. The diluted 
supernatants were transferred to a flat-bottom 96-well plate containing a mix of the capture 
beads. A standard range was added to the same plate by serial dilution of standard solutions (Bio-
Rad), containing a known concentration of each antigen. The plate was incubated on an orbital 
shaker for 1h, in order for the capture antibodies to bind their antigens. The plate was then rinsed 
with wash buffer on an automatic wash station, which rinses the wells while holding the magnetic 
beads at the bottom of the wells. The biotinylated detection antibodies, diluted according to the 
manufacturer’s instructions, were then incubated with the beads for 30 minutes. Finally, after 
rinsing, streptavidin-PE was added to each well and incubated for 10 minutes, so that the 
streptavidin could bind to the detection antibody’s biotin. After a last rinsing step, the beads were 
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resuspended in assay buffer and analyzed on an assay reader (Bio-Plex 200, Bio-Rad). The 
statistical analysis of the results was performed with Kruskal-Wallis test. This nonparametric test 
was chosen as the number of replicates was too low to assess their Gaussian distribution, and 
hence to fulfill the conditions for an ANOVA test. Differences were considered significant for 
p<0.05. 
 
 
II.2.a. The “PDA + P8RI” coating favors rapid and functional 
endothelialization of CoCr surfaces 
Representative images of immunostained endothelial cells are presented on Figure 59. The 
major difference between the three groups is that the adhesion of endothelial cells appears much 
lesser on bare CoCr surfaces than on “PDA” and “P8RI” surfaces, since the ECs detached only from 
the bare surfaces. The “PDA” and “P8RI” coatings on experimental CoCr disks both allowed the 
formation of a functional confluent layer of endothelial cells, as evidenced by the distribution of 
CD31 at intercellular junctions. 
 
 
PDA 
B 
P8RI 
C 
CoCr 
A 
E F D 
Figure 59. Immunostained HCAEC after 2 days of culture on CoCr disks. Green: CD31. Blue: Hoechst.
A-C: low magnification (bar = 500 µm). D-F: higher magnification (bar = 100 µm). Pictures A and D show 
that the layer of endothelial cells was detached from bare CoCr disks during the process of 
immunostaining. This was not the case on “PDA” and “P8RI” disks. 
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II.2.b.  The “PDA + P8RI” coating tends to induce an anti-inflammatory 
and anti-thrombotic phenotype in endothelial cells 
As can be seen on Figure 60, the variability between the technical replicates of the multiplex 
assays was generally low, and clear differences between groups (cells cultivated on bare CoCr, 
“PDA” or “P8RI” surfaces) were found within one experiment. In particular, a tendency 
consistently appeared in IL-6, IL-8, CD62E and VCAM-1: concentrations on “PDA” were lower than 
on “CoCr”, and concentrations on “P8RI” lower than on “PDA”. This experiment thus suggested an 
anti-inflammatory effect of the PDA coating compared to bare CoCr, and a further effect of P8RI 
immobilization. 
 
 
 The synthesis of the results obtained from all cell culture supernatant analyses is 
presented on Figure 61. The multiplex assay was performed on five biological replicates 
(endothelial cells from five different donors). Each point on the graphs of Figure 61 represents 
the average of the technical replicates for one experiment. As in the experiment presented on 
Figure 60, the concentrations of IL-6, IL-8, CD62E and VCAM-1 are lower in the “PDA” and “P8RI” 
groups than in the “CoCr” group. An additional effect of P8RI immobilization is observed on IL-8, 
but also on PAI-1 concentrations, suggesting a slight anti-thrombotic effect of the P8RI coating. 
However, given the low number of replicates and high variability between experiments, the 
differences did not reach the statistical significance according to the Kruskal-Wallis test. 
Figure 60. Results of a multiplex assay analysis of cell culture supernatants from a 
representative experiment performed with HUVECs. Absolute concentrations (in pg/mL) are 
expressed. *: p<0.05. **: p<0.01. ***: p<0.001.
EXPERIMENTAL WORK 
110 
Therefore, the apparent anti-thrombotic and anti-inflammatory effects of “PDA” and “P8RI” 
coatings can only be expressed in terms of tendency. 
The same experiment was performed on CoCr disks on which P8RI had been immobilized on 
a PEG linker, after plasma functionalization of the surface, by our collaborators in Québec (as 
described in section I.1.a). The multiplex assay carried out on the supernatants of the HCAECs 
cultured on these disks gave similar results to the ones presented here. 
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Figure 61. Results of multiplex assay analyses of cell culture supernatants. Each point is a 
biological replicate. For each analyte and each experiment, concentrations were normalized with 
respect to “CoCr” group. 
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III. In vivo evaluation of the biocompatibility of P8RI-coated 
surfaces  
Bare and “PDA+P8RI”-coated coronary stents and FDSs were implanted in animal models in 
order to assess the effect of the coating on the stents’ in vivo environment. Large and medium 
animals (pigs and rabbits) were used for the implantation of coronary stents and FDSs 
respectively, since the arteries of these animals are large enough to be compatible with the size 
of stents designed for human use. 
We applied the coating strategy that we had developed to commercially available stents. The 
biocompatibility of the “PDA+P8RI” coating could hence be evaluated also in vivo, by comparing 
the performance of the “PDA+P8RI”-coated stents with that of the parent bare metal or active 
device, made of the same alloy. 
The Multilink BMS, made of CoCr, was suitable for both P8RI immobilization strategies 
developed during this study (the PDA-P8RI coating and the direct immobilization of P8RI on 
plasma-functionalized CoCr), whereas only the PDA-based strategy could be applied to the nitinol 
Silk FDS. Thus, BMSs (Multilink, Abbott) and DESs (Xience) were compared to “Plasma-P8RI” and 
“PDA-P8RI” coronary stents, whereas commercially available nitinol FDSs (Silk) were compared 
only to “PDA-P8RI” FDSs. 
P8RI-coated and control coronary stents were implanted in the coronary arteries of farm pigs, 
whereas P8RI-coated and control FDSs were implanted in the right carotid arteries of rabbits, 
after creation of elastase-induced saccular aneurysms. Due to the size of the target arteries in 
these animals, which are large enough to be compatible with the size of stents designed for human 
use, these models are widely used for the issue of in vivo stent biocompatibility (Schwartz et al. 
2008; Brinjikji et al. 2016). 
 
III.1. Implantation of coronary stents in farm pigs 
The primary objective of this first set of in vivo experiments was the evaluation of the effect 
of surface-immobilized P8RI on early stent strut endothelialization and on local inflammation. 
For this reason, the experimental and control stents were implanted in the three coronary 
arteries of healthy animals and the stented arteries were evaluated 7 days after stent 
implantation. According to a study by Pérez de Prado and colleagues (Pérez de Prado et al. 2011), 
this period is sufficient for the complete endothelialization of BMSs, but not DESs. Thus, it was 
deemed to be suitable for the comparison of the performances of BMSs, DESs, and P8RI-coated 
stents in vivo. 
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Four groups of Multilink (Abbott) stents, with different coatings, were implanted in the 
coronary arteries of 9 male farm pigs: bare metal stents (unmodified), everolimus-eluting stents 
(Xience, Abbott), “PDA-P8RI” stents (that had been coated with the PDA-based strategy) and 
“Plasma-P8RI” stents, on which P8RI had been immobilized on a PEG linker after plasma 
amination of the oxide surface. These last stents were prepared at the Laboratory for Biomaterials 
and Bioengineering (Québec) by the PhD student Sergio-Augustin Diaz Rodriguez, under the 
supervision of Dr Pascale Chevallier and Pr Diego Mantovani (as part of a research collaboration 
on the present project). 
The four groups of stents were sterilized by beta radiations (25 kGy) by Ionisos (Chaumesnil, 
France), a service provider. This sterilization technique was chosen because it was reported not 
to induce changes in irradiated proteins (Silva et al. 2004), contrary to the ethylene oxide 
sterilization technique that is commonly uses for the sterilization of commercial stents (Starbuck 
and Busch 1963; Pekkarinen et al. 2005; Dias et al. 2009). 
The protocol for the study of the coronary stents in farm pigs was in accordance with the 
Guide for the Care and Use of Laboratory Animals (National Institutes of Health 1985) and the 
European Directive 2010/63/EU, and was approved by the local ethic committee (Agence 
nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail, 14 rue Pierre 
et Marie Curie, 94701 Maisons-Alfort Cedex, n° APAFiS : 2017032116276884). The pigs were 
housed at the Centre de Recherche Biomédicale (CRBM) at the veterinary school of Alfort, where 
all the in vivo experiments were conducted by Dr Romain Gallet assisted by the chief of the 
experimental surgery animal department, Dr Alain Bizé, an by Lucine Sambin, in Bijan Ghaleh’s 
team. 
After a “pre-load” with ticagrelor (180mg) and aspirin (75mg) and an overnight fast, the 
animals were sedated, intubated (endotracheal intubation) and connected to a ventilator; 
anesthesia was maintained with gas anesthetics throughout the procedure. After administration 
of heparin (intravenous bolus, 5000 UI) and antibiotic prophylaxis, arterial access was obtained 
under sterile conditions by femoral or carotid artery cutdown. Thereafter, coronary angiography 
was performed to select the part of the coronary tree in which to leave the implant as previously 
described (van der Giessen et al. 1991). Briefly, on the basis of the angiograms, at least one 
segment, with a diameter of 2.5-3.0 mm, was selected (except when the anatomical 
characteristics of the animal did not allow it) in each of the three epicardial coronary arteries (left 
anterior interventricular, left circumflex artery and right coronary artery). The location of these 
arteries on the myocardium is shown on Figure 62. Thereafter, an angioplasty catheter with the 
stent crimped on its deflated balloon was advanced to the selected site for implantation over a 
standard guidewire. The balloon was inflated to a maximal pressure of 8 atm for 30 seconds, 
deflated, and slowly withdrawn, leaving the stent in place. A total of 5 to 9 stents per group were 
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implanted, in 2 to 3 animals per group. After repeated angiography of the stented coronary 
arteries to confirm patency, the arteriotomy was repaired, the skin closed, and the animals 
allowed to recover from anesthesia. Aspirin (75mg/day) and ticagrelor (90mg, twice a day) were 
pursued until the termination of the study. 
 
 
 
 
 
The stents were implanted under angiographic monitoring, as shown on Figure 63. Seven 
days after stent implantation, the animals were terminated under anesthesia. The stented arteries 
were explanted, thoroughly rinsed with PBS and fixed in 2.5% glutaraldehyde at 4°C for at least 
48h. Before being processed for scanning electron microscope (SEM) observation, they were cut 
longitudinally into halves, so as to expose their luminal side, as shown on Figure 64. As electron 
microscopes operate under vacuum, samples dehydration is indispensable. Just before imaging, 
they were washed in deionized water and dehydrated in ethanol baths of increasing 
Figure 62. Coronary arteries. The arteries in which stents were implanted 
are highlighted in bold characters. 
Figure 63. Angiograms of a stent implantation procedure. A. Visualization of the left coronary arteries 
by contrast agent injection. B. Stent deployment by balloon inflation. 
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concentration. They were then coated by gold sputtering. Metallization is a necessary step for 
biological samples imaging by SEM, as this technique requires an electrically conductive surface 
in order to avoid the accumulation of electrons on the surface. The metallized samples were then 
imaged with a scanning electron microscope in secondary electrons imaging mode. 
 
These experiments were performed very recently, and the quantitative analysis of the 
endothelialization on the stented arteries is currently ongoing. Figure 65 shows a representative 
example of SEM imaging of the luminal side of a circumflex artery implanted with a “PDA+P8RI”-
coated stent. The degree of stent strut endothelialization can be evaluated on pictures taken at 
intermediate magnification (see Figure 65B), and adherent leukocytes can be identified on high 
magnification images. On this “PDA+P8RI”-coated stent, the endothelialization appears complete, 
the density of adherent leukocytes is low and their appearance is spheric (non activated), and 
there are no thrombi. Similar features can be observed on the Plasma-P8RI stent shown in Figure 
66. 
At variance, the stent struts were so weakly covered by the endothelium in the case of the 
artery implanted with the DES that the metal structure readily got off the arterial wall at the time 
of SEM examination, as shown in Figure 67. Furthermore, the morphology of the endothelial cells 
was altered with loose junctions and the appearance of several microvesicles at their luminal side. 
The shape of the adherent leukocytes was spheric (non activated), in agreement with the 
immunosuppressive effect of the eluted drug (everolimus), but platelets and fibrin filaments were 
readily visible in these specimen (same figure), in spite of the double anti-platelet therapy 
administered to the pigs during the study period. 
The endothelialization was not an issue with BMSs, as shown in Figure 68, but there again 
striking differences could be detected in terms of platelet/fibrin deposition as compared to P8RI-
coated stents. Moreover, the shape of the leukocytes was granular and distorted by the presence 
of several pseudopods, suggesting an activated phenotype of the adherent leukocytes on these 
stents. 
  
Figure 64. Photograph of a stented porcine coronary artery.The luminal side is 
exposed by cutting the artery longitudinally after explantation. The stent struts are 
clearly visible to the naked eye. 
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Figure 66. SEM images of a “Plasma-P8RI” stent in a porcine coronary artery. A, B: lower 
magnification views. C, D: details of adherent cells. 
Figure 65. SEM images of a “PDA-P8RI” stent in a porcine coronary artery. A. Global view of the internal 
surface of the half-artery. The stent struts are clearly visible. B. Higher magnification view of stent struts. The 
struts endothelialization is complete. C-D. A few round-shaped adherent leukocytes can be seen. 
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Figure 68. SEM images of a bare metal stent in a porcine coronary artery. A, B: lower 
magnification views. C, D: details of adherent cells. 
Figure 67. SEM images of a drug eluting stent in a porcine coronary artery. A, B: lower 
magnification views. C, D: details of adherent cells. 
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These observations can be quantitatively assessed by image analysis on the different groups 
of stents, in terms of degree of stent strut endothelialization, platelet and fibrin deposits and 
leukocytes adherence and morphology. A custom computer program is being prepared and the 
analysis will be performed in the coming weeks. 
 
 
III.2. Implantation of flow diverting stents in a rabbit elastase 
aneurysm model  
In order to assess the effect of the “PDA+P8RI” coating on the performances of FDSs in terms 
of aneurysm occlusion and integration at the blood/vessel interface, we conducted in vivo 
experiments with bare and P8RI-coated FDSs, in a rabbit elastase aneurysm model. 
 
Figure 69. Creation of the rabbit elastase aneurysm model. Following exposure of the right carotid 
sheath and creation of a small arteriotomy, a sheath is introduced into the right common carotid artery. A 
balloon is introduced through the sheath and placed at the origin of the right common carotid artery and 
inflated. The right common carotid artery is ligated. Following this, elastase is introduced into the artery 
and allowed to incubate for 20 min. The sheath and balloon are then withdrawn and the superior aspect of 
the aneurysm is cinched off. The aneurysm continues to grow and then generally stabilizes at 1 month due 
to a combination of elastin digestion and hemodynamic forces. Figure reproduced from Brinjikji et al. 
(2016).  
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The FDSs used in this study were Silk stents, supplied by the manufacturer, Balt, who was a 
research partner, co-funded by the national agency for its participation to the present project 
(ANR Project IMPLANTS, ref ANR-14-CE17-0014) 
P8RI-coated Silk FDS stents were prepared following the procedure described in section I.4.d. 
and sterilized by beta radiations prior to their implantation in vivo. 
The rabbit elastase aneurysm is one of the most commonly used models for the testing of 
FDSs. As shown on Figure 69, it consists in creating an artificial aneurysm in the proximal segment 
of the right common carotid artery, by incubating elastase in the ligated artery for 20 minutes, so 
that this protease can hydrolyze elastin in the artery wall and promote its dilative remodeling. 
The aneurysm then grows over the course of a few weeks. Despite its extracranial location, this 
procedure results in a stable aneurysm with hemodynamic, morphological and histological 
features similar to those of human intracranial aneurysms (Sekhar and Heros 1981; Altes et al. 
2000; Short et al. 2001; Hoh et al. 2004; Brinjikji et al. 2016). 
All the in vivo experimental procedures described in this section were performed in our 
laboratory (Inserm U1148) by the interventional neuroradiologists Dr Aymeric Rouchaud and 
Dr Jildaz Caroff, who have practiced the rabbit saccular intracerebral aneurysm induced by 
elastase treatment under the supervision of Dr Laurent Spelle and run it routinely for research 
study purposes (Rouchaud et al. 2016b; Caroff et al. 2017). 
The elastase aneurysm model was run in three separate sets of experiments. The first two 
were run in the absence of anti-platelet treatment. The presence of a healing thrombus in the 
stented arteries of these series prevented the analysis of the luminal endothelialization. We 
therefore performed a third series of experiments for which we created the model in 8 male New 
Zealand rabbits. Three weeks after the creation of the aneurysms, unmodified (n=4) and P8RI-
coated (N=4) FDSs were implanted in the native right subclavian artery of each animal, so as to 
occlude the experimental saccular aneurysm. The SEM analysis was not suitable for the 
evaluation of the biocompatibility of the device in this model, due to the asymmetric positioning 
of the saccular aneurysm which prevented its longitudinal opening and observation on the 
luminal side. Thus, in two rabbits, an additional FDS was implanted further in the contralateral 
subclavian artery, in order to assess the integration of the devices in the vessel wall by scanning 
electron microscopy (SEM) observation of its luminal side. 
The animals were administered 75mg of aspirin daily and terminated 4 weeks after FDS 
implantation. This duration was chosen because it had been shown that the inflammatory 
reaction in aneurysms created with this model is stopped 4 weeks after endovascular treatment, 
thus resulting in an aneurysm filled with acellular connective tissue, resembling the stable 
aneurysms seen in humans (Dai et al. 2006; Brinjikji et al. 2016). Immediately after the sacrifice 
of each animal, the subclavian artery segment containing the FDS was explanted, together with 
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the aneurysm. The explanted arteries were then processed for histology. After paraformaldehyde 
fixation, they were dehydrated by successive incubations in ethanol baths of increasing 
concentration. Then, they were impregnated with a methyl methacrylate solution. Finally, the 
polymerization of the methyl methacrylate monomers was triggered by the addition of benzoyl 
peroxide and N, N-dimethyl-p-toluidine. 
 
 
This process resulted in the embedding of the explanted arteries in a poly(methyl 
methacrylate) (PMMA) resin, as shown on Figure 70. Although it is more complex than the usual 
histology techniques (paraffin embedding and cryosection), PMMA embedding is necessary for 
the sectioning of soft tissues, such as arteries, containing hard materials, like metallic stents. 
Indeed, the PMMA resin greatly decreases the difference in hardness between the stent struts and 
the surrounding tissue, which makes it possible to section the sample into thin slices without 
tearing off the tissue. 
The embedded arteries were then sectioned transversally in a microtome equipped with a 
tungsten carbide blade, which is harder than the steel blade used for the sectioning of usual 
paraffin-embedded tissues. The resulting histology slides were stained by Masson’s trichrome, 
which colors the connective tissues in blue, the cytoplasm in pink and the nuclei in purple. In 
order to better distinguish the smooth muscle cells, alpha-smooth muscle actin (αSMA) was 
stained by immunofluorescence in serial sections. 
The two extra FDSs which had been implanted in the subclavian arteries of the rabbits, 
distally from the aneurysm, were processed for SEM observation, as detailed in the previous 
section. The processing of the explanted arteries was performed by Guillaume Even, Marion 
Morvan and Christine Choqueux (all staff members at our laboratory). 
Figure 70. Photograph of an explanted stented artery embedded in PMMA. The arrow points to the 
aneurysm, which is occluded by the stent in the native artery. 
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At the present time, the imaging of the stained slides has just been achieved, and we have not 
yet completed the analysis of the results. Thus, the following observations should be considered 
as preliminary. 
Figure 71 shows SEM images of a P8RI-coated stent implanted in the contralateral, untouched 
subclavian artery of a rabbit, remotely from the aneurysm. Over its 4 week-period of 
implantation, the FDS has been entirely covered by neointimal growth, which yields the 
appearance of a velvet cover over the stent struts. A few adherent cells, identified as non-activated 
leukocytes because of their round shape, can be seen at the luminal surface of the vessel. 
Representative examples of the transversal resin sections of implanted bare and P8RI-coated 
stents, stained by Masson’s trichrome and immunofluorescence, are shown on Figure 72 and 
Figure 73 respectively. The struts of both types of stents have been covered by neointimal 
formation over the entire circumference of the vessel. However, the characteristics of the tissue 
that covers the stent struts strikingly differ with the type of stents. On the P8RI-coated stent the 
struts are way back in the arterial wall, covered by a thick, organized neointima, with layers of 
SMCs (see Figure 73 B and F) and oriented sheets of ECM, and exhibit a continuous endothelial 
monolayer (well visible on Figure 72 D and F). This organization is seen both in front of the 
aneurysmal neck and away from it. Contrastingly, on the bare stent, the struts are barely covered 
Figure 71. SEM images of a FDS implanted in the subclavian artery of a rabbit. The luminal 
side of the half-artery is shown. B, C, D are high magnification pictures of the region shown in A. 
1 month after implantation, the FDS is entirely covered with arterial tissue. A small number of 
adherent leukocytes, such as the ones shown in D, can be seen on pictures B and C. 
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by a thin neointima which appears poorly organized, devoid of SMCs (see Figure 73 A and E) and 
covered with a discontinuous endothelium (see Figure 72 C and E). The better organization and 
the presence of SMCs and a continuous endothelium on the neointima that covers the P8RI-coated 
stent constitute promising results, since the impermeability of the neointima covering the stent 
structure, especially in front of the aneurysmal neck, is key to successful aneurysm occlusion and 
stable arterial healing. Besides, the media of the aneurysmal wall (Figure 72 A and B) also appears 
less organized in the animal treated with a bare FDS, since it does not exhibit the layers of oriented 
SMCs seen in the other animal. Moreover, red blood cells and infiltrated leukocytes (identified by 
white and yellow arrows respectively on Figure 72 A) are visible in the aneurysmal wall of the 
animal treated with a bare FDS. Their presence indicates that neoangiogenesis and inflammation 
take place in the aneurysm wall, making it more susceptible to rupture. These phenomena are not 
seen in the aneurysmal wall of the animal treated with a “PDA-P8RI”-coated FDS. These 
observations thus represent another promising result. The careful examination of the images 
from the other animals of the same series will tell us whether these observations are consistent. 
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Figure 72. Histological sections of implanted FDSs stained with Masson’s trichrome. Blue: 
connective tissue. Pink: cytoplasm. Purple: nuclei. An: aneurysm. St: position of a stent strut. Left (A, 
C, E, G): bare FDS. Right (B, D, F, H): “PDA-P8RI”-coated FDS. A, B: detail of the aneurysmal wall. C, D: 
detail of the tissue surrounding the stent struts in front of the aneurysm. E, F: detail of the arterial
wall far from the aneurysm. G, H: global views of the sections. The white arrows highlight 
erythrocytes, identified by their pink color, small, round shape and absence of nucleus. The yellow 
arrows show infiltrated leukocytes, identified by their shape and their round nucleus. 
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Figure 73. Histological sections of implanted FDSs immunostained for αSMA. Blue: Hoechst staining 
(nuclei). Red: αSMA (SMCs). Green: self-fluorescence (connective tissue). Left (A, C, E): bare FDS. Right (B, 
D, F): “PDA+P8RI”-coated FDS. A, B: detail of the arterial wall far from the aneurysm. C, D: global views of 
the sections. E, F: detail of the tissue surrounding the stent struts in front of the aneurysm. The tissue that 
covers the stent struts on the “PDA+P8RI”-coated stent is rich in SMCs (B, F), contrary to that of the bare 
stent (A, E). 
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I. Strategic choices and characteristics of the P8RI coatings 
I.1. Direct binding of P8RI on the alloy or use of an intermediate 
layer? 
Concerns about the biocompatibility of stent polymer coatings have led to the recent 
development of polymer-free DESs: the Coroflex Isar stent manufactured by Braun and the 
Biofreedom by Biosensors, also sold under the name Lumeno Free by Cordis. On the Coroflex Isar 
stent, probucol is used as the drug matrix, whereas on the Biofreedom stent, the drug is adsorbed 
on the micro-structured surface of the stent. These approaches might be suitable for the 
controlled elution of drugs, but they do not allow the covalent and oriented grafting of bioactive 
molecules. 
In the present work, the immobilization of P8RI on alloy surfaces, in a covalent and oriented 
manner, was performed both with the use of an intermediate PDA layer, and directly on plasma-
aminated surfaces. The plasma-based method has the advantage of avoiding all polymer-related 
issues, but possesses neither the versatility of the PDA-based approach (since the plasma-assisted 
treatment of alloy surfaces is strongly dependent on the physico-chemical characteristics of the 
oxide layer (Lewis et al. 2011)) nor the scalability of a dip-coating process. Indeed, low-pressure 
plasma functionalization, contrary to the atmospheric-pressure treatments that we attempted to 
develop, requires the use of vacuum, which implies high maintenance and relatively expensive 
processes, and is therefore a hindrance for the potential industrial application of this method. 
Thus, both the PDA-based and the plasma-based immobilization approaches have their 
strengths, but, considering the technical conditions of both strategies, we believe that the PDA-
based approach is more reliable and suitable for a potential development on an industrial scale. 
 
I.2. Why choose PDA rather than polymers already used for 
stents? 
When it comes to the choice of a polymeric interface for the immobilization of bioactive 
molecules (such as P8RI) on stents, one could think that the most obvious options are the 
polymers already used in the coatings of commercially available stents. They have the advantage 
of having already been accepted for this use by the competent authorities (by FDA approval or CE 
marking), and they have presumably been selected for their satisfactory adhesion and 
biocompatibility properties. 
However, there have been concerns about the biocompatibility of polymer coatings used in 
stents. Table 16 shows the polymers used for the coatings of drug-eluting stents reimbursed by 
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the French social security system. The non-degradable polymer coatings of first-generation DESs 
(Cypher and Taxus) were suspected to induce late neointimal hyperplasia (Carter et al. 2004), 
local inflammatory reactions (Virmani et al. 2004) and late stent thrombosis (McFadden et al. 
2004; Virmani et al. 2004). 
 
Inscription 
date Manufacturer Model Alloy Coating Drug Matrix Drug 
2003 Cordis Cypher 316L St. st. Parylene C PEVA + PBMA Sirolimus 
2004 Boston Scientific Taxus St. st. - SIBS Paclitaxel 
2006 Medtronic Endeavor MP35N CoCr - PC-based polymer Zotarolimus 
2008 Abbott/ Boston Scientific Xience V/ Promus L-605 CoCr PBMA PVDF-HFP Everolimus 
2010 Biosensors Biomatrix 316L St. st. - PLA Biolimus A9 
2010 Boston Scientific Promus  Element PtCr PBMA PVDF-HFP Everolimus 
2010 Terumo Nobori 316L St. St. Parylene C PLA Biolimus A9 
2011 Medtronic Resolute Integrity MP35N CoCr - 
Mix of PBMA, 
PHMA, PVP, 
PVA Zotarolimus 
2014 Biotronik Orsiro L-605 CoCr a-SiC:H PLA Sirolimus 
2015 Boston Scientific Synergy PtCr - PLGA Everolimus 
2015 Braun Coroflex Isar L-605 CoCr - - Sirolimus + Probucol 
2015 CID Vascular Cre8 L-605 CoCr Carbon Sirolimus + fatty acids Sirolimus 
2015 Terumo Ultimaster L-605 CoCr - PLCL Sirolimus 
2016 Translumina Yukon Choice PC 316L St. St. - PLA + shellac Sirolimus 
2017 Balton Bioss Lim C L-605 CoCr - PLGA Sirolimus 
2017 Biosensors/ Cordis Biofreedom/ Lumeno Free 316L St. st. - - Biolimus A9 
2017 Cordis Lumeno  Alpha CoCr - PLA Biolimus A9 
Table 16. Drug-eluting stents included in the list of products reimbursed by the French social 
security system.Similar models of the same line (e.g.: Xience V and Xience Alpine) have been omitted. St. 
st.: stainless steel. PtCr: Platinum-chromium alloy. PBMA: poly (n-butyl methacrylate). a-SiC:H: amorphous 
silicon carbide. PEVA: poly (ethylene-vinyl acetate). SIBS: poly(styrene-b-isobutylene-b-styrene). PC: 
phosphorylcoline. PVDF-HFP: poly(vinylidenefluoride-co-hexafluoropropylene). PLA: poly(lactic acid). 
PHMA: poly(hexylmethacrylate). PVP: polyvinylpyrrolidone. PVA: poly(vinyl alcohol). PLGA: poly(lactic-
co-glycolic acid). PLCL: poly(DL-lactide-co-caprolactone). 
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As a consequence, a second generation of DESs (which eluted everolimus, zotarolimus and 
Biolimus A9 instead of sirolimus) was developed with different polymers. In particular, most 
recent DESs are coated with biodegradable polymers (pure poly-L-lactic acid or lactic acid-based 
copolymers), which are supposed to reduce the incidence of late thrombosis and restenosis. Yet, 
correlations between several biodegradable polymers and inflammatory reactions have been 
shown (Giessen et al. 1996; Lincoff et al. 1997), and, at this time, biodegradable polymer DESs 
have not demonstrated a clinical improvement compared to durable polymer DESs (Bundhun et 
al. 2017; Kalra et al. 2017). Thus, the search for more biocompatible polymers for stent coatings 
is not over yet. In this regard, PDA appears as a promising candidate. Our results, as well as those 
of other groups (Ku et al. 2010; Yang et al. 2012; Luo et al. 2013b), demonstrate that PDA coatings 
promote endothelial cell adhesion and proliferation and decrease platelet adhesion, and Huang’s 
group showed that PDA reduced SMCs proliferation (Yang et al. 2012). Long-term in vivo studies 
are necessary to determine whether PDA-coated stents – and “PDA+P8RI”-coated stents – can 
decrease the incidence of late adverse events (thrombosis and restenosis) compared to existing 
stents polymeric coatings. 
 
I.3. Choice of the strategy for the immobilization of P8RI on PDA  
Ever since the first article on dopamine self-polymerization (Lee et al. 2007), PDA coatings 
have been used as an intermediate layer for the immobilization of numerous bioactive molecules. 
Most research groups have chosen the most direct possible method: a simple incubation of the 
PDA-coated substrates in a solution containing the molecules of interest. The covalent grafting of 
the molecules takes place thanks to the latent reactivity of PDA towards amines and thiols. Such 
an approach was used for the immobilization of bioactive molecules of various types: proteins 
(e.g. trypsin (Lee et al. 2009)), glycosaminoglycans (e.g. hyaluronic acid (Wu et al. 2016)), 
peptides (e.g. bivalirudin (Lu et al. 2012)), very small molecules (e.g. cystamine (Zhou et al. 
2011)) and nanoparticles (e.g. VEGF-loaded heparin/poly-L-lysine nanoparticles (Liu et al. 
2015b)). This is the method we first adopted for the immobilization of the P8RI peptide. Its 
extreme simplicity makes it low-cost and easily scalable, while ensuring a strong anchoring of the 
peptide to the coating through covalent bonding. 
However, in order to better control the orientation of the grafted bioactive molecules and to 
make them more accessible to contacting cells, other studies have chosen to add a linker between 
the PDA coating and the immobilized molecule. Chen and colleagues (Chen et al. 2015a) grafted 
staphylococcal protein A on PDA before immobilizing anti-CD34 antibodies on the proteins, 
through their Fc constant region. Yuan and colleagues (Yuan et al. 2013) used a more 
conventional bifunctional linker for the grafting of chitosan: glutaraldehyde. In the present study, 
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we used a linker which combined the reaction efficiency and bioorthogonality of copper-free click 
chemistry with the availability and affordability of common commercial bifunctional linkers: the 
BCN-amine linker presented on Figure 46. 
A third option exists for the immobilization of bioactive molecules on PDA coatings: the 
copolymerization of the molecules of interest with dopamine. The codeposition of dopamine and 
heparin, phosphorylcholine-based polymer or PEGylated poly(ethyleneimine) have been 
reported (Bae et al. 2012; Yao et al. 2012; Sin et al. 2016). However, this method does not allow 
the control of the orientation of the grafted molecules. Besides, it involves the use of much larger 
quantities of bioactive molecules than the surface immobilization techniques presented above. 
Therefore, it is better adapted to relatively inexpensive glycosaminoglycans or polymers than to 
proteins or peptides. Thus, this method was not considered fit for the present study.  
 
I.4. Importance of the thickness of the coating in the “PDA-P8RI” 
strategy 
During this project, we have not measured the thickness of the PDA coating. However, in the 
absence of personal experimental data, we can rely on the literature to provide estimates. 
The first article on polydopamine (Lee et al. 2007) reported the measurement of the thickness 
of PDA coatings deposited in the same conditions that we used (2 mg/mL dopamine in Tris buffer, 
pH 8.5, at room temperature) on silicon substrates patterned by photolithography. The 
measurement was done by AFM, on coatings resulting from different deposition durations. The 
measured values are presented on Figure 74. The thickness of the coating resulting from the 
deposition duration we used (22h) was approximatively 45 nm. 
 
 
Figure 74. Thickness evolution of PDA coating on Si as measured by AFM of patterned surfaces. 
Adapted from Lee et al., 2007. The thickness of the coating after 22h of deposition is comprised between 
45 and 50 nm. 
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Other research groups measured the thickness of PDA coatings deposited in identical 
conditions. Ellipsometry measurements on silicon substrates gave values around 45 nm (Zhu and 
Edmondson 2011) or 30 nm (Ball et al. 2012). Stylus profiler measurements on patterned silicon 
substrates (Li et al. 2009) resulted in higher values: around 100 nm. Bourmaud et al. (2009) 
reported a thickness of 150 nm of PDA coatings on poly(lactic acid), measured by AFM after 
scratching of the coating. Overall, the thickness of PDA coatings deposited in the conditions that 
we used can hence be considered to be between 30 and 150 nm. 
The additional thickness of the immobilized linker and peptide can be roughly estimated as 
follows: the length of a C-C, C-N or C-O covalent bond is approximatively 0.15 nm. There are 
25 bonds in the peptide backbone, and 12 in the BCN-amine linker. Thus, the size of a linear 
“linker + peptide” molecule is: 37 x 0.15 = 5.6 nm. Therefore, the immobilization of the linker and 
the peptide on the PDA coating adds only a few nanometers to the total thickness of the coating. 
In summary, the thickness of the “PDA+P8RI” coating can be estimated to range between 30 
and 160 nm. As discussed above for the PP-HMDSN coating, this low thickness is desirable in 
order to limit the amount of potentially toxic products released during in vivo coating 
degradation. 
 
I.5. Adhesion and stability of the “PDA + P8RI” coating 
Stent coatings are subjected to demanding conditions, first during the expansion of the stents, 
and secondly when they are exposed to arterial blood flow. Huang’s group (Yang et al. 2012) 
showed that PDA coated-stents (coated with the same protocol as the one we used) remained 
intact after balloon expansion. No delamination or degradation was observed. More generally, 
polydopamine is known for its excellent adhesive properties: Zhu and Edmonson (2011) showed 
that a PDA coating on polystyrene remained adherent after a tape peel test. Polydopamine has 
also been used as an intermediate adhesive layer, under zirconia and graphene oxide coatings 
(Ou et al. 2011, 2012), cyclodextrins based polymer coatings (Sobocinski et al. 2014), or 
polytetrafluoroethylene (PTFE) films (Beckford and Zou 2014). In their article, Beckford and Zou 
showed that the intermediate PDA layer drastically improved the friction and wear resistance of 
PTFE films on stainless steel. 
As regards the stability of PDA-based coatings in aqueous medium, the “PDA-linker-P8RI” 
coating did not show any sign of degradation at the end of the one-month static ageing test in PBS 
that we performed. This is consistent with the results of other groups, which had demonstrated 
the stability of PDA coatings (deposited with the same protocol as the one we used) in static 
ageing tests carried out for one week in deionized water (Saidin et al. 2013), and for one month 
in PBS (Yang et al. 2012). These tests were carried out in static conditions, but pseudo-arterial 
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flow conditions would of course mimic more closely the in vivo environment of the stents. No 
report of in vitro stability tests in flow conditions has been found in the literature. We plan to 
perform ageing tests on the “PDA + P8RI” coating in the dynamic test bench presented on Figure 
37, as we did on PP-HMDSN coatings. 
In sum, the adhesion and stability studies carried out thus far in this thesis work and by other 
research groups all point to the conclusion that PDA coatings possess the adhesion and stability 
properties required for their use as stent coatings. 
 
 
II. Technical consideration: cell-based assays on metallic 
samples 
Similarly to the evaluation of the mechanical properties of the coating, the in vitro 
biocompatibility experiments on platelets and endothelial cells presented in this study were 
performed in static conditions. Here again, in vitro flow systems would reproduce more closely 
the in vivo environment of these cells. The phenotype of endothelial cells, in particular, is known 
to undergo significant changes depending on the applied shear stress. We have observed in our 
laboratory that endothelial cells cultivated in flow chambers align with the flow direction and 
form better-defined intercellular junctions than the same cells cultivated in static conditions. The 
effect of hemodynamic forces on the expression of several endothelial genes has also been proved 
(Resnick and Gimbrone 1995). 
Flow systems for cell culture are commercially available, and our laboratory is equipped with 
one of them. However, flow chambers usually consist in transparent channels designed for the 
seeding of cells on the walls, and real-time observation by optical microscopy. They are not 
designed for the insertion of non-transparent biomaterial samples. We carried out several 
attempts to develop a flow system adapted to CoCr disks in the course of this study, using either 
commercial flow chambers (µ-Slide 3D Perfusion, Ibidi) or custom-made PDMS chambers. 
However, the imperfect fitting of the CoCr disks in the chambers induced artefacts and the 
experiments carried out with these chambers were flawed by poor reproducibility. 
We met similar difficulties when we tried to develop an endothelial cell migration assay on 
coated CoCr disks. The cell migration assay would have been a closer model to the in vivo situation 
where endothelial cells progressively cover stent struts, compared to the direct seeding of 
endothelial cells on the disks. Unfortunately, it proved very difficult to ensure a good contact 
between the CoCr disks and the surrounding collagen gel on which the cells were cultivated, 
without contaminating the surface of the disks with collagen. 
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The technical limitations we encountered are inherent in the field of biomaterials, which 
stands at the crossroads of experimental biology (characterized by sub-millimeter-scale systems 
and stringent reproducibility and sterility requirements) and materials science (which generally 
involves custom-made, non-standard samples). There is today a range of commercial cell culture 
systems adapted to the testing of porous scaffolds such as hydrogels (Ebers’ P3D chambers, Ibidi’s 
µ-Slide 3D Perfusion, Cellec Biotek’s U-Cup, Cellix’s VenaT4, etc.). Maybe the next years will see 
the development and propagation of commercial flow systems adapted to solid, non-transparent 
biomaterials. This might go together with a standardization of the shape and dimensions of 
laboratory-made biomaterials samples. 
 
III. Scientific and industrial context of the project 
III.1. Alternative approaches to improve stents endothelialization 
Ever since the association between late stent thrombosis and delay in endothelialization of 
DESs was shown (Joner et al. 2006), several coatings designed to improve stent endothelialization 
through the immobilization of bioactive molecules have been developed. Two main types of 
bioactive molecules can be distinguished: extracellular matrix (ECM)-derived molecules which 
promote the adhesion of endothelial cells, and antibodies or aptamers designed for the capture 
of circulating endothelial progenitor cells (EPCs). 
As regards the first approach, either whole ECM glycoproteins such as fibronectin (Li et al. 
2011; Montaño-Machado et al. 2017), or integrin-binding peptides derived from the proteins and 
glycoproteins of the ECM, such as RGDS, REDV, YIGSR or cyclic RGD (Joner et al. 2012; Castellanos 
et al. 2017), have been immobilized on metallic alloys and shown to improve endothelial cell 
adhesion and proliferation. However, the binding motifs of the ECM components are not specific 
to the integrins of endothelial cells. Integrin-binding peptides such as RGD or RGDS have been 
shown to improve the adhesion and spreading of vascular smooth muscle cells (SMCs) (Massia 
and Stark 2001; Mann and West 2002) and neutrophils (Kim et al. 2014). It is therefore 
questionable whether stents coated with these glycoproteins or peptides would result in reduced 
neointimal hyperplasia, and thus a lower restenosis rate, compared with BMSs. Long-term in vivo 
studies would be necessary to answer this question. At the present time, they have not yet been 
performed.  
The second main strategy to improve stent endothelialization is the capture of circulating 
EPCs through the immobilization of anti-CD34 antibodies. An anti-CD34 antibody-coated stent, 
called Genous, is presently commercialized by OrbusNeich. Immobilized anti-CD34 antibodies 
have been shown to enhance EPCs adhesion in vitro (Chen et al. 2015a) and to promote rapid 
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stent endothelialization in vivo (Lin et al. 2010; van Beusekom et al. 2012). However, this 
promising approach has not fully solved the problem of stent biocompatibility, as clinical trials 
have found the Genous stent to be inferior to DESs in terms of restenosis prevention (Beijk et al. 
2010; Klomp et al. 2011). This observation has led OrbusNeich to develop the Combo stent, which 
combines anti-CD34 antibodies with a sirolimus-eluting coating. A known limitation of anti-CD34 
coatings is that CD34 positive cells represent a very small fraction of the PBMCs (0.002%), and 
that most CD34 positive cells (99.6%) are not EPCs. Some CD34 positive cells are also able to 
differentiate into vascular SMCs (Wendel et al. 2010). In order to address this concern, DNA 
aptamers which specifically target EPCs, rather than all CD34 positive cells, have recently been 
immobilized on stainless steel and proved to selectively promote the adhesion and proliferation 
of EPCs in vitro (Li et al. 2016). Short-term in vivo studies are needed to show whether these 
aptamers, which target such a small population of circulating cells (EPCs represent about 
0.000008% of the PBMCs), result in an improvement of stent endothelialization. 
In summary, the balance between stent endothelialization improvement and restenosis 
prevention appears difficult to achieve. Still, amongst the molecular targets considered for that 
purpose, CD31 presents the distinct advantage of being specifically expressed by cells of the 
blood/vessel interface, and not SMCs. Thus, P8RI, the CD31-agonist peptide on which this work 
is based, is not expected to promote SMC adhesion or proliferation, contrary to ECM 
glycoproteins, integrin-binding peptides or anti-CD34 antibodies. As for the alternative 
approaches presented here, long-term in vivo studies will be necessary to assess the effect of 
P8RI-based coatings on neointimal hyperplasia, and thus restenosis. 
Besides the question of their specificity, the nature of the bioactive molecules used for 
improving stent endothelialization is also of primary importance. Peptides have often been 
preferred to whole proteins or antibodies because their biological activity does not require 
complex 3D folding or the exposition of particular binding sites, which could be compromised by 
non-oriented immobilization techniques. Peptides (and DNA aptamers) are also significantly less 
expensive than most proteins and antibodies, which is an important concern in the context of a 
highly competitive stent market. 
 
III.2. Next generation stents: a highly competitive market 
There is still a dire need for better vascular stents, despite the improvements in their 
successive generations, since they continue to provoke severe complications in a number of cases. 
The incidence of stent thrombosis at 3 years after the implantation of a BMS or a second-
generation DES is of 1.0 to 1.5% (results from a study on 18334 patients (Tada et al. 2013)), and 
the incidence of angiographic restenosis is about 30% for BMSs and 12% for second generation 
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DESs (results from a study on 10004 patients (Cassese et al. 2013)). Flow diverters have been 
shown to cause in-stent thrombosis and thromboembolic events in a number of cases, despite 
treatment with dual antiplatelet therapy (Al-Mufti et al. 2016): the incidence of thromboembolic 
events in patients under DAPT has been reported to be between 2% and 7% (Saatci et al. 2012; 
Tan et al. 2014; Pierot et al. 2016).  
The research on new coatings designed to improve the biocompatibility of vascular stents is 
therefore very active. However, researchers in this field must not ignore that appropriate 
biological effects, satisfactory adhesion and stability properties, and the absence of toxic 
degradation products are not the only requirements for a new stent coating. If it is to reach the 
market, the coating process reproducibility, scalability and cost should not be overlooked. 
The requirements of reproducibility and scalability are common to all medical devices. The 
simplicity of the “PDA+P8RI” coating procedure is a great advantage in that respect: a dip-coating 
process can easily be adapted to industrial scale, and it has already been used for stent coating 
(Chen et al. 2015b). As for the base components, dopamine and custom peptides produced 
according to regulatory “Good Manufacturing Practices” (GMP) already exist (dopamine under 
the form of drugs such as Intropin, Dopastat or Dopastropin, and peptides as supplied by private 
companies). Thus, the deposition process of the “PDA+P8RI” coating is well suited to an 
adaptation to GMP-compliant industrial-scale production. 
The issue of cost control is particularly relevant to the coronary stent industry. Indeed, the 
prices of BMSs and DESs have globally undergone a dramatic decrease over the last fifteen years. 
The evolution of the prices of the BMSs and DESs reimbursed by the French social security system 
is given on Figure 75 as an example. Today, a large number of similar BMSs and DESs are available. 
They often use the same alloys, polymers, and drugs as competitive models (as shown on Table 
16), and show similar results in clinical trials. Thus, the competition between these products is 
strong and it drives the average selling prices down. Where prices are set by public authorities 
(in France for instance), the alignment of prices can even be legally mandatory. For these reasons, 
the control of the costs of any new stent coating is highly necessary. The most expensive 
component of the “PDA+P8RI” coating is the peptide, and its production cost is not prohibitive: it 
is inferior to that of proteins such as the anti-CD34 antibody immobilized on the Genous stent 
(manufactured by OrbusNeich). The coating process (dip-coating at room temperature) is very 
economical, since it does not require complex equipment or important quantities of energy. 
In short, the development of new stent coatings must take into account the requirements of 
industrial production in a competitive market. The “PDA+P8RI” coating process is compatible 
with these exigencies. 
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IV. Perspectives 
IV.1. “PDA+P8RI”-based dual stent coating 
The approach we adopted to improve stents biocompatibility was the surface immobilization 
of P8RI, a CD31 agonist peptide. The main issue we wanted to address with this coating was stent 
strut endothelialization, because, as detailed in the introduction, it is a critical step of the 
complications that can arise after stenting. Still, “PDA+P8RI”-coated stents might benefit from 
additional anti-thrombotic properties (besides the not statistically significant decrease in platelet 
adhesion that we observed on “PDA+P8RI” coatings in vitro) during the first weeks after stent 
implantation, when the coating is not yet degraded. As PDA is a convenient platform for the 
immobilization of many types of biomolecules, the “PDA+P8RI” coating could easily be 
transformed into a dual coating, with the addition of a second bioactive molecule, with anti-
thrombotic properties, such as heparin (heparin immobilization on PDA has already been 
reported by Jiang and colleagues (2010)). 
The idea to co-immobilize two molecules with complementary effects on stents is not new: 
Huang’s group has developed a dual heparin/fibronectin coating in order to provide anti-
thrombotic and pro-endothelialization properties to stents (Li et al. 2011); Montaño and 
colleagues have targeted the same objective with a phosphorylcholine/fibronectin coating 
(Montaño-Machado et al. 2017). Dual coatings with pro-endothelialization and anti-SMC 
proliferation effects have also been developed: a hyaluronic acid/sirolimus-in-polymer coating 
Figure 75. Evolution of the prices of the BMSs and DESs reimbursed by the 
French social security system between 2003 and 2017. Prices are set by the 
French state and are the same for all BMSs models and all DESs models.  
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by Kim and colleagues (2016), and the anti-CD34 antibody/sirolimus-in-polymer coating present 
on OrbusNeich’s Combo stents. 
In a nutshell, if the ongoing in vivo assessment of the “PDA+P8RI” coating yields encouraging 
results in terms of endothelialization, it might be interesting for the continuation of the project to 
test the effect of the co-immobilization of an anti-thrombotic bioactive molecule such as heparin. 
 
 
IV.2. What will the stent of the future be? 
Today, the stents commonly used for coronary artery disease treatment are either BMSs or 
DESs. Both types of stents are based on metallic alloys and are designed to stay in place during 
the lifetime of the patient. Hence the necessity to develop more biocompatible coatings to avoid 
long-term complications. However, a different type of stents has been developed, which could 
represent a breakthrough in the field: bioresorbable vascular stents (BVSs). These stents are 
designed to degrade in a few months, thus providing temporary scaffolding to the vessel (with 
the additional elution of antiproliferative drug) while avoiding neointimal hyperplasia and late 
stent thrombosis (Onuma and Serruys 2011). Around 20 models of BVSs are currently in clinical 
trials and some have already obtained CE marking (Tenekecioglu et al. 2016). In most cases, it is 
still too early to know know whether they will perform better than DESs. 
The Absorb BVS manufactured by Abbott has been the most tested in clinical trials (2008 
patients were enrolled in the latest trial). However, it was withdrawn from the market earlier this 
year, after the 2-year results of the ABSORB III trial revealed its significantly higher target lesion 
failure and target vessel myocardial infarction incidence compared with the Xience DES (Ellis and 
Kereiakes 2015). 
Despite this setback, the ongoing clinical trials on other models of BVSs might show better 
results. It must also be noted that, as the development of BVSs is very recent, the next years might 
bring considerable improvement in their design. In particular, because of the mechanical 
properties of the currently used bioresorbable materials, the strut thickness of existing BVSs is 
comprised between 100 and 175 µm (156 µm for the Absorb stent), whereas recent DESs have a 
strut thickness of about 80 µm (Foin et al. 2014). The correlation between stent strut thickness 
and neointimal hyperplasia is well known (Rittersma et al. 2004); thus, the development of 
biodegradable materials with better mechanical properties might bring a dramatic improvement 
in the clinical outcome of patients implanted with BVSs. 
The future will tell us if BVSs can hold their promise to advantageously replace BMSs and 
DESs. Maybe BVSs will be added to the therapeutic arsenal of interventional cardiologists along 
with BMSs and DESs, each type of stent being more adapted to particular indications. This is 
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currently the case with DESs and BMSs: although most implanted coronary stents are DESs (74% 
in France in 2014, according to a report by the ANSM (Schapiro-Dufour et al. 2016)), BMSs are 
recommended for patients with high bleeding risk under anticoagulant treatment. As BVSs are 
best adapted to young patients with simple lesions, DESs and BMSs might remain the best option 
for complex lesions. 
Future BVSs might benefit from a coating that promotes their fast endothelialization and thus 
helps prevent thrombosis while the stent is not fully degraded. Of course, such a coating can only 
be compatible with a BVS if it degrades faster than the stent. The “PDA+P8RI” coating is expected 
to fulfil this requirement, since melanin films (which have a chemical structure close to that of 
PDA) implanted in vivo were shown to be resorbed after 8 weeks (Bettinger et al. 2009). Still, we 
obviously need more time and experience with BVSs to determine fast endothelialization is really 
achieved with this type of stents. 
Another type of progress might be made in the field of vascular stents in a more distant future, 
in the context of personalized medicine: the development of ‘smart’ stents, which would collect 
and send information about their in vivo environment. This information, monitored by a medical 
practitioner, should help diagnose potential complications such as in-stent thrombosis and 
restenosis, or indicate the progress of stent struts endothelialization. Several research projects 
have been published on smart stents equipped with pressure sensors (Menudet 2011; Chen et al. 
2014; Park et al. 2016), mass sensors (Musick et al. 2010), or flow and temperature sensors (Son 
et al. 2015), but, to this day, they are still far from clinical application. A French start-up, Instent, 
was created in 2014 in order to develop a connected stent able to monitor thrombosis. However, 
it has recently changed the target application of its technology and is now developing a smart 
guidewire for ischemic stroke, under the name Sensome. Thus, it will be years before we know 
whether smart stents can significantly improve the follow-up of patients with stented arteries. 
However, one thing is certain: the development of real-time remote health monitoring will 
require a substantial change in the organization of medical practitioners’ work, so that they can 
efficiently adapt to their emerging new role. 
In summary, the arterial stent of the future might be bioresorbable, and it might be later 
equipped with sensors and antennas; but its in vivo environment will be the same as that of 
current stents; thus, it might still benefit from the advances in bioactive coatings, such as those 
envisaged by my work, in order to ensure that the biomaterial is accepted as ‘peacefully’ as 
possible by the living cells of the patient’s vascular system. 
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General conclusion 
The project of this thesis aims at reducing the complications associated with coronary stents 
and flow diverting stents. The objectives set for this thesis work were to immobilize the CD31 
agonist peptide P8RI on the surface of coronary stents and FDSs, and to carry out the in vitro and 
in vivo evaluation of the biological properties of the resulting surfaces, in terms of anti-
thrombotic, anti-inflammatory, and, above all, pro-endothelialization properties. 
The immobilization of P8RI on alloy surfaces was successfully carried out with the use of an 
intermediary bio-inspired polydopamine layer. The covalent and oriented grafting of the peptide 
was realized through a series of simple dip-coating steps, in aqueous medium, thus rendering the 
coating process perfectly suitable for potential future applications at the industrial scale. The in 
vitro and in vivo evaluations of the coated surfaces yielded promising, although still preliminary, 
results, in terms of pro-endothelialization and anti-inflammatory effects. 
The need for better coronary stents and FDSs is undisputed. Many different solutions are 
being investigated and developed all over the world. The scalability of the ‘PDA-P8RI’ coating 
process that we developed, associated with the known biocompatibility of PDA and the biological 
effects that were presented in this work, make the PDA-P8RI coating a plausible candidate 
amongst the numerous projects that compete to reach the bedside. Further studies will tell us 
whether it can live up to our expectations. 
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Résumé 
 
Au cours des dernières décennies, les stents coronaires et les stents déviateurs de flux 
intracrâniens ont révolutionné le traitement endovasculaire de deux pathologies artérielles 
différentes : la maladie coronarienne et les anévrismes intracrâniens. Ces deux types 
d’endoprothèses métalliques ont des mécanismes de fonctionnement différents, mais ils sont tous 
deux associés à des complications qui découlent de problèmes de biocompatibilité. En particulier, 
la couverture rapide de ces endoprothèses par des cellules endothéliales présentant un 
phénotype anti-inflammatoire et anti-thrombotique est cruciale pour leur intégration à 
l’interface vaisseau/sang. Par conséquent, le développement de solutions visant à améliorer 
l’endothélialisation et l’intégration de ces deux types de stents dans la paroi vasculaire 
représenterait un progrès majeur dans leur domaine respectif. 
Dans ce contexte, cette thèse porte sur l’immobilisation d’une molécule bioactive à la surface 
de stents coronaires et de stents déviateurs de flux, afin de résoudre leurs problèmes de 
biocompatibilité. La molécule bioactive utilisée est un peptide synthétique, appelé P8RI, qui 
promeut les fonctions régulatrices de la glycoprotéine transmembranaire CD31 : l’inhibition de 
l’activation des plaquettes et des leucocytes, ainsi que l’amélioration de la survie, de la migration 
et de la fonction de barrière des cellules endothéliales. 
La première partie de ce travail de thèse a consisté à développer un procédé d’immobilisation 
du P8RI sur des stents métalliques. Nous avons successivement adopté trois approches : 
l’immobilisation directe du peptide sur des surfaces d’alliage fonctionnalisées par plasma ; le 
dépôt chimique en phase vapeur assisté par plasma d’une couche intermédiaire de polymère ; et 
le dépôt d’une couche de polydopamine par auto-polymérisation, suivi de l’immobilisation d’un 
bras d’ancrage et de la liaison du P8RI par chimie click sans cuivre. 
Nous avons ensuite réalisé une évaluation in vitro de la biocompatibilité des surfaces d’alliage 
ainsi revêtues, en termes de propriétés anti-thrombotiques, anti-inflammatoires et pro-
endothélialisation. Les surfaces sur lesquelles le P8RI avait été immobilisé ont montré une 
tendance à diminuer l’adhésion plaquettaire, à améliorer l’adhérence et la fonction de barrière de 
cellules endothéliales vasculaires humaines, et à promouvoir un phénotype anti-inflammatoire et 
anti-thrombotique chez ces dernières. 
Enfin, nous avons évalué in vivo des stents coronaires et déviateurs de flux recouverts de P8RI. 
Les stents coronaires ont été implantés dans des artères coronaires de porcs, et les résultats 
préliminaires ont montré une endothélialisation plus complète et une moindre densité de 
leucocytes adhérents sur les stents recouverts de P8RI que sur les témoins. Quant aux stents 
déviateurs de flux recouverts de P8RI, implantés dans un modèle d’anévrisme carotidien induit 
par incubation d'élastase chez le lapin, ils ont été associés à la formation d’une néointima plus 
épaisse et mieux organisée que sur les témoins, en particulier au niveau du collet anévrismal, ce 
qui implique de moindres risques de persistance du flux sanguin et de rupture d’anévrisme. 
